RNA INTERFERENCE IN SKIN INDICATIONS

Abstract

The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.

Description

FIELD OF INVENTION

The invention pertains to the field of RNA interference (RNAi). The invention more specifically relates to nucleic acid molecules with improved in vivo delivery properties without the use of a delivering agent and their use in efficient gene silencing.

BACKGROUND OF INVENTION

Complementary oligonucleotide sequences are promising therapeutic agents and useful research tools in elucidating gene functions. However, prior art oligonucleotide molecules suffer from several problems that may impede their clinical development, and frequently make it difficult to achieve intended efficient inhibition of gene expression (including protein synthesis) using such compositions in vivo.

A major problem has been the delivery of these compounds to cells and tissues. Conventional double-stranded RNAi compounds, 19-29 bases long, form a highly negatively-charged rigid helix of approximately 1.5 by 10-15 nm in size. This rod type molecule cannot get through the cell-membrane and as a result has very limited efficacy both in vitro and in vivo. As a result, all conventional RNAi compounds require some kind of a delivery vehicle to promote their tissue distribution and cellular uptake. This is considered to be a major limitation of the RNAi technology.

There have been previous attempts to apply chemical modifications to oligonucleotides to improve their cellular uptake properties. One such modification was the attachment of a cholesterol molecule to the oligonucleotide. A first report on this approach was by Letsinger et al., in 1989. Subsequently, ISIS Pharmaceuticals, Inc. (Carlsbad, Calif.) reported on more advanced techniques in attaching the cholesterol molecule to the oilgonucleotide (Manoharan, 1992).

With the discovery of siRNAs in the late nineties, similar types of modifications were attempted on these molecules to enhance their delivery profiles. Cholesterol molecules conjugated to slightly modified (Soutschek, 2004) and heavily modified (Wolfrum, 2007) siRNAs appeared in the literature. Yamada et al., 2008 also reported on the use of advanced linker chemistries which further improved cholesterol mediated uptake of siRNAs. In spite of all this effort, the uptake of these types of compounds appears to be inhibited in the presence of biological fluids resulting in highly limited to efficacy in gene silencing in vivo, limiting the applicability of these compounds in a clinical setting.

Therefore, it would be of great benefit to improve upon the prior art oligonucleotides by designing oligonucleotides that have improved delivery properties in vivo and are clinically meaningful.

SUMMARY OF INVENTION

Described herein are asymmetric chemically modified nucleic acid molecules with minimal double stranded regions, and the use of such molecules in gene silencing. RNAi molecules associated with the invention contain single stranded regions and double stranded regions, and can contain a variety of chemical modifications within both the single stranded and double stranded regions of the molecule. Additionally, the RNAi molecules can be attached to a hydrophobic conjugate such as a conventional and advanced sterol-type molecule. This new class of RNAi molecules has superior efficacy both in vitro and in vivo than previously described RNAi molecules.

In some aspects the invention is a method involving administering a double stranded nucleic acid molecule selected from the nucleic acid molecules contained in Tables 1-3 such that an antisense and a sense strand make up the double stranded nucleic acid molecule, to a subject, wherein the nucleic acid molecule is administered on the skin of the subject.

In other aspects the invention is a method involving administering a double stranded nucleic acid molecule selected from the nucleic acid molecules contained in Tables 1-3 such that an antisense and a sense strand make up the double stranded nucleic acid molecule, to a subject, wherein the nucleic acid molecule is administered via intradermal injection.

A method for treating compromised skin is provided according to other aspects of the invention. The method involves administering to a subject a therapeutically effective amount for treating compromised skin of a double stranded nucleic acid molecule comprising a guide strand, with a minimal length of 16 nucleotides, and a passenger strand forming a double stranded nucleic acid, having a double stranded region and a single stranded region, the double stranded region having 8-15 nucleotides in length, the single stranded region having 4-12 nucleotides in length, wherein position 1 of the guide strand is 5′ phosphorylated or has a 2′ O-methyl modification, wherein the passenger strand is linked to a lipophilic group, wherein at least 40% of the nucleotides of the double stranded nucleic acid are modified, and wherein the double stranded nucleic acid molecule has one end that is blunt or includes a one nucleotide overhang.

In another aspect the invention is a method for delivering a nucleic acid to a subject by administering to a subject prior to or simultaneous with a medical procedure a therapeutically effective amount for treating compromised skin of a double stranded nucleic acid molecule comprising a guide strand, with a minimal length of 16 nucleotides, and a passenger strand forming a double stranded nucleic acid, having a double stranded region and a single stranded region, the double stranded region having 8-15 nucleotides in length, the single stranded region having 4-12 nucleotides in length, wherein position 1 of the guide strand is 5′ phosphorylated or has a 2′ O-methyl modification, wherein the passenger strand is linked to a lipophilic group, wherein at least 40% of the nucleotides of the double stranded nucleic acid are modified, and wherein the double stranded nucleic acid molecule has one end that is blunt or includes a one nucleotide overhang. In one embodiment the medical procedure is surgery. Optionally the surgery is elective.

A method for promoting wound healing is provided in another aspect. The method involves administering a therapeutically effective amount for promoting wound healing of a double stranded nucleic acid molecule comprising a guide strand, with a minimal length of 16 nucleotides, and a passenger strand forming a double stranded nucleic acid, having a double stranded region and a single stranded region, the double stranded region having 8-15 nucleotides in length, the single stranded region having 4-12 nucleotides in length, wherein position 1 of the guide strand is 5′ phosphorylated or has a 2′ O-methyl modification, wherein the passenger strand is linked to a lipophilic group, wherein at least 40% of the nucleotides of the double stranded nucleic acid are modified, and wherein the double stranded nucleic acid molecule has one end that is blunt or includes a one nucleotide overhang.

In some embodiments the subject has a wound, such as a chronic wound. The wound may be a result of elective surgery. In some embodiments the wound is external. In other embodiments the wound is internal.

The nucleic acid molecule may in some embodiments be administered before or after an injury. For example the nucleic acid molecule may be administered before or to after the injury via intradermal injection or locally to the skin.

In some embodiments the nucleic acid molecule is administered before a surgery. The surgery may be for instance epithelial grafting or skin grafting.

In some embodiments the nucleic acid molecule is administered to a graft donor site. In other embodiments the nucleic acid molecule is administered to a graft recipient site. In yet other embodiments the nucleic acid molecule is administered after burn injury.

Optionally the nucleic acid molecule may be administered prior to injury or surgery.

The double stranded nucleic acid molecule is directed against a gene encoding for a protein selected from the group consisting of: Transforming growth factor β (TGFβ1, TGFβ2), Osteopontin, Connective tissue growth factor (CTGF), Platelet-derived growth factor (PDGF), Hypoxia inducible factor-1α (HIF1α), Collagen I and/or III, Prolyl 4-hydroxylase (P4H), Procollagen C-protease (PCP), Matrix metalloproteinase 2, 9 (MMP2, 9), Integrins, Connexin, Histamine H1 receptor, Tissue transglutaminase, Mammalian target of rapamycin (mTOR), HoxB13, VEGF, IL-6, SMAD proteins, Ribosomal protein S6 kinases (RSP6) and Cyclooxygenase-2 (COX-2) in some embodiments.

In one embodiment the double stranded nucleic acid molecule is administered on the skin of the subject in need thereof. It may be in the form of a cream or ointment. In other embodiments the nucleic acid molecule is administered by local injection.

A composition of a double stranded nucleic acid molecule selected from the nucleic acid molecules contained in Tables 1-3 such that an antisense and a sense strand make up the double stranded nucleic acid molecule formulated for delivery to the skin is provided according to another aspect of the invention.

In another aspect the invention is a composition of a double stranded nucleic acid molecule comprising a guide strand, with a minimal length of 16 nucleotides, and a passenger strand forming a double stranded nucleic acid, having a double stranded region and a single stranded region, the double stranded region having 8-15 nucleotides in length, the single stranded region having 4-12 nucleotides in length, wherein position 1 of the guide strand is 5′ phosphorylated or has a 2′ O-methyl modification, wherein the passenger strand is linked to a lipophilic group, wherein at least 40% of the nucleotides of the double stranded nucleic acid are modified, and wherein the double stranded nucleic acid molecule has one end that is blunt or includes a one nucleotide overhang formulated for delivery to the skin. In one embodiment the nucleic acid molecule is in the form of a cream or ointment.

In some aspects the invention is methods for inhibiting scar tissue formation or for promoting epithelial regeneration. The methods involve administering a therapeutically effective amount for inhibiting scar tissue formation of a double stranded nucleic acid molecule selected from the nucleic acid molecules listed in Tables 1-3, to a subject in need thereof, to a subject in need thereof, to a subject in need thereof.

Alternatively the methods for inhibiting scar tissue formation or for promoting epithelial regeneration involve contacting epithelial cells with an effective amount for promoting epithelial regeneration of a double stranded nucleic acid molecule comprising a guide strand and a passenger strand, wherein the region of the molecule that is double stranded is from 8-14 nucleotides long, wherein the guide strand contains a single stranded region that is 4-12 nucleotides long, and wherein the single stranded region of the guide strand contains 2-12 phosphorothioate modifications, to a subject in need thereof.

Alternatively the methods for inhibiting scar tissue formation or for promoting epithelial regeneration involve administering to skin of a subject a therapeutically effective amount for inhibiting scar tissue formation or for promoting epithelial regeneration of a double stranded nucleic acid molecule comprising a guide strand, with a minimal length of 16 nucleotides, and a passenger strand forming a double stranded nucleic acid, having a double stranded region and a single stranded region, the double stranded region having 8-15 nucleotides in length, the single stranded region having 4-12 nucleotides in length, wherein position 1 of the guide strand is 5′ phosphorylated and/or has a 2′ O-methyl modification, wherein the passenger strand is linked to a lipophilic group, wherein at least 40% of the nucleotides of the double stranded nucleic acid are modified, and wherein the double stranded nucleic acid molecule has one end that is blunt or includes a one or two nucleotide overhang.

BRIEF DESCRIPTION OF DRAWINGS

The accompanying drawings are not intended to be drawn to scale. In the drawings, each identical or nearly identical component that is illustrated in various figures is represented by a like numeral. For purposes of clarity, not every component may be labeled in every drawing. In the drawings:

FIG. 1 is a schematic depicting proposed structures of asymmetric double stranded RNA molecules (adsRNA). Bold lines represent sequences carrying modification patterns compatible with RISC loading. Striped lines represent polynucleotides carrying modifications compatible with passenger strands. Plain lines represent a single stranded polynucleotide with modification patterns optimized for cell interaction and uptake. FIG. 1A depicts adsRNA with extended guide or passenger strands; FIG. 1B depicts adsRNA with length variations of a cell penetrating polynucleotide; FIG. 1C depicts adsRNA with 3′ and 5′ conjugates; FIG. 1D depicts adsRNAs with mismatches.

FIG. 2 is a schematic depicting asymmetric dsRNA molecules with different chemical modification patterns. Several examples of chemical modifications that might be used to increase hydrophobicity are shown including 4-pyridyl, 2-pyridyl, isobutyl and indolyl based position 5 uridine modifications.

FIG. 3 is a schematic depicting the use of dsRNA binding domains, protamine (or other Arg rich peptides), spermidine or similar chemical structures to block duplex charge to facilitate cellular entry.

FIG. 4 is a schematic depicting positively charged chemicals that might be used for polynucleotide charge blockage.

FIG. 5 is a schematic depicting examples of structural and chemical compositions of single stranded RISC entering polynucleotides. The combination of one or more modifications including 2′d, 2′Ome, 2′F, hydrophobic and phosphothioate modifications can be used to optimize single strand entry into the RISC.

FIG. 6 is a schematic depicting examples of structural and chemical composition of RISC substrate inhibitors. Combinations of one or more chemical modifications can be used to mediate efficient uptake and efficient binding to preloaded RISC complex.

FIG. 7 is a schematic depicting structures of polynucleotides with sterol type molecules attached, where R represent a polycarbonic tail of 9 carbons or longer. FIG. 7A depicts an adsRNA molecule; FIG. 7B depicts an siRNA molecule of approximately 17-30 bp long; FIG. 7C depicts a RISC entering strand; FIG. 7D depicts a substrate analog strand. Chemical modification patterns, as depicted in FIG. 7, can be optimized to promote desired function.

FIG. 8 is a schematic depicting examples of naturally occurring phytosterols with a polycarbon chain that is longer than 8, attached at position 17. More than 250 different types of phytosterols are known.

FIG. 9 is a schematic depicting examples of sterol-like structures, with variations in the size of the polycarbon chains attached at position 17.

FIG. 10 presents schematics and graphs demonstrating that the percentage of liver uptake and plasma clearance of lipid emulsions containing sterol type molecules is directly affected by the size of the polycarbon chain attached at position 17. This figure is adapted from Martins et al, Journal of Lipid Research (1998).

FIG. 11 is a schematic depicting micelle formation. FIG. 11A depicts a polynucleotide with a hydrophobic conjugate; FIG. 11B depicts linoleic acid; FIG. 11C depicts a micelle formed from a mixture of polynucleotides containing hydrophobic conjugates combined with fatty acids.

FIG. 12 is a schematic depicting how alteration in lipid composition can affect pharmacokinetic behavior and tissue distribution of hydrophobically modified and/or hydrophobically conjugated polynucleotides. In particular, use of lipid mixtures enriched in linoleic acid and cardiolipin results in preferential uptake by cardiomyocites.

FIG. 13 is a schematic showing examples of RNAi constructs and controls used to target MAP4K4 expression. RNAi construct 12083 corresponds to SEQ ID NOs:597 and 598. RNAi construct 12089 corresponds to SEQ ID NO:599.

FIG. 14 is a graph showing MAP4K4 expression following transfection with RNAi constructs associated with the invention. RNAi constructs tested were: 12083 (Nicked), 12085 (13nt Duplex), 12089 (No Stem Pairing) and 12134 (13nt miniRNA). Results of transfection were compared to an untransfected control sample. RNAi construct 12083 corresponds to SEQ ID NOs:597 and 598. RNAi construct 12085 corresponds to SEQ ID NOs:600 and 601. RNAi construct 12089 corresponds to SEQ ID NO:599. RNAi construct 12134 corresponds to SEQ ID NOs:602 and 603.

FIG. 15 is a graph showing expression of MAP4K4 24 hours post-transfection with RNAi constructs associated with the invention. RNAi constructs tested were: 11546 (MAP4K4 rxRNA), 12083 (MAP4K4 Nicked Construct), 12134 (12 bp soloRNA) and 12241 (14/3/14 soloRNA). Results of transfection were compared to a filler control sample. RNAi construct 11546 corresponds to SEQ ID NOs:604 and 605. RNAi construct 12083 corresponds to SEQ ID NOs:597 and 598. RNAi construct 12134 corresponds to SEQ ID NOs:602 and 603. RNAi construct 12241 corresponds to SEQ ID NOs:606 and 607.

FIG. 16 presents a graph and several tables comparing parameters associated with silencing of MAP4K4 expression following transfection with RNAi constructs associated with the invention. The rxRNA construct corresponds to SEQ ID NOs:604 and 605. The 14-3-14 soloRNA construct corresponds to SEQ ID NOs:606 and 607. The 13/19 duplex (nicked construct) corresponds to SEQ ID NOs:597 and 598. The 12-bp soloRNA construct corresponds to SEQ ID NOs:602 and 603.

FIG. 17 is a schematic showing examples of RNAi constructs and controls used to target SOD1 expression. The 12084 RNAi construct corresponds to SEQ ID NOs:612 and 613.

FIG. 18 is a graph showing SOD1 expression following transfection with RNAi constructs associated with the invention. RNAi constructs tested were: 12084 (Nicked), 12086 (13nt Duplex), 12090 (No Stem Pairing) and 12035 (13nt MiniRNA). Results of transfection were compared to an untransfected control sample. The 12084 RNAi construct corresponds to SEQ ID NOs:612 and 613. The 12086 RNAi construct corresponds to SEQ ID NOs:608 and 609. The 12035 RNAi construct corresponds to SEQ ID NOs:610 and 611.

FIG. 19 is a graph showing expression of SOD1 24 hours post-transfection with RNAi constructs associated with the invention. RNAi constructs tested were: 10015 (SOD1 rxRNA) and 12084 (SOD1 Nicked Construct). Results of transfection were compared to a filler control sample. The 10015 RNAi construct corresponds to SEQ ID NOs:614 and 615. The 12084 RNAi construct corresponds to SEQ ID NOs:612 and 613.

FIG. 20 is a schematic indicating that RNA molecules with double stranded regions that are less than 10 nucleotides are not cleaved by Dicer.

FIG. 21 is a schematic revealing a hypothetical RNAi model for RNA induced gene silencing.

FIG. 22 is a graph showing chemical optimization of asymmetric RNAi compounds. The presence of chemical modifications, in particular 2′F UC, phosphorothioate modifications on the guide strand, and complete CU 2′OMe modification of the passenger strands results in development of functional compounds. Silencing of MAP4K4 following lipid-mediated transfection is shown using RNAi molecules with specific modifications. RNAi molecules tested had sense strands that were 13 nucleotides long and contained the following modifications: unmodified; C and U 2′OMe; C and U 2′OMe and 3′ Chl; rxRNA 2′OMe pattern; or full 2′OMe, except base 1. Additionally, the guide (anti-sense) strands of the RNAi molecules tested contained the following modifications: unmodified; unmodified with 5′P; C and U 2′F; C and U 2′F with 8 PS 3′ end; and unmodified (17 nt length). Results for rxRNA 12/10 Duplex and negative controls are also shown.

FIG. 23 demonstrates that the chemical modifications described herein significantly increase in vitro efficacy in un-assisted delivery of RNAi molecules in HeLa cells. The structure and sequence of the compounds were not altered; only the chemical modification patterns of the molecules were modified. Compounds lacking 2′ F, 2′O-me, phosphorothioate modification, or cholesterol conjugates were completely inactive in passive uptake. A combination of all 4 of these types of modifications produced the highest levels of activity (compound 12386).

FIG. 24 is a graph showing MAP4K4 expression in Hela cells following passive uptake transfection of: NT Accell modified siRNA, MAP4K4 Accell siRNA, Non-Chl nanoRNA (12379) and sd-nanoRNA (12386).

FIG. 25 is a graph showing expression of MAP4K4 in HeLa cells following passive uptake transfection of various concentrations of RNA molecules containing the following parameters: Nano Lead with no 3′Chl; Nano Lead; Accell MAP4K4; 21mer GS with 8 PS tail; 21mer GS with 12 PS tail; and 25mer GS with 12 PS tail.

FIG. 26 is a graph demonstrating that reduction in oligonucleotide content increases the efficacy of unassisted uptake. Similar chemical modifications were applied to asymmetric compounds, traditional siRNA compounds and 25 mer RNAi compounds. The asymmetric small compounds demonstrated the most significant efficacy.

FIG. 27 is a graph demonstrating the importance of phosphorothioate content for un-assisted delivery. FIG. 27A demonstrates the results of a systematic screen that revealed that the presence of at least 2-12 phosphorothioates in the guide strand significantly improves uptake; in some embodiments, 4-8 phosphorothioate modifications were found to be preferred. FIG. 27B reveals that the presence or absence of phosphorothioate modifications in the sense strand did not alter efficacy.

FIG. 28 is a graph showing expression of MAP4K4 in primary mouse hepatocytes following passive uptake transfection of: Accell Media-Ctrl-UTC; MM APOB Alnylam; Active APOB Alnylam; nanoRNA without chl; nanoRNA MAP4K4; Mouse MAP4K4 Accell Smartpool; DY547 Accell Control; Luc Ctrl rxRNA with Dy547; MAP4K4 rxRNA with DY547; and AS Strand Alone (nano).

FIG. 29 is a graph showing expression of ApoB in mouse primary hepatocytes following passive uptake transfection of: Accell Media-Ctrl-UTC; MM APOB Alnylam; Active APOB Alnylam; nanoRNA without chl; nanoRNA MAP4K4; Mouse MAP4K4 Accell Smartpool; DY547 Accell Control; Luc Ctrl rxRNA with Dy547; MAP4K4 rxRNA with DY547; and AS Strand Alone (nano).

FIG. 30 is a graph showing expression of MAP4K4 in primary human hepatocytes following passive uptake transfection of: 11550 MAP4K4 rxRNA; 12544 MM MAP4K4 nanoRNA; 12539 Active MAP4K4 nanoRNA; Accell Media; and UTC.

FIG. 31 is a graph showing ApoB expression in primary human hepatoctyes following passive uptake transfection of: 12505 Active ApoB chol-siRNA; 12506 MM ApoB chol-siRNA; Accell Media; and UTC.

FIG. 32 is an image depicting localization of sd-rxRNA^nano localization.

FIG. 33 is an image depicting localization of Chol-siRNA (Alnylam).

FIG. 34 is a schematic of 1^st generation (G1) sd-rxRNA^nano molecules associated with the invention indicating regions that are targeted for modification, and functions associated with different regions of the molecules.

FIG. 35 depicts modification patterns that were screened for optimization of sd-rxRNA^nano (G1). The modifications that were screened included, on the guide strand, lengths of 19, 21 and 25 nucleotides, phosphorothioate modifications of 0-18 nucleotides, and replacement of 2′F modifications with 2′OMe, 5 Methyl C and/or ribo Thymidine modifications. Modifications on the sense strand that were screened included nucleotide lengths of 11, 13 and 19 nucleotides, phosphorothiote modifications of 0-4 nucleotides and 2′OMe modifications.

FIG. 36 is a schematic depicting modifications of sd-rxRNAN^nano that were screened for optimization.

FIG. 37 is a graph showing percent MAP4K4 expression in Hek293 cells following transfection of: Risc Free siRNA; rxRNA; Nano (unmodified); GS alone; Nano Lead (no Chl); Nano (GS: (3) 2′OMe at positions 1, 18, and 19, 8 PS, 19 nt); Nano (GS: (3) 2′OMe at positions 1, 18, and 19, 8 PS, 21 nt); Nano (GS: (3) 2′OMe at positions 1, 18, and 19, 12 PS, 21 nt); and Nano (GS: (3) 2′OMe at positions 1, 18, and 19, 12 PS, 25 nt);

FIG. 38 is a graph showing percent MAP4K4 expression in HeLa cells following passive uptake transfection of: GS alone; Nano Lead; Nano (GS: (3) 2′OMe at positions 1, 18, and 19, 8 PS, 19 nt); Nano (GS: (3) 2′OMe at positions 1, 18, and 19, 8 PS, 21 nt); Nano (GS: (3) 2′OMe at positions 1, 18, and 19, 12 PS, 21 nt); Nano (GS: (3) 2′OMe at positions 1, 18, and 19, 12 PS, 25 nt).

FIG. 39 is a graph showing percent MAP4K4 expression in Hek293 cells following lipid mediated transfection of: Guide Strand alone (GS: 8PS, 19 nt); Guide Strand alone (GS: 18PS, 19 nt); Nano (GS: no PS, 19 nt); Nano (GS: 2 PS, 19 nt); Nano (GS: 4 PS, 19 nt); Nano (GS: 6 PS, 19 nt); Nano Lead (GS: 8 PS, 19 nt); Nano (GS: 10 PS, 19 nt); Nano (GS: 12 PS, 19 nt); and Nano (GS: 18 PS, 19 nt).

FIG. 40 is a graph showing percent MAP4K4 expression in Hek293 cells following lipid mediated transfection of: Guide Strand alone (GS: 8PS, 19 nt); Guide Strand alone (GS: 18PS, 19 nt); Nano (GS: no PS, 19 nt); Nano (GS: 2 PS, 19 nt); Nano (GS: 4 PS, 19 nt); Nano (GS: 6 PS, 19 nt); Nano Lead (GS: 8 PS, 19 nt); Nano (GS: 10 PS, 19 nt); Nano (GS: 12 PS, 19 nt); and Nano (GS: 18 PS, 19 nt).

FIG. 41 is a graph showing percent MAP4K4 expression in HeLa cells following passive uptake transfection of: Nano Lead (no Chl); Guide Strand alone (18 PS); Nano (GS: 0 PS, 19 nt); Nano (GS: 2 PS, 19 nt); Nano (GS: 4 PS, 19 nt); Nano (GS: 6 PS, 19 nt); Nano Lead (GS: 8 PS, 19 nt); Nano (GS: 10 PS, 19 nt); Nano (GS: 12 PS, 19 nt); and Nano (GS: 18 PS, 19 nt).

FIG. 42 is a graph showing percent MAP4K4 expression in HeLa cells following passive uptake transfection of: Nano Lead (no Chl); Guide Strand alone (18 PS); Nano (GS: 0 PS, 19 nt); Nano (GS: 2 PS, 19 nt); Nano (GS: 4 PS, 19 nt); Nano (GS: 6 PS, 19 nt); Nano Lead (GS: 8 PS, 19 nt); Nano (GS: 10 PS, 19 nt); Nano (GS: 12 PS, 19 nt); and Nano (GS: 18 PS, 19 nt).

FIG. 43 is a schematic depicting guide strand chemical modifications that were screened for optimization.

FIG. 44 is a graph showing percent MAP4K4 expression in Hek293 cells following reverse transfection of: RISC free siRNA; GS only (2′F C and Us); GS only (2′OMe C and Us); Nano Lead (2′F C and Us); nano (GS: (3) 2′OMe, positions 16-18); nano (GS: (3) 2′OMe, positions 16, 17 and 19); nano (GS: (4) 2′OMe, positions 11, 16-18); nano (GS: (10) 2′OMe,C and Us); nano (GS: (6) 2′OMe, positions 1 and 5-9); nano (GS: (3) 2′OMe, positions 1, 18 and 19); and nano (GS: (5) 2′OMe Cs).

FIG. 45 is a graph demonstrating efficacy of various chemical modification patterns. In particular, 2-OMe modification in positions 1 and 11-18 was well tolerated. 2′OMe modifications in the seed area resulted in a slight reduction of efficacy (but were still highly efficient). Ribo-modifications in the seed were well tolerated. This data enabled the generation of self delivering compounds with reduced or no 2′F modifications. This is significant because 2′F modifications may be associated with toxicity in vivo.

FIG. 46 is a schematic depicting sense strand modifications.

FIG. 47 is a graph demonstrating sense strand length optimization. A sense strand length between 10-15 bases was found to be optimal in this assay. Increasing sense strand length resulted in a reduction of passive uptake of these compounds but may be tolerated for other compounds. Sense strands containing LNA modification demonstrated similar efficacy to non-LNA containing compounds. In some embodiments, the addition of LNA or other thermodynamically stabilizing compounds can be beneficial, resulting in converting non-functional sequences into functional sequences.

FIG. 48 is a graph showing percent MAP4K4 expression in HeLa cells following passive uptake transfection of: Guide Strand Alone (2′F C and U); Nano Lead; Nano Lead (No Chl); Nano (SS: 11 nt 2′OMe C and Us, Chl); Nano (SS: 11nt, complete 2′OMe, Chl); Nano (SS: 19 nt, 2′OMe C and Us, Chl); Nano (SS: 19 nt, 2′OMe C and Us, no Chl).

FIG. 49 is a graph showing percent MAP4K4 expression in HeLa cells following passive uptake transfection of: Nano Lead (No Chl); Nano (SS no PS); Nano Lead (SS:2 PS); Nano (SS:4 PS).

FIG. 50 is a schematic depicting a sd-rxRNA^nano second generation (GII) lead molecule.

FIG. 51 presents a graph indicating EC50 values for MAP4K4 silencing in the presence of sd-rxRNA, and images depicting localization of DY547-labeled rxRNA^ori and DY547-labeled sd-rxRNA.

FIG. 52 is a graph showing percent MAP4K4 expression in HeLa cells in the presence of optimized sd-rxRNA molecules.

FIG. 53 is a graph depicting the relevance of chemistry content in optimization of sd-rxRNA efficacy.

FIG. 54 presents schematics of sterol-type molecules and a graph revealing that sd-rxRNA compounds are fully functional with a variety of linker chemistries. GII asymmetric compounds were synthesized with sterol type molecules attached through TEG and amino caproic acid linkers. Both linkers showed identical potency. This functionality independent of linker chemistry indicates a significant difference between the molecules described herein and previously described molecules, and offers significant advantages for the molecules described herein in terms of scale up and synthesis.

FIG. 55 demonstrates the stability of chemically modified sd-rxRNA compounds in human serum in comparison to non modified RNA. The oligonucleotides were incubated in 75% serum at 37° C. for the number of hours indicated. The level of degradation was determined by running the samples on non-denaturing gels and staining with SYBGR.

FIG. 56 is a graph depicting optimization of cellular uptake of sd-rxRNA through minimizing oligonucleotide content.

FIG. 57 is a graph showing percent MAP4K4 expression after spontaneous cellular uptake of sd-rxRNA in mouse PEC-derived macrophages, and phase and fluorescent images showing localization of sd-rxRNA.

FIG. 58 is a graph showing percent MAP4K4 expression after spontaneous cellular uptake of sd-rxRNA (targeting) and sd-rxRNA (mismatch) in mouse primary hepatocytes, and phase and fluorescent images showing localization of sd-rxRNA.

FIG. 59 presents images depicting localization of DY547-labeled sd-rxRNA delivered to RPE cells with no formulation.

FIG. 60 is a graph showing silencing of MAP4K4 expression in RPE cells treated with sd-rxRNA^nano without formulation.

FIG. 61 presents a graph and schematics of RNAi compounds showing the chemical/structural composition of highly effective sd-rxRNA compounds. Highly effective compounds were found to have the following characteristics: antisense strands of 17-21 nucleotides, sense strands of 10-15 nucleotides, single-stranded regions that contained 2-12 phosphorothioate modifications, preferentially 6-8 phosphorothioate modifications, and sense strands in which the majority of nucleotides were 2′OMe modified, with or without phosphorothioate modification. Any linker chemistry can be used to attach these molecules to hydrophobic moieties such as cholesterol at the 3′ end of the sense strand. Version GIIa-b of these RNA compounds demonstrate that elimination of 2′F content has no impact on efficacy.

FIG. 62 presents a graph and schematics of RNAi compounds demonstrating the superior performance of sd-rxRNA compounds compared to compounds published by Wolfrum et. al. Nature Biotech, 2007. Both generation I and II compounds (GI and GIIa) developed herein show great efficacy. By contrast, when the chemistry described in Wolfrum et al. (all oligos contain cholesterol conjugated to the 3′ end of the sense strand) was applied to the same sequence in a context of conventional siRNA (19 bp duplex with two overhang) the compound was practically inactive. These data emphasize the significance of the combination of chemical modifications and assymetrical molecules described herein, producing highly effective RNA compounds.

FIG. 63 presents images showing that sd-rxRNA accumulates inside cells while other less effective conjugate RNAs accumulate on the surface of cells.

FIG. 64 presents images showing that sd-rxRNA molecules, but not other molecules, are internalized into cells within minutes.

FIG. 65 presents images demonstrating that sd-rxRNA compounds have drastically better cellular and tissue uptake characteristics when compared to conventional cholesterol conjugated siRNAs (such as those published by Soucheck et al). FIG. 65A,B compare uptake in RPE cells, FIG. 65C,D compare uptake upon local administration to skin and FIG. 65E,F compare uptake by the liver upon systemic administration. The level of uptake is at least an order of magnitude higher for the sd-rxRNA compounds relative to the regular siRNA-cholesterol compounds.

FIG. 66 presents images depicting localization of rxRNA^ori and sd-rxRNA following local delivery.

FIG. 67 presents images depicting localization of sd-rxRNA and other conjugate RNAs following local delivery.

FIG. 68 presents a graph revealing the results of a screen performed with sd-rxRNAGII chemistry to identify functional compounds targeting the SPP1 gene. Multiple effective compounds were identified, with 14131 being the most effective. The compounds were added to A-549 cells and the level of the ratio of SPP1/PPIB was determined by B-DNA after 48 hours.

FIG. 69 presents a graph and several images demonstrating efficient cellular uptake of sd-rxRNA within minutes of exposure. This is a unique characteristics of the sd-rxRNA compounds described herein, not observed with any other RNAi compounds. The Soutschek et al. compound was used as a negative control.

FIG. 70 presents a graph and several images demonstrating efficient uptake and silencing of sd-rxRNA compounds in multiple cell types with multiple sequences. In each case silencing was confirmed by looking at target gene expression using a Branched DNA assay.

FIG. 71 presents a graph revealing that sd-rxRNA is active in the presence and absence of serum. A slight reduction in efficacy (2-5 fold) was observed in the presence of serum. This minimal reduction in efficacy in the presence of serum differentiates the sd-rxRNA compounds described herein from previously described RNAi compounds, which had a greater reduction in efficacy, and thus creates a foundation for in vivo efficacy of the sd-rxRNA molecules described herein.

FIG. 72 presents images demonstrating efficient tissue penetration and cellular uptake upon single intradermal injection of sd-rxRNA compounds described herein. This represents a model for local delivery of sd-rxRNA compounds as well as an effective demonstration of delivery of sd-rxRNA compounds and silencing of genes in dermatological applications.

FIG. 73 presents images and a graph demonstrating efficient cellular uptake and in vivo silencing with sd-rxRNA following intradermal injection.

FIG. 74 presents graphs demonstrating that sd-rxRNA compounds have improved blood clearance and induce effective gene silencing in vivo in the liver upon systemic administration.

FIG. 75 presents a graph demonstrating that the presence of 5-Methyl C in an RNAi compound resulted in an increase in potency of lipid mediated transfection, demonstrating that hydrophobic modification of Cs and Us in the content of RNAi compounds can be beneficial. In some embodiments, these types of modifications can be used in the context of 2′ ribose modified bases to insure optimal stability and efficacy.

FIG. 76 presents a graph showing percent MAP4K4 expression in HeLa cells following passive uptake transfection of: Guide strand alone; Nano Lead; Nano Lead (No cholesterol); Guide Strand w/5MeC and 2′F Us Alone; Nano Lead w/GS SMeC and 2′F Us; Nano Lead w/GS riboT and 5 Methyl Cs; and Nano Lead w/Guide dT and 5 Methyl Cs.

FIG. 77 presents images comparing localization of sd-rxRNA and other RNA conjugates following systemic delivery to the liver.

FIG. 78 presents schematics demonstrating 5-uridyl modifications with improved hydrophobicity characteristics. Incorporation of such modifications into sd-rxRNA compounds can increase cellular and tissue uptake properties. FIG. 78B presents a new type of RNAi compound modification which can be applied to compounds to improve cellular uptake and pharmacokinetic behavior. This type of modification, when applied to sd-rxRNA compounds, may contribute to making such compounds orally available.

FIG. 79 presents schematics revealing the structures of synthesized modified sterol type molecules, where the length and structure of the C17 attached tail is modified. Without wishing to be bound by any theory, the length of the C17 attached tail may contribute to improving in vitro and in vivo efficacy of sd-rxRNA compounds.

FIG. 80 presents a schematic demonstrating the lithocholic acid route to long side chain cholesterols.

FIG. 81 presents a schematic demonstrating a route to 5-uridyl phosphoramidite synthesis.

FIG. 82 presents a schematic demonstrating synthesis of tri-functional hydroxyprolinol linker for 3′-cholesterol attachment.

FIG. 83 presents a schematic demonstrating synthesis of solid support for the manufacture of a shorter asymmetric RNAi compound strand.

FIG. 84 demonstrates SPPI sd-rxRNA compound selection. Sd-rxRNA compounds targeting SPP1 were added to A549 cells (using passive transfection) and the level of SPP1 expression was evaluated after 48 hours. Several novel compounds effective in SPP1 silencing were identified, the most potent of which was compound 14131.

FIG. 85 demonstrates independent validation of sd-rxRNA compounds 14116, 14121, 14131, 14134, 14139, 14149, and 14152 efficacy in SPP1 silencing.

FIG. 86 demonstrates results of sd-rxRNA compound screens to identify sd-rxRNA compounds functional in CTGF knockdown.

FIG. 87 demonstrates results of sd-rxRNA compound screens to identify sd-rxRNA functional in CTGF knockdown.

FIG. 88 demonstrates a systematic screen identifying the minimal length of the asymmetric compounds. The passenger strand of 10-19 bases was hybridized to a guide strand of 17-25 bases. In this assay, compounds with duplex regions as short as 10 bases were found to be effective in inducing.

FIG. 89 demonstrates that positioning of the sense strand relative to the guide strand is critical for RNAi Activity. In this assay, a blunt end was found to be optimal, a 3′ overhang was tolerated, and a 5′ overhang resulted in complete loss of functionality.

FIG. 90 demonstrates that the guide strand, which has homology to the target only at nucleotides 2-17, resulted in effective RNAi when hybridized with sense strands of different lengths. The compounds were introduced into HeLa cells via lipid mediated transfection.

FIG. 91 is a schematic depicting a panel of sterol-type molecules which can be used as a hydrophobic entity in place of cholesterol. In some instances, the use of sterol-type molecules comprising longer chains results in generation of sd-rxRNA compounds with significantly better cellular uptake and tissue distribution properties.

FIG. 92 presents schematics depicting a panel of hydrophobic molecules which might be used as a hydrophobic entity in place of cholesterol. These list just provides representative examples; any small molecule with substantial hydrophobicity can be used.

DETAILED DESCRIPTION

Aspects of the invention relate to methods and compositions involved in gene silencing. The invention is based at least in part on the surprising discovery that asymmetric nucleic acid molecules with a double stranded region of a minimal length such as 8-14 nucleotides, are effective in silencing gene expression. Molecules with such a short double stranded region have not previously been demonstrated to be effective in mediating RNA interference. It had previously been assumed that that there must be a double stranded region of 19 nucleotides or greater. The molecules described herein are optimized through chemical modification, and in some instances through attachment of hydrophobic conjugates.

The invention is based at least in part on another surprising discovery that asymmetric nucleic acid molecules with reduced double stranded regions are much more effectively taken up by cells compared to conventional siRNAs. These molecules are highly efficient in silencing of target gene expression and offer significant advantages over previously described RNAi molecules including high activity in the presence of serum, efficient self delivery, compatibility with a wide variety of linkers, and reduced presence or complete absence of chemical modifications that are associated with toxicity.

In contrast to single-stranded polynucleotides, duplex polynucleotides have been difficult to deliver to a cell as they have rigid structures and a large number of negative charges which makes membrane transfer difficult. Unexpectedly, it was found that the polynucleotides of the present invention, although partially double-stranded, are recognized in vivo as single-stranded and, as such, are capable of efficiently being delivered across cell membranes. As a result the polynucleotides of the invention are capable in many instances of self delivery. Thus, the polynucleotides of the invention may be formulated in a manner similar to conventional RNAi agents or they may be delivered to the cell or subject alone (or with non-delivery type carriers) and allowed to self deliver. In one embodiment of the present invention, self delivering asymmetric double-stranded RNA molecules are provided in which one portion of the molecule resembles a conventional RNA duplex and a second portion of the molecule is single stranded.

The polynucleotides of the invention are referred to herein as isolated double stranded or duplex nucleic acids, oligonucleotides or polynucleotides, nano molecules, nano RNA, sd-rxRNA^nano, sd-rxRNA or RNA molecules of the invention.

The oligonucleotides of the invention in some aspects have a combination of asymmetric structures including a double stranded region and a single stranded region of 5 nucleotides or longer, specific chemical modification patterns and are conjugated to lipophilic or hydrophobic molecules. This new class of RNAi like compounds have superior efficacy in vitro and in vivo. Based on the data described herein it is believed that the reduction in the size of the rigid duplex region in combination with phosphorothioate modifications applied to a single stranded region are new and important for achieving the observed superior efficacy. Thus, the RNA molecules described herein are different in both structure and composition as well as in vitro and in vivo activity.

In a preferred embodiment the RNAi compounds of the invention comprise an asymmetric compound comprising a duplex region (required for efficient RISC entry of 10-15 bases long) and single stranded region of 4-12 nucleotides long; with a 13 nucleotide duplex. A 6 nucleotide single stranded region is preferred in some embodiments. The single stranded region of the new RNAi compounds also comprises 2-12 phosphorothioate internucleotide linkages (referred to as phosphorothioate modifications). 6-8 phosphorothioate internucleotide linkages are preferred in some embodiments. Additionally, the RNAi compounds of the invention also include a unique chemical modification pattern, which provides stability and is compatible with RISC entry. The combination of these elements has resulted in unexpected properties which are highly useful for delivery of RNAi reagents in vitro and in vivo.

The chemically modification pattern, which provides stability and is compatible with RISC entry includes modifications to the sense, or passenger, strand as well as the antisense, or guide, strand. For instance the passenger strand can be modified with any chemical entities which confirm stability and do not interfere with activity. Such modifications include 2′ ribo modifications (O-methyl, 2′ F, 2 deoxy and others) and backbone modification like phosphorothioate modifications. A preferred chemical modification pattern in the passenger strand includes Omethyl modification of C and U nucleotides within the passenger strand or alternatively the passenger strand may be completely Omethyl modified.

The guide strand, for example, may also be modified by any chemical modification which confirms stability without interfering with RISC entry. A preferred chemical modification pattern in the guide strand includes the majority of C and U nucleotides being 2′ F modified and the 5′ end being phosphorylated. Another preferred chemical modification pattern in the guide strand includes 2′Omethyl modification of position 1 and C/U in positions 11-18 and 5′ end chemical phosphorylation. Yet another preferred chemical modification pattern in the guide strand includes 2′Omethyl modification of position 1 and C/U in positions 11-18 and 5′ end chemical phosphorylation and 2′F modification of C/U in positions 2-10.

It was surprisingly discovered according to the invention that the above-described chemical modification patterns of the oligonucleotides of the invention are well tolerated and actually improved efficacy of asymmetric RNAi compounds. See, for instance, FIG. 22.

It was also demonstrated experimentally herein that the combination of modifications to RNAi when used together in a polynucleotide results in the achievement of optimal efficacy in passive uptake of the RNAi. Elimination of any of the described components (Guide strand stabilization, phosphorothioate stretch, sense strand stabilization and hydrophobic conjugate) or increase in size results in sub-optimal efficacy and in some instances complete lost of efficacy. The combination of elements results in development of compound, which is fully active following passive delivery to cells such as HeLa cells. (FIG. 23). The degree to which the combination of elements results in efficient self delivery of RNAi molecules was completely unexpected.

The data shown in FIGS. 26, 27 and 43 demonstrated the importance of the various modifications to the RNAi in achieving stabilization and activity. For instance, FIG. 26 demonstrates that use off asymmetric configuration is important in getting efficacy in passive uptake. When the same chemical composition is applied to compounds of traditional configurations (19-21 bases duplex and 25 mer duplex) the efficacy was drastically decreased in a length dependent manner. FIG. 27 demonstrated a systematic screen of the impact of phosphorothioate chemical modifications on activity. The sequence, structure, stabilization chemical modifications, hydrophobic conjugate were kept constant and compound phosphorothioate content was varied (from 0 to 18 PS bond). Both compounds having no phosphorothioate linkages and having 18 phosphorothioate linkages were completely inactive in passive uptake. Compounds having 2-16 phosphorothioate linkages were active, with compounds having 4-10 phosphorothioate being the most active compounds.

The data in the Examples presented below demonstrates high efficacy of the oligonucleotides of the invention both in vitro in variety of cell types (supporting data) and in vivo upon local and systemic administration. For instance, the data compares the ability of several competitive RNAi molecules having different chemistries to silence a gene. Comparison of sd-rxRNA (oligonucleotides of the invention) with RNAs described in Soucheck et al. and Wolfrum at al., as applied to the same targeting region, demonstrated that only sd-rxRNA chemistry showed a significant functionality in passive uptake. The composition of the invention achieved EC50 values of 10-50 pM. This level of efficacy is un-attainable with conventional chemistries like those described in Sauthceck at al and Accell. Similar comparisons were made in other systems, such as in vitro (RPE cell line), in vivo upon local administration (wounded skin) and systemic (50 mg/kg) as well as other genes (FIGS. 65 and 68). In each case the oligonucleotides of the invention achieved better results. FIG. 64 includes data demonstrating efficient cellular uptake and resulting silencing by sd-rxRNA compounds only after 1 minute of exposure. Such an efficacy is unique to this composition and have not been seen with other types of molecules in this class. FIG. 70 demonstrates efficient uptake and silencing of sd-rxRNA compounds in multiple cell types with multiple sequences. The sd-rxRNA compounds are also active in cells in presence and absence of serum and other biological liquids. FIG. 71 demonstrates only a slight reduction in activity in the presence of serum. This ability to function in biologically aggressive environment effectively further differentiates sd-rxRNA compounds from other compounds described previously in this group, like Accell and Soucheck et al, in which uptake is drastically inhibited in a presence of serum.

Significant amounts of data also demonstrate the in vivo efficacy of the compounds of the invention. For instance FIGS. 72-74 involve multiple routes of in vivo delivery of the compounds of the invention resulting in significant activity. FIG. 72, for example, demonstrates efficient tissue penetration and cellular uptake upon single intradermal injection. This is a model for local delivery of sd-rxRNA compounds as well as an effective delivery mode for sd-rxRNA compounds and silencing genes in any dermatology applications. FIG. 73 demonstrated efficient tissue penetration, cellular uptake and silencing upon local in vivo intradermal injection of sd-rxRNA compounds. The data of FIG. 74 demonstrate that sd-rxRNA compounds result in highly effective liver uptake upon IV administration. Comparison to Souicheck at al molecule showed that the level of liver uptake at identical dose level was quite surprisingly, at least 50 fold higher with the sd-rxRNA compound than the Souicheck at al molecule.

The sd-rxRNA can be further improved in some instances by improving the hydrophobicity of compounds using of novel types of chemistries. For example one chemistry is related to use of hydrophobic base modifications. Any base in any position might be modified, as long as modification results in an increase of the partition coefficient of the base. The preferred locations for modification chemistries are positions 4 and 5 of the pyrimidines. The major advantage of these positions is (a) ease of synthesis and (b) lack of interference with base-pairing and A form helix formation, which are essential for RISC complex loading and target recognition. Examples of these chemistries is shown in FIGS. 75-83. A version of sd-rxRNA compounds where multiple deoxy Uridines are present without interfering with overall compound efficacy was used. In addition major improvement in tissue distribution and cellular uptake might be obtained by optimizing the structure of the hydrophobic conjugate. In some of the preferred embodiment the structure of sterol is modified to alter (increase/decrease) C17 attached chain. This type of modification results in significant increase in cellular uptake and improvement of tissue uptake prosperities in vivo.

This invention is not limited in its application to the details of construction and the arrangement of components set forth in the following description or illustrated in the drawings. The invention is capable of other embodiments and of being practiced or of being carried out in various ways. Also, the phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting. The use of “including,” “comprising,” or “having,” “containing,” “involving,” and variations thereof herein, is meant to encompass the items listed thereafter and equivalents thereof as well as additional items.

Thus, aspects of the invention relate to isolated double stranded nucleic acid molecules comprising a guide (antisense) strand and a passenger (sense) strand. As used herein, the term “double-stranded” refers to one or more nucleic acid molecules in which at least a portion of the nucleomonomers are complementary and hydrogen bond to form a double-stranded region. In some embodiments, the length of the guide strand ranges from 16-29 nucleotides long. In certain embodiments, the guide strand is 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29 nucleotides long. The guide strand has complementarity to a target gene. Complementarity between the guide strand and the target gene may exist over any portion of the guide strand. Complementarity as used herein may be perfect complementarity or less than perfect complementarity as long as the guide strand is sufficiently complementary to the target that it mediates RNAi. In some embodiments complementarity refers to less than 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, or 1% mismatch between the guide strand and the target. Perfect complementarity refers to 100% complementarity. Thus the invention has the advantage of being able to tolerate sequence variations that might be expected due to genetic mutation, strain polymorphism, or evolutionary divergence. For example, siRNA sequences with insertions, deletions, and single point mutations relative to the target sequence have also been found to be effective for inhibition. Moreover, not all positions of a siRNA contribute equally to target recognition. Mismatches in the center of the siRNA are most critical and essentially abolish target RNA cleavage. Mismatches upstream of the center or upstream of the cleavage site referencing the antisense strand are tolerated but significantly reduce target RNA cleavage. Mismatches downstream of the center or cleavage site referencing the antisense strand, preferably located near the 3′ end of the antisense strand, e.g. 1, 2, 3, 4, 5 or 6 nucleotides from the 3′ end of the antisense strand, are tolerated and reduce target RNA cleavage only slightly.

While not wishing to be bound by any particular theory, in some embodiments, the guide strand is at least 16 nucleotides in length and anchors the Argonaute protein in RISC. In some embodiments, when the guide strand loads into RISC it has a defined seed region and target mRNA cleavage takes place across from position 10-11 of the guide strand. In some embodiments, the 5′ end of the guide strand is or is able to be phosphorylated. The nucleic acid molecules described herein may be referred to as minimum trigger RNA.

In some embodiments, the length of the passenger strand ranges from 8-14 nucleotides long. In certain embodiments, the passenger strand is 8, 9, 10, 11, 12, 13 or 14 nucleotides long. The passenger strand has complementarity to the guide strand. Complementarity between the passenger strand and the guide strand can exist over any portion of the passenger or guide strand. In some embodiments, there is 100% complementarity between the guide and passenger strands within the double stranded region of the molecule.

Aspects of the invention relate to double stranded nucleic acid molecules with minimal double stranded regions. In some embodiments the region of the molecule that is double stranded ranges from 8-14 nucleotides long. In certain embodiments, the region of the molecule that is double stranded is 8, 9, 10, 11, 12, 13 or 14 nucleotides long. In certain embodiments the double stranded region is 13 nucleotides long. There can be 100% complementarity between the guide and passenger strands, or there may be one or more mismatches between the guide and passenger strands. In some embodiments, on one end of the double stranded molecule, the molecule is either blunt-ended or has a one-nucleotide overhang. The single stranded region of the molecule is in some embodiments between 4-12 nucleotides long. For example the single stranded region can be 4, 5, 6, 7, 8, 9, 10, 11 or 12 nucleotides long. However, in certain embodiments, the single stranded region can also be less than 4 or greater than 12 nucleotides long. In certain embodiments, the single stranded region is 6 nucleotides long.

RNAi constructs associated with the invention can have a thermodynamic stability (ΔG) of less than −13 kkal/mol. In some embodiments, the thermodynamic stability (ΔG) is less than −20 kkal/mol. In some embodiments there is a loss of efficacy when (ΔG) goes below −21 kkal/mol. In some embodiments a (ΔG) value higher than −13 kkal/mol is compatible with aspects of the invention. Without wishing to be bound by any theory, in some embodiments a molecule with a relatively higher (ΔG) value may become active at a relatively higher concentration, while a molecule with a relatively lower (ΔG) value may become active at a relatively lower concentration. In some embodiments, the (ΔG) value may be higher than −9 kkcal/mol. The gene silencing effects mediated by the RNAi constructs associated with the invention, containing minimal double stranded regions, are unexpected because molecules of almost identical design but lower thermodynamic stability have been demonstrated to be inactive (Rana et al. 2004).

Without wishing to be bound by any theory, results described herein suggest that a stretch of 8-10 bp of dsRNA or dsDNA will be structurally recognized by protein components of RISC or co-factors of RISC. Additionally, there is a free energy requirement for the triggering compound that it may be either sensed by the protein components and/or stable enough to interact with such components so that it may be loaded into the Argonaute protein. If optimal thermodynamics are present and there is a double stranded portion that is preferably at least 8 nucleotides then the duplex will be recognized and loaded into the RNAi machinery.

In some embodiments, thermodynamic stability is increased through the use of LNA bases. In some embodiments, additional chemical modifications are introduced. Several non-limiting examples of chemical modifications include: 5′ Phosphate, 2′-O-methyl, 2′-O-ethyl, 2′-fluoro, ribothymidine, C-5 propynyl-dC (pdC) and C-5 propynyl-dU (pdU); C-5 propynyl-C (pC) and C-5 propynyl-U (pU); 5-methyl C, 5-methyl U, 5-methyl dC, 5-methyl dU methoxy, (2,6-diaminopurine), 5′-Dimethoxytrityl-N4-ethyl-2′-deoxyCytidine and MGB (minor groove binder). It should be appreciated that more than one chemical modification can be combined within the same molecule.

Molecules associated with the invention are optimized for increased potency and/or reduced toxicity. For example, nucleotide length of the guide and/or passenger strand, and/or the number of phosphorothioate modifications in the guide and/or passenger strand, can in some aspects influence potency of the RNA molecule, while replacing 2′-fluoro (2′F) modifications with 2′-O-methyl (2′OMe) modifications can in some aspects influence toxicity of the molecule. Specifically, reduction in 2′F content of a molecule is predicted to reduce toxicity of the molecule. The Examples section presents molecules in which 2′F modifications have been eliminated, offering an advantage over previously described RNAi compounds due to a predicted reduction in toxicity. Furthermore, the number of phosphorothioate modifications in an RNA molecule can influence the uptake of the molecule into a cell, for example the efficiency of passive uptake of the molecule into a cell. Preferred embodiments of molecules described herein have no 2′F modification and yet are characterized by equal efficacy in cellular uptake and tissue penetration. Such molecules represent a significant improvement over prior art, such as molecules described by Accell and Wolfrum, which are heavily modified with extensive use of 2′F.

In some embodiments, a guide strand is approximately 18-19 nucleotides in length and has approximately 2-14 phosphate modifications. For example, a guide strand can contain 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or more than 14 nucleotides that are phosphate-modified. The guide strand may contain one or more modifications that confer increased stability without interfering with RISC entry. The phosphate modified nucleotides, such as phosphorothioate modified nucleotides, can be at the 3′ end, 5′ end or spread throughout the guide strand. In some embodiments, the 3′ terminal 10 nucleotides of the guide strand contains 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 phosphorothioate modified nucleotides. The guide strand can also contain 2′F and/or 2′OMe modifications, which can be located throughout the molecule. In some embodiments, the nucleotide in position one of the guide strand (the nucleotide in the most 5′ position of the guide strand) is 2′OMe modified and/or phosphorylated. C and U nucleotides within the guide strand can be 2′F modified. For example, C and U nucleotides in positions 2-10 of a 19 nt guide strand (or corresponding positions in a guide strand of a different length) can be 2′F modified. C and U nucleotides within the guide strand can also be 2′OMe modified. For example, C and U nucleotides in positions 11-18 of a 19 nt guide strand (or corresponding positions in a guide strand of a different length) can be 2′OMe modified. In some embodiments, the nucleotide at the most 3′ end of the guide strand is to unmodified. In certain embodiments, the majority of Cs and Us within the guide strand are 2′F modified and the 5′ end of the guide strand is phosphorylated. In other embodiments, position 1 and the Cs or Us in positions 11-18 are 2′OMe modified and the 5′ end of the guide strand is phosphorylated. In other embodiments, position 1 and the Cs or Us in positions 11-18 are 2′OMe modified, the 5′ end of the guide strand is phosphorylated, and the Cs or Us in position 2-10 are 2′F modified.

In some aspects, an optimal passenger strand is approximately 11-14 nucleotides in length. The passenger strand may contain modifications that confer increased stability. One or more nucleotides in the passenger strand can be 2′OMe modified. In some embodiments, one or more of the C and/or U nucleotides in the passenger strand is 2′OMe modified, or all of the C and U nucleotides in the passenger strand are 2′OMe modified. In certain embodiments, all of the nucleotides in the passenger strand are 2′OMe modified. One or more of the nucleotides on the passenger strand can also be phosphate-modified such as phosphorothioate modified. The passenger strand can also contain 2′ ribo, 2′F and 2 deoxy modifications or any combination of the above. As demonstrated in the Examples, chemical modification patterns on both the guide and passenger strand are well tolerated and a combination of chemical modifications is shown herein to lead to increased efficacy and self-delivery of RNA molecules.

Aspects of the invention relate to RNAi constructs that have extended single-stranded regions relative to double stranded regions, as compared to molecules that have been used previously for RNAi. The single stranded region of the molecules may be modified to promote cellular uptake or gene silencing. In some embodiments, phosphorothioate modification of the single stranded region influences cellular uptake and/or gene silencing. The region of the guide strand that is phosphorothioate modified can include nucleotides within both the single stranded and double stranded regions of the molecule. In some embodiments, the single stranded region includes 2-12 phosphorothioate modifications. For example, the single stranded region can include 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 phosphorothioate modifications. In some instances, the single stranded region contains 6-8 phosphorothioate modifications.

Molecules associated with the invention are also optimized for cellular uptake. In RNA molecules described herein, the guide and/or passenger strands can be attached to a conjugate. In certain embodiments the conjugate is hydrophobic. The hydrophobic conjugate can be a small molecule with a partition coefficient that is higher than 10. The conjugate can be a sterol-type molecule such as cholesterol, or a molecule with an increased length polycarbon chain attached to C17, and the presence of a conjugate can influence the ability of an RNA molecule to be taken into a cell with or without a lipid transfection reagent. The conjugate can be attached to the passenger or guide strand through a hydrophobic linker. In some embodiments, a hydrophobic linker is 5-12C in length, and/or is hydroxypyrrolidine-based. In some embodiments, a hydrophobic conjugate is attached to the passenger strand and the CU residues of either the passenger and/or guide strand are modified. In some embodiments, at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% of the CU residues on the passenger strand and/or the guide strand are modified. In some aspects, molecules associated with the invention are self-delivering (sd). As used herein, “self-delivery” refers to the ability of a molecule to be delivered into a cell without the need for an additional delivery vehicle such as a transfection reagent.

Aspects of the invention relate to selecting molecules for use in RNAi. Based on the data described herein, molecules that have a double stranded region of 8-14 nucleotides can be selected for use in RNAi. In some embodiments, molecules are selected based on their thermodynamic stability (ΔG). In some embodiments, molecules will be selected that have a (ΔG) of less than −13 kkal/mol. For example, the (ΔG) value may be −13, −14, −15, −16, −17, −18, −19, −21, −22 or less than −22 kkal/mol. In other embodiments, the (ΔG) value may be higher than −13 kkal/mol. For example, the (ΔG) value may be −12, −11, −10, −9, −8, −7 or more than −7 kkal/mol. It should be appreciated that ΔG can be calculated using any method known in the art. In some embodiments ΔG is calculated using Mfold, available through the Mfold internet site (http://mfold.bioinfo.rpi.edu/cai-bin/rna-form1.cgi). Methods for calculating ΔG are described in, and are incorporated by reference from, the following references: Zuker, M. (2003) Nucleic Acids Res., 31(13):3406-15; Mathews, D. H., Sabina, J., Zuker, M. and Turner, D. H. (1999) J. Mol. Biol. 288:911-940; Mathews, D. H., Disney, M. D., Childs, J. L., Schroeder, S. J., Zuker, M., and Turner, D. H. (2004) Proc. Natl. Acad. Sci. 101:7287-7292; Duan, S., Mathews, D. H., and Turner, D. H. (2006) Biochemistry 45:9819-9832; Wuchty, S., Fontana, W., Hofacker, 1. L., and Schuster, P. (1999) Biopolymers 49:145-165.

Aspects of the invention relate to using nucleic acid molecules described herein, with minimal double stranded regions and/or with a (ΔG) of less than −13 kkal/mol, for gene silencing. RNAi molecules can be administered in vivo or in vitro, and gene silencing effects can be achieved in vivo or in vitro.

In certain embodiments, the polynucleotide contains 5′- and/or 3′-end overhangs. The number and/or sequence of nucleotides overhang on one end of the polynucleotide may be the same or different from the other end of the polynucleotide. In certain embodiments, one or more of the overhang nucleotides may contain chemical modification(s), such as phosphorothioate or 2′-OMe modification.

In certain embodiments, the polynucleotide is unmodified. In other embodiments, at least one nucleotide is modified. In further embodiments, the modification includes a 2′-H or 2′-modified ribose sugar at the 2nd nucleotide from the 5′-end of the guide sequence. The “2nd nucleotide” is defined as the second nucleotide from the 5′-end of the polynucleotide.

As used herein, “2′-modified ribose sugar” includes those ribose sugars that do not have a 2′-OH group. “2′-modified ribose sugar” does not include 2′-deoxyribose (found in unmodified canonical DNA nucleotides). For example, the 2′-modified ribose sugar may be 2′-O-alkyl nucleotides, 2′-deoxy-2′-fluoro nucleotides, 2′-deoxy nucleotides, or combination thereof.

In certain embodiments, the 2′-modified nucleotides are pyrimidine nucleotides (e.g., C/U). Examples of 2′-O-alkyl nucleotides include 2′-O-methyl nucleotides, or 2′-O-allyl nucleotides.

In certain embodiments, the miniRNA polynucleotide of the invention with the above-referenced 5′-end modification exhibits significantly (e.g., at least about 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or more) less “off-target” gene silencing when compared to similar constructs without the specified 5′-end modification, thus greatly improving the overall specificity of the RNAi reagent or therapeutics.

As used herein, “off-target” gene silencing refers to unintended gene silencing due to, for example, spurious sequence homology between the antisense (guide) sequence and the unintended target mRNA sequence.

According to this aspect of the invention, certain guide strand modifications further increase nuclease stability, and/or lower interferon induction, without significantly decreasing RNAi activity (or no decrease in RNAi activity at all).

In some embodiments, wherein the RNAi construct involves a hairpin, the 5′-stem sequence may comprise a 2′-modified ribose sugar, such as 2′-O-methyl modified nucleotide, at the 2^nd nucleotide on the 5′-end of the polynucleotide and, in some embodiments, no other modified nucleotides. The hairpin structure having such modification may have enhanced target specificity or reduced off-target silencing compared to a similar construct without the 2′-O-methyl modification at said position.

Certain combinations of specific 5′-stem sequence and 3′-stem sequence modifications may result in further unexpected advantages, as partly manifested by enhanced ability to inhibit target gene expression, enhanced serum stability, and/or increased target specificity, etc.

In certain embodiments, the guide strand comprises a 2′-O-methyl modified nucleotide at the 2^nd nucleotide on the 5′-end of the guide strand and no other modified nucleotides.

In other aspects, the miniRNA structures of the present invention mediates sequence-dependent gene silencing by a microRNA mechanism. As used herein, the term “microRNA” (“miRNA”), also referred to in the art as “small temporal RNAs” (“stRNAs”), refers to a small (10-50 nucleotide) RNA which are genetically encoded (e.g., by viral, mammalian, or plant genomes) and are capable of directing or mediating RNA silencing. An “miRNA disorder” shall refer to a disease or disorder characterized by an aberrant expression or activity of an miRNA.

microRNAs are involved in down-regulating target genes in critical pathways, such as development and cancer, in mice, worms and mammals. Gene silencing through a microRNA mechanism is achieved by specific yet imperfect base-pairing of the miRNA and its target messenger RNA (mRNA). Various mechanisms may be used in microRNA-mediated down-regulation of target mRNA expression.

miRNAs are noncoding RNAs of approximately 22 nucleotides which can regulate gene expression at the post transcriptional or translational level during plant and animal development. One common feature of miRNAs is that they are all excised from an approximately 70 nucleotide precursor RNA stem-loop termed pre-miRNA, probably by Dicer, an RNase III-type enzyme, or a homolog thereof. Naturally-occurring miRNAs are expressed by endogenous genes in vivo and are processed from a hairpin or stem-loop precursor (pre-miRNA or pri-miRNAs) by Dicer or other RNAses. miRNAs can exist transiently in vivo as a double-stranded duplex but only one strand is taken up by the RISC complex to direct gene silencing.

In some embodiments a version of sd-rxRNA compounds, which are effective in cellular uptake and inhibiting of miRNA activity are described. Essentially the compounds are similar to RISC entering version but large strand chemical modification patterns are optimized in the way to block cleavage and act as an effective inhibitor of the RISC action. For example, the compound might be completely or mostly Omethyl modified with the PS content described previously. For these types of compounds the 5′ phosphorilation is not necessary. The presence of double stranded region is preferred as it is promotes cellular uptake and efficient RISC loading.

Another pathway that uses small RNAs as sequence-specific regulators is the RNA interference (RNAi) pathway, which is an evolutionarily conserved response to the presence of double-stranded RNA (dsRNA) in the cell. The dsRNAs are cleaved into ˜20-base pair (bp) duplexes of small-interfering RNAs (siRNAs) by Dicer. These small RNAs get assembled into multiprotein effector complexes called RNA-induced silencing complexes (RISCs). The siRNAs then guide the cleavage of target mRNAs with perfect complementarity.

Some aspects of biogenesis, protein complexes, and function are shared between the siRNA pathway and the miRNA pathway. The subject single-stranded polynucleotides may mimic the dsRNA in the siRNA mechanism, or the microRNA in the miRNA mechanism.

In certain embodiments, the modified RNAi constructs may have improved stability in serum and/or cerebral spinal fluid compared to an unmodified RNAi constructs having the same sequence.

In certain embodiments, the structure of the RNAi construct does not induce interferon response in primary cells, such as mammalian primary cells, including primary cells from human, mouse and other rodents, and other non-human mammals. In certain embodiments, the RNAi construct may also be used to inhibit expression of a target gene in an invertebrate organism.

To further increase the stability of the subject constructs in vivo, the 3′-end of the hairpin structure may be blocked by protective group(s). For example, protective groups such as inverted nucleotides, inverted abasic moieties, or amino-end modified nucleotides may be used. Inverted nucleotides may comprise an inverted deoxynucleotide. Inverted abasic moieties may comprise an inverted deoxyabasic moiety, such as a 3′,3′-linked or 5′,5′-linked deoxyabasic moiety.

The RNAi constructs of the invention are capable of inhibiting the synthesis of any target protein encoded by target gene(s). The invention includes methods to inhibit expression of a target gene either in a cell in vitro, or in vivo. As such, the RNAi constructs of the invention are useful for treating a patient with a disease characterized by the overexpression of a target gene.

The target gene can be endogenous or exogenous (e.g., introduced into a cell by a virus or using recombinant DNA technology) to a cell. Such methods may include introduction of RNA into a cell in an amount sufficient to inhibit expression of the target gene. By way of example, such an RNA molecule may have a guide strand that is complementary to the nucleotide sequence of the target gene, such that the composition inhibits expression of the target gene.

The invention also relates to vectors expressing the subject hairpin constructs, and cells comprising such vectors or the subject hairpin constructs. The cell may be a mammalian cell in vivo or in culture, such as a human cell.

The invention further relates to compositions comprising the subject RNAi constructs, and a pharmaceutically acceptable carrier or diluent.

Another aspect of the invention provides a method for inhibiting the expression of a target gene in a mammalian cell, comprising contacting the mammalian cell with any of the subject RNAi constructs.

The method may be carried out in vitro, ex vivo, or in vivo, in, for example, mammalian cells in culture, such as a human cell in culture.

The target cells (e.g., mammalian cell) may be contacted in the presence of a delivery reagent, such as a lipid (e.g., a cationic lipid) or a liposome.

Another aspect of the invention provides a method for inhibiting the expression of a target gene in a mammalian cell, comprising contacting the mammalian cell with a vector expressing the subject RNAi constructs.

In one aspect of the invention, a longer duplex polynucleotide is provided, including a first polynucleotide that ranges in size from about 16 to about 30 nucleotides; a second polynucleotide that ranges in size from about 26 to about 46 nucleotides, wherein the first polynucleotide (the antisense strand) is complementary to both the second polynucleotide (the sense strand) and a target gene, and wherein both polynucleotides form a duplex and wherein the first polynucleotide contains a single stranded region longer than 6 bases in length and is modified with alternative chemical modification pattern, and/or includes a conjugate moiety that facilitates cellular delivery. In this embodiment, between about 40% to about 90% of the nucleotides of the passenger strand between about 40% to about 90% of the nucleotides of the guide strand, and between about 40% to about 90% of the nucleotides of the single stranded region of the first polynucleotide are chemically modified nucleotides.

In an embodiment, the chemically modified nucleotide in the polynucleotide duplex may be any chemically modified nucleotide known in the art, such as those discussed in detail above. In a particular embodiment, the chemically modified nucleotide is selected from the group consisting of 2′ F modified nucleotides, 2′-O-methyl modified and 2′deoxy nucleotides. In another particular embodiment, the chemically modified nucleotides results from “hydrophobic modifications” of the nucleotide base. In another particular embodiment, the chemically modified nucleotides are phosphorothioates. In an additional particular embodiment, chemically modified nucleotides are combination of phosphorothioates, 2′-O-methyl, 2′deoxy, hydrophobic modifications and phosphorothioates. As these groups of modifications refer to modification of the ribose ring, back bone and nucleotide, it is feasible that some modified nucleotides will carry a combination of all three modification types.

In another embodiment, the chemical modification is not the same across the various regions of the duplex. In a particular embodiment, the first polynucleotide (the passenger strand), has a large number of diverse chemical modifications in various positions. For this polynucleotide up to 90% of nucleotides might be chemically modified and/or have mismatches introduced. In another embodiment, chemical modifications of the first or second polynucleotide include, but not limited to, 5′ position modification of Uridine and Cytosine (4-pyridyl, 2-pyridyl, indolyl, phenyl (C₆H₅OH); tryptophanyl (C8H6N)CH2CH(NH2)CO), isobutyl, butyl, aminobenzyl; phenyl; naphthyl, etc), where the chemical modification might alter base pairing capabilities of a nucleotide. For the guide strand an important feature of this aspect of the invention is the position of the chemical modification relative to the 5′ end of the antisense and sequence. For example, chemical phosphorylation of the 5′ end of the guide strand is usually beneficial for efficacy. O-methyl modifications in the seed region of the sense strand (position 2-7 relative to the 5′ end) are not generally well tolerated, whereas 2′F and deoxy are well tolerated. The mid part of the guide strand and the 3′ end of the guide strand are more permissive in a type of chemical modifications applied. Deoxy modifications are not tolerated at the 3′ end of the guide strand.

A unique feature of this aspect of the invention involves the use of hydrophobic modification on the bases. In one embodiment, the hydrophobic modifications are preferably positioned near the 5′ end of the guide strand, in other embodiments, they localized in the middle of the guides strand, in other embodiment they localized at the 3′ end of the guide strand and yet in another embodiment they are distributed thought the whole length of the polynucleotide. The same type of patterns is applicable to the passenger strand of the duplex.

The other part of the molecule is a single stranded region. The single stranded region is expected to range from 7 to 40 nucleotides.

In one embodiment, the single stranded region of the first polynucleotide contains modifications selected from the group consisting of between 40% and 90% hydrophobic base modifications, between 40%-90% phosphorothioates, between 40%-90% modification of the ribose moiety, and any combination of the preceding.

Efficiency of guide strand (first polynucleotide) loading into the RISC complex might be altered for heavily modified polynucleotides, so in one embodiment, the duplex polynucleotide includes a mismatch between nucleotide 9, 11, 12, 13, or 14 on the guide strand (first polynucleotide) and the opposite nucleotide on the sense strand (second polynucleotide) to promote efficient guide strand loading.

More detailed aspects of the invention are described in the sections below.

Duplex Characteristics

Double-stranded oligonucleotides of the invention may be formed by two separate complementary nucleic acid strands. Duplex formation can occur either inside or outside the cell containing the target gene.

As used herein, the term “duplex” includes the region of the double-stranded nucleic acid molecule(s) that is (are) hydrogen bonded to a complementary sequence. Double-stranded oligonucleotides of the invention may comprise a nucleotide sequence that is sense to a target gene and a complementary sequence that is antisense to the target gene. The sense and antisense nucleotide sequences correspond to the target gene sequence, e.g., are identical or are sufficiently identical to effect target gene inhibition (e.g., are about at least about 98% identical, 96% identical, 94%, 90% identical, 85% identical, or 80% identical) to the target gene sequence.

In certain embodiments, the double-stranded oligonucleotide of the invention is double-stranded over its entire length, i.e., with no overhanging single-stranded sequence at either end of the molecule, i.e., is blunt-ended. In other embodiments, the individual nucleic acid molecules can be of different lengths. In other words, a double-stranded oligonucleotide of the invention is not double-stranded over its entire length. For instance, when two separate nucleic acid molecules are used, one of the molecules, e.g., the first molecule comprising an antisense sequence, can be longer than the second molecule hybridizing thereto (leaving a portion of the molecule single-stranded). Likewise, when a single nucleic acid molecule is used a portion of the molecule at either end can remain single-stranded.

In one embodiment, a double-stranded oligonucleotide of the invention contains mismatches and/or loops or bulges, but is double-stranded over at least about 70% of the length of the oligonucleotide. In another embodiment, a double-stranded oligonucleotide of the invention is double-stranded over at least about 80% of the length of the oligonucleotide. In another embodiment, a double-stranded oligonucleotide of the invention is double-stranded over at least about 90%-95% of the length of the oligonucleotide. In another embodiment, a double-stranded oligonucleotide of the invention is double-stranded over at least about 96%-98% of the length of the oligonucleotide. In certain embodiments, the double-stranded oligonucleotide of the invention contains at least or up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 mismatches.

Modifications

The nucleotides of the invention may be modified at various locations, including the sugar moiety, the phosphodiester linkage, and/or the base.

Sugar moieties include natural, unmodified sugars, e.g., monosaccharide (such as pentose, e.g., ribose, deoxyribose), modified sugars and sugar analogs. In general, possible modifications of nucleomonomers, particularly of a sugar moiety, include, for example, replacement of one or more of the hydroxyl groups with a halogen, a heteroatom, an aliphatic group, or the functionalization of the hydroxyl group as an ether, an amine, a thiol, or the like.

One particularly useful group of modified nucleomonomers are 2′-O-methyl nucleotides. Such 2′-O-methyl nucleotides may be referred to as “methylated,” and the corresponding nucleotides may be made from unmethylated nucleotides followed by alkylation or directly from methylated nucleotide reagents. Modified nucleomonomers may be used in combination with unmodified nucleomonomers. For example, an oligonucleotide of the invention may contain both methylated and unmethylated nucleomonomers.

Some exemplary modified nucleomonomers include sugar- or backbone-modified ribonucleotides. Modified ribonucleotides may contain a non-naturally occurring base (instead of a naturally occurring base), such as uridines or cytidines modified at the 5′-position, e.g., 5′-(2-amino)propyl uridine and 5′-bromo uridine; adenosines and guanosines modified at the 8-position, e.g., 8-bromo guanosine; deaza nucleotides, e.g., 7-deaza-adenosine; and N-alkylated nucleotides, e.g., N6-methyl adenosine. Also, sugar-modified ribonucleotides may have the 2′-OH group replaced by a H, alxoxy (or OR), R or alkyl, halogen, SH, SR, amino (such as NH₂, NHR, NR₂), or CN group, wherein R is lower alkyl, alkenyl, or alkynyl.

Modified ribonucleotides may also have the phosphodiester group connecting to adjacent ribonucleotides replaced by a modified group, e.g., of phosphorothioate group. More generally, the various nucleotide modifications may be combined.

Although the antisense (guide) strand may be substantially identical to at least a portion of the target gene (or genes), at least with respect to the base pairing properties, the sequence need not be perfectly identical to be useful, e.g., to inhibit expression of a target gene's phenotype. Generally, higher homology can be used to compensate for the use of a shorter antisense gene. In some cases, the antisense strand generally will be substantially identical (although in antisense orientation) to the target gene.

The use of 2′-O-methyl modified RNA may also be beneficial in circumstances in which it is desirable to minimize cellular stress responses. RNA having 2′-O-methyl nucleomonomers may not be recognized by cellular machinery that is thought to recognize unmodified RNA. The use of 2′-O-methylated or partially 2′-O-methylated RNA may avoid the interferon response to double-stranded nucleic acids, while maintaining target RNA inhibition. This may be useful, for example, for avoiding the interferon or other cellular stress responses, both in short RNAi (e.g., siRNA) sequences that induce the interferon response, and in longer RNAi sequences that may induce the interferon response.

Overall, modified sugars may include D-ribose, 2′-O-alkyl (including 2′-O-methyl and 2′-O-ethyl), i.e., 2′-alkoxy, 2′-amino, 2′-S-alkyl, 2′-halo (including 2′-fluoro), 2′-methoxyethoxy, 2′-allyloxy (—OCH₂CH═CH₂), 2′-propargyl, 2′-propyl, ethynyl, ethenyl, propenyl, and cyano and the like. In one embodiment, the sugar moiety can be a hexose and incorporated into an oligonucleotide as described (Augustyns, K., et al., Nucl. Acids. Res. 18:4711 (1992)). Exemplary nucleomonomers can be found, e.g., in U.S. Pat. No. 5,849,902, incorporated by reference herein.

The term “alkyl” includes saturated aliphatic groups, including straight-chain alkyl groups (e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, etc.), branched-chain alkyl groups (isopropyl, tert-butyl, isobutyl, etc.), cycloalkyl (alicyclic) groups (cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl), alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. In certain embodiments, a straight chain or branched chain alkyl has 6 or fewer carbon atoms in its backbone (e.g., C₁-C₆ for straight chain, C₃-C₆ for branched chain), and more preferably 4 or fewer. Likewise, preferred cycloalkyls have from 3-8 carbon atoms in their ring structure, and more preferably have 5 or 6 carbons in the ring structure. The term C₁-C₆ includes alkyl groups containing 1 to 6 carbon atoms.

Moreover, unless otherwise specified, the term alkyl includes both “unsubstituted alkyls” and “substituted alkyls,” the latter of which refers to alkyl moieties having independently selected substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. Cycloalkyls can be further substituted, e.g., with the substituents described above. An “alkylaryl” or an “arylalkyl” moiety is an alkyl substituted with an aryl (e.g., phenylmethyl (benzyl)). The term “alkyl” also includes the side chains of natural and unnatural amino acids. The term “n-alkyl” means a straight chain (i.e., unbranched) unsubstituted alkyl group.

The term “alkenyl” includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double bond. For example, the term “alkenyl” includes straight-chain alkenyl groups (e.g., ethylenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl, etc.), branched-chain alkenyl groups, cycloalkenyl (alicyclic) groups (cyclopropenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl), alkyl or alkenyl substituted cycloalkenyl groups, and cycloalkyl or cycloalkenyl substituted alkenyl groups. In certain embodiments, a straight chain or branched chain alkenyl group has 6 or fewer carbon atoms in its backbone (e.g., C2-C₆ for straight chain, C₃-C₆ for branched chain). Likewise, cycloalkenyl groups may have from 3-8 carbon atoms in their ring structure, and more preferably have 5 or 6 carbons in the ring structure. The term C₂-C₆ includes alkenyl groups containing 2 to 6 carbon atoms.

Moreover, unless otherwise specified, the term alkenyl includes both “unsubstituted alkenyls” and “substituted alkenyls,” the latter of which refers to alkenyl moieties having independently selected substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, alkyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.

The term “alkynyl” includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but which contain at least one triple bond. For example, the term “alkynyl” includes straight-chain alkynyl groups (e.g., ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl, etc.), branched-chain alkynyl groups, and cycloalkyl or cycloalkenyl substituted alkynyl groups. In certain embodiments, a straight chain or branched chain alkynyl group has 6 or fewer carbon atoms in its backbone (e.g., C₂-C₆ for straight chain, C₃-C₆ for branched chain). The term C₂-C₆ includes alkynyl groups containing 2 to 6 carbon atoms.

Moreover, unless otherwise specified, the term alkynyl includes both “unsubstituted alkynyls” and “substituted alkynyls,” the latter of which refers to alkynyl moieties having independently selected substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, alkyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.

Unless the number of carbons is otherwise specified, “lower alkyl” as used herein means an alkyl group, as defined above, but having from one to five carbon atoms in its backbone structure. “Lower alkenyl” and “lower alkynyl” have chain lengths of, for example, 2-5 carbon atoms.

The term “alkoxy” includes substituted and unsubstituted alkyl, alkenyl, and alkynyl groups covalently linked to an oxygen atom. Examples of alkoxy groups include methoxy, ethoxy, isopropyloxy, propoxy, butoxy, and pentoxy groups. Examples of substituted alkoxy groups include halogenated alkoxy groups. The alkoxy groups can be substituted with independently selected groups such as alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulffiydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfmyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moieties. Examples of halogen substituted alkoxy groups include, but are not limited to, fluoromethoxy, difluoromethoxy, trifluoromethoxy, chloromethoxy, dichloromethoxy, trichloromethoxy, etc.

The term “hydrophobic modifications’ include bases modified in a fashion, where (1) overall hydrophobicity of the base is significantly increases, (2) the base is still capable of forming close to regular Watson-Crick interaction. Some, of the examples of base modifications include but are not limited to 5-position uridine and cytidine modifications like phenyl,

4-pyridyl, 2-pyridyl, indolyl, and isobutyl, phenyl (C6H5OH); tryptophanyl (C8H6N)CH2CH(NH2)CO), Isobutyl, butyl, aminobenzyl; phenyl; naphthyl, For purposes of the present invention, the term “overhang” refers to terminal non-base pairing nucleotide(s) resulting from one strand or region extending beyond the terminus of the complementary strand to which the first strand or region forms a duplex. One or more polynucleotides that are capable of forming a duplex through hydrogen bonding can have overhangs. The overhand length generally doesn't exceed 5 bases in length.

The term “heteroatom” includes atoms of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, sulfur and phosphorus.

The term “hydroxy” or “hydroxyl” includes groups with an —OH or —O⁻ (with an appropriate counterion).

The term “halogen” includes fluorine, bromine, chlorine, iodine, etc. The term “perhalogenated” generally refers to a moiety wherein all hydrogens are replaced by halogen atoms.

The term “substituted” includes independently selected substituents which can be placed on the moiety and which allow the molecule to perform its intended function. Examples of substituents include alkyl, alkenyl, alkynyl, aryl, (CR′R″)_0-3NR′R″, (CR′R″)_0-3CN, NO₂, halogen, (CR′R″)_0-3C(halogen)₃, (CR′R″)_0-3CH(halogen)₂, (CR′R″)_0-3CH₂(halogen), (CR′R″)_0-3CONR′R″, (CR′R″)_0-3S(O)_1-2NR′R″, (CR′R″)_0-3CHO, (CR′R″)_0-3O(CR′R″)_0-3H, (CR′R″)_0-3S(O)_0-2R′, (CR′R″)_0-3O(CR′R″)_0-3H, (CR′R″)_0-3COR′, (CR′R″)_0-3CO₂R′, or (CR′R″)_0-3OR′ groups; wherein each R′ and R″ are each independently hydrogen, a C₁-C₅ alkyl, C₂-C₅ alkenyl, C₂-C₅ alkynyl, or aryl group, or R′ and R″ taken together are a benzylidene group or a —(CH₂)₂O(CH₂)₂— group.

The term “amine” or “amino” includes compounds or moieties in which a nitrogen atom is covalently bonded to at least one carbon or heteroatom. The term “alkyl amino” includes groups and compounds wherein the nitrogen is bound to at least one additional alkyl group. The term “dialkyl amino” includes groups wherein the nitrogen atom is bound to at least two additional alkyl groups.

The term “ether” includes compounds or moieties which contain an oxygen bonded to two different carbon atoms or heteroatoms. For example, the term includes “alkoxyalkyl,” which refers to an alkyl, alkenyl, or alkynyl group covalently bonded to an oxygen atom which is covalently bonded to another alkyl group.

The term “base” includes the known purine and pyrimidine heterocyclic bases, deazapurines, and analogs (including heterocyclic substituted analogs, e.g., aminoethyoxy phenoxazine), derivatives (e.g., 1-alkyl-, 1-alkenyl-, heteroaromatic- and 1-alkynyl derivatives) and tautomers thereof. Examples of purines include adenine, guanine, inosine, diaminopurine, and xanthine and analogs (e.g., 8-oxo-N⁶-methyladenine or 7-diazaxanthine) and derivatives thereof. Pyrimidines include, for example, thymine, uracil, and cytosine, and their analogs (e.g., 5-methylcytosine, 5-methyluracil, 5-(1-propynyl)uracil, 5-(1-propynyl)cytosine and 4,4-ethanocytosine). Other examples of suitable bases include non-purinyl and non-pyrimidinyl bases such as 2-aminopyridine and triazines.

In a preferred embodiment, the nucleomonomers of an oligonucleotide of the invention are RNA nucleotides. In another preferred embodiment, the nucleomonomers of an oligonucleotide of the invention are modified RNA nucleotides. Thus, the oligonucleotides contain modified RNA nucleotides.

The term “nucleoside” includes bases which are covalently attached to a sugar moiety, preferably ribose or deoxyribose. Examples of preferred nucleosides include ribonucleosides and deoxyribonucleosides. Nucleosides also include bases linked to amino acids or amino acid analogs which may comprise free carboxyl groups, free amino groups, or protecting groups. Suitable protecting groups are well known in the art (see P. G. M. Wuts and T. W. Greene, “Protective Groups in Organic Synthesis”, 2^nd Ed., Wiley-Interscience, New York, 1999).

The term “nucleotide” includes nucleosides which further comprise a phosphate group or a phosphate analog.

As used herein, the term “linkage” includes a naturally occurring, unmodified phosphodiester moiety (—O—(PO²⁻)—O—) that covalently couples adjacent nucleomonomers. As used herein, the term “substitute linkage” includes any analog or derivative of the native phosphodiester group that covalently couples adjacent nucleomonomers. Substitute linkages include phosphodiester analogs, e.g., phosphorothioate, phosphorodithioate, and P-ethyoxyphosphodiester, P-ethoxyphosphodiester, P-alkyloxyphosphotriester, methylphosphonate, and nonphosphorus containing linkages, e.g., acetals and amides. Such substitute linkages are known in the art (e.g., Bjergarde et al. 1991. Nucleic Acids Res. 19:5843; Caruthers et al. 1991. Nucleosides Nucleotides. 10:47). In certain embodiments, non-hydrolizable linkages are preferred, such as phosphorothioate linkages.

In certain embodiments, oligonucleotides of the invention comprise hydrophobicly modified nucleotides or “hydrophobic modifications.” As used herein “hydrophobic modifications” refers to bases that are modified such that (1) overall hydrophobicity of the base is significantly increased, and/or (2) the base is still capable of forming close to regular Watson-Crick interaction. Several non-limiting examples of base modifications include 5-position uridine and cytidine modifications such as phenyl, 4-pyridyl, 2-pyridyl, indolyl, and isobutyl, phenyl (C6H5OH); tryptophanyl (C8H6N)CH2CH(NH2)CO), Isobutyl, butyl, aminobenzyl; phenyl; and naphthyl.

In certain embodiments, oligonucleotides of the invention comprise 3′ and 5′ termini (except for circular oligonucleotides). In one embodiment, the 3′ and 5′ termini of an oligonucleotide can be substantially protected from nucleases e.g., by modifying the 3′ or 5′ linkages (e.g., U.S. Pat. No. 5,849,902 and WO 98/13526). For example, oligonucleotides can be made resistant by the inclusion of a “blocking group.” The term “blocking group” as used herein refers to substituents (e.g., other than OH groups) that can be attached to oligonucleotides or nucleomonomers, either as protecting groups or coupling groups for synthesis (e.g., FITC, propyl (CH₂—CH₂—CH₃), glycol (—O—CH₂—CH₂—O—) phosphate (PO₃²⁻), hydrogen phosphonate, or phosphoramidite). “Blocking groups” also include “end blocking groups” or “exonuclease blocking groups” which protect the 5′ and 3′ termini of the oligonucleotide, including modified nucleotides and non-nucleotide exonuclease resistant structures.

Exemplary end-blocking groups include cap structures (e.g., a 7-methylguanosine cap), inverted nucleomonomers, e.g., with 3′-3′ or 5′-5′ end inversions (see, e.g., Ortiagao et al. 1992. Antisense Res. Dev. 2:129), methylphosphonate, phosphoramidite, non-nucleotide groups (e.g., non-nucleotide linkers, amino linkers, conjugates) and the like. The 3′ terminal nucleomonomer can comprise a modified sugar moiety. The 3′ terminal nucleomonomer comprises a 3′-O that can optionally be substituted by a blocking group that prevents 3′-exonuclease degradation of the oligonucleotide. For example, the 3′-hydroxyl can be esterified to a nucleotide through a 3′→3′ internucleotide linkage. For example, the alkyloxy radical can be methoxy, ethoxy, or isopropoxy, and preferably, ethoxy. Optionally, the 3′→3′linked nucleotide at the 3′ terminus can be linked by a substitute linkage. To reduce nuclease degradation, the 5′ most 3′→5′ linkage can be a modified linkage, e.g., a phosphorothioate or a P-alkyloxyphosphotriester linkage. Preferably, the two 5′ most 3′→5′ linkages are modified linkages. Optionally, the 5′ terminal hydroxy moiety can be esterified with a phosphorus containing moiety, e.g., phosphate, phosphorothioate, or P-ethoxyphosphate.

Another type of conjugates that can be attached to the end (3′ or 5′ end), the loop region, or any other parts of the miniRNA might include a sterol, sterol type molecule, peptide, small molecule, protein, etc. In some embodiments, a miniRNA may contain more than one conjugates (same or different chemical nature). In some embodiments, the conjugate is cholesterol.

Another way to increase target gene specificity, or to reduce off-target silencing effect, is to introduce a 2′-modification (such as the 2′-O methyl modification) at a position corresponding to the second 5′-end nucleotide of the guide sequence. This allows the positioning of this 2′-modification in the Dicer-resistant hairpin structure, thus enabling one to design better RNAi constructs with less or no off-target silencing.

In one embodiment, a hairpin polynucleotide of the invention can comprise one nucleic acid portion which is DNA and one nucleic acid portion which is RNA. Antisense (guide) sequences of the invention can be “chimeric oligonucleotides” which comprise an RNA-like and a DNA-like region.

The language “RNase H activating region” includes a region of an oligonucleotide, e.g., a chimeric oligonucleotide, that is capable of recruiting RNase H to cleave the target RNA strand to which the oligonucleotide binds. Typically, the RNase activating region contains a minimal core (of at least about 3-5, typically between about 3-12, more typically, between about 5-12, and more preferably between about 5-10 contiguous nucleomonomers) of DNA or DNA-like nucleomonomers. (See, e.g., U.S. Pat. No. 5,849,902). Preferably, the RNase H activating region comprises about nine contiguous deoxyribose containing nucleomonomers.

The language “non-activating region” includes a region of an antisense sequence, e.g., a chimeric oligonucleotide, that does not recruit or activate RNase H. Preferably, a non-activating region does not comprise phosphorothioate DNA. The oligonucleotides of the invention comprise at least one non-activating region. In one embodiment, the non-activating region can be stabilized against nucleases or can provide specificity for the target by being complementary to the target and forming hydrogen bonds with the target nucleic acid molecule, which is to be bound by the oligonucleotide.

In one embodiment, at least a portion of the contiguous polynucleotides are linked by a substitute linkage, e.g., a phosphorothioate linkage.

In certain embodiments, most or all of the nucleotides beyond the guide sequence (2′-modified or not) are linked by phosphorothioate linkages. Such constructs tend to have improved pharmacokinetics due to their higher affinity for serum proteins. The phosphorothioate linkages in the non-guide sequence portion of the polynucleotide generally do not interfere with guide strand activity, once the latter is loaded into RISC.

Antisense (guide) sequences of the present invention may include “morpholino oligonucleotides.” Morpholino oligonucleotides are non-ionic and function by an RNase H-independent mechanism. Each of the 4 genetic bases (Adenine, Cytosine, Guanine, and Thymine/Uracil) of the morpholino oligonucleotides is linked to a 6-membered morpholine ring. Morpholino oligonucleotides are made by joining the 4 different subunit types by, e.g., non-ionic phosphorodiamidate inter-subunit linkages. Morpholino oligonucleotides have many advantages including: complete resistance to nucleases (Antisense & Nucl. Acid Drug Dev. 1996. 6:267); predictable targeting (Biochemica Biophysica Acta. 1999. 1489:141); reliable activity in cells (Antisense & Nucl. Acid Drug Dev. 1997. 7:63); excellent sequence specificity (Antisense & Nucl. Acid Drug Dev. 1997. 7:151); minimal non-antisense activity (Biochemica Biophysica Acta. 1999. 1489:141); and simple osmotic or scrape delivery (Antisense & Nucl. Acid Drug Dev. 1997. 7:291). Morpholino oligonuclcotides are also preferred because of their non-toxicity at high doses. A discussion of the preparation of morpholino oligonucleotides can be found in Antisense & Nucl. Acid Drug Dev. 1997. 7:187.

The chemical modifications described herein are believed, based on the data described herein, to promote single stranded polynucleotide loading into the RISC. Single stranded polynucleotides have been shown to be active in loading into RISC and inducing gene silencing. However, the level of activity for single stranded polynucleotides appears to be 2 to 4 orders of magnitude lower when compared to a duplex polynucleotide.

The present invention provides a description of the chemical modification patterns, which may (a) significantly increase stability of the single stranded polynuclcotide (b) promote efficient loading of the polynucleotide into the RISC complex and (c) improve uptake of the single stranded nucleotide by the cell. FIG. 5 provides some non-limiting examples of the chemical modification patterns which may be beneficial for achieving single stranded polynucleotide efficacy inside the cell. The chemical modification patterns may include combination of ribose, backbone, hydrophobic nucleoside and conjugate type of modifications. In addition, in some of the embodiments, the 5′ end of the single polynucleotide may be chemically phosphorylated.

In yet another embodiment, the present invention provides a description of the chemical modifications patterns, which improve functionality of RISC inhibiting polynucleotides. Single stranded polynucleotides have been shown to inhibit activity of a preloaded RISC complex through the substrate competition mechanism. For these types of molecules, conventionally called antagomers, the activity usually requires high concentration and in vivo delivery is not very effective. The present invention provides a description of the chemical modification patterns, which may (a) significantly increase stability of the single stranded polynucleotide (b) promote efficient recognition of the polynucleotide by the RISC as a substrate and/or (c) improve uptake of the single stranded nucleotide by the cell. FIG. 6 provides some non-limiting examples of the chemical modification patterns that may be beneficial for achieving single stranded polynucleotide efficacy inside the cell. The chemical modification patterns may include combination of ribose, backbone, hydrophobic nucleoside and conjugate type of modifications.

The modifications provided by the present invention are applicable to all polynucleotides. This includes single stranded RISC entering polynucleotides, single stranded RISC inhibiting polynucleotides, conventional duplexed polynucleotides of variable length (15-40 bp), asymmetric duplexed polynucleotides, and the like. Polynucleotides may be modified with wide variety of chemical modification patterns, including 5′ end, ribose, backbone and hydrophobic nucleoside modifications.

Synthesis

Oligonucleotides of the invention can be synthesized by any method known in the art, e.g., using enzymatic synthesis and/or chemical synthesis. The oligonucleotides can be synthesized in vitro (e.g., using enzymatic synthesis and chemical synthesis) or in vivo (using recombinant DNA technology well known in the art).

In a preferred embodiment, chemical synthesis is used for modified polynucleotides. Chemical synthesis of linear oligonucleotides is well known in the art and can be achieved by solution or solid phase techniques. Preferably, synthesis is by solid phase methods. Oligonucleotides can be made by any of several different synthetic procedures including the phosphoramidite, phosphite triester, H-phosphonate, and phosphotriester methods, typically by automated synthesis methods.

Oligonucleotide synthesis protocols are well known in the art and can be found, e.g., in U.S. Pat. No. 5,830,653; WO 98/13526; Stec et al. 1984. J. Am. Chem. Soc. 106:6077; Stec et al. 1985. J. Org. Chem. 50:3908; Stec et al. J. Chromatog. 1985. 326:263; LaPlanche et al. 1986. Nucl. Acid. Res. 1986. 14:9081; Fasman G. D., 1989. Practical Handbook of Biochemistry and Molecular Biology. 1989. CRC Press, Boca Raton, Fla.; Lamone. 1993. Biochem. Soc. Trans. 21:1; U.S. Pat. No. 5,013,830; U.S. Pat. No. 5,214,135; U.S. Pat. No. 5,525,719; Kawasaki et al. 1993. J. Med Chem. 36:831; WO 92/03568; U.S. Pat. No. 5,276,019; and U.S. Pat. No. 5,264,423.

The synthesis method selected can depend on the length of the desired oligonucleotide and such choice is within the skill of the ordinary artisan. For example, the phosphoramidite and phosphite triester method can produce oligonucleotides having 175 or more nucleotides, while the H-phosphonate method works well for oligonucleotides of less than 100 nucleotides. If modified bases are incorporated into the oligonucleotide, and particularly if modified phosphodiester linkages are used, then the synthetic procedures are altered as needed according to known procedures. In this regard, Uhlmann et al. (1990, Chemical Reviews 90:543-584) provide references and outline procedures for making oligonucleotides with modified bases and modified phosphodiester linkages. Other exemplary methods for making oligonucleotides are taught in Sonveaux. 1994. “Protecting Groups in Oligonucleotide Synthesis”; Agrawal. Methods in Molecular Biology 26:1. Exemplary synthesis methods are also taught in “Oligonucleotide Synthesis—A Practical Approach” (Gait, M. J. IRL Press at Oxford University Press. 1984). Moreover, linear oligonucleotides of defined sequence, including some sequences with modified nucleotides, are readily available from several commercial sources.

The oligonucleotides may be purified by polyacrylamide gel electrophoresis, or by any of a number of chromatographic methods, including gel chromatography and high pressure liquid chromatography. To confirm a nucleotide sequence, especially unmodified nucleotide sequences, oligonucleotides may be subjected to DNA sequencing by any of the known procedures, including Maxam and Gilbert sequencing, Sanger sequencing, capillary electrophoresis sequencing, the wandering spot sequencing procedure or by using selective chemical degradation of oligonucleotides bound to Hybond paper. Sequences of short oligonucleotides can also be analyzed by laser desorption mass spectroscopy or by fast atom bombardment (McNeal, et al., 1982, J. Am. Chem. Soc. 104:976; Viari, et al., 1987, Biomed Environ. Mass Spectrom. 14:83; Grotjahn et al., 1982, Nuc. Acid Res. 10:4671). Sequencing methods are also available for RNA oligonucleotides.

The quality of oligonucleotides synthesized can be verified by testing the oligonucleotide by capillary electrophoresis and denaturing strong anion HPLC (SAX-HPLC) using, e.g., the method of Bergot and Egan. 1992. J. Chrom. 599:35.

Other exemplary synthesis techniques are well known in the art (see, e.g., Sambrook et al., Molecular Cloning: a Laboratory Manual, Second Edition (1989); DNA Cloning, Volumes I and II (DN Glover Ed. 1985); Oligonucleotide Synthesis (M J Gait Ed, 1984; Nucleic Acid Hybridisation (B D Hames and S J Higgins eds. 1984); A Practical Guide to Molecular Cloning (1984); or the series, Methods in Enzymology (Academic Press, Inc.)).

In certain embodiments, the subject RNAi constructs or at least portions thereof are transcribed from expression vectors encoding the subject constructs. Any art recognized vectors may be use for this purpose. The transcribed RNAi constructs may be isolated and purified, before desired modifications (such as replacing an unmodified sense strand with a modified one, etc.) are carried out.

Delivery/Carrier

Uptake of Oligonucleotides by Cells

Oligonucleotides and oligonucleotide compositions are contacted with (i.e., brought into contact with, also referred to herein as administered or delivered to) and taken up by one or more cells or a cell lysate. The term “cells” includes prokaryotic and eukaryotic cells, preferably vertebrate cells, and, more preferably, mammalian cells. In a preferred embodiment, the oligonucleotide compositions of the invention are contacted with human cells.

Oligonucleotide compositions of the invention can be contacted with cells in vitro, e.g., in a test tube or culture dish, (and may or may not be introduced into a subject) or in vivo, e.g., in a subject such as a mammalian subject. Oligonucleotides are taken up by cells at a slow rate by endocytosis, but endocytosed oligonucleotides are generally sequestered and not available, e.g., for hybridization to a target nucleic acid molecule. In one embodiment, cellular uptake can be facilitated by electroporation or calcium phosphate precipitation. However, these procedures are only useful for in vitro or ex vivo embodiments, are not convenient and, in some cases, are associated with cell toxicity.

In another embodiment, delivery of oligonucleotides into cells can be enhanced by suitable art recognized methods including calcium phosphate, DMSO, glycerol or dextran, electroporation, or by transfection, e.g., using cationic, anionic, or neutral lipid compositions or liposomes using methods known in the art (see e.g., WO 90/14074; WO 91/16024; WO 91/17424; U.S. Pat. No. 4,897,355; Bergan et al. 1993. Nucleic Acids Research. 21:3567). Enhanced delivery of oligonucleotides can also be mediated by the use of vectors (See e.g., Shi, Y. 2003. Trends Genet 2003 Jan. 19:9; Reichhart J M et al. Genesis. 2002. 34(1-2):1604, Yu et al. 2002. Proc. Natl. Acad Sci. USA 99:6047; Sui et al. 2002. Proc. Natl. Acad Sci. USA 99:5515) viruses, polyamine or polycation conjugates using compounds such as polylysine, protamine, or Ni, N12-bis (ethyl) spermine (see, e.g., Bartzatt, R. et al. 1989. Blotechnol. Appl. Blochem. 11:133; Wagner E. et al. 1992. Proc. Natl. Acad. Sci. 88:4255).

In certain embodiments, the miniRNA of the invention may be delivered by using various beta-glucan containing particles, such as those described in US 2005/0281781 A1, WO 2006/007372, and WO 2007/050643 (all incorporated herein by reference). In certain embodiments, the beta-glucan particle is derived from yeast. In certain embodiments, the payload trapping molecule is a polymer, such as those with a molecular weight of at least about 1000 Da, 10,000 Da, 50,000 Da, 100 kDa, 500 kDa, etc. Preferred polymers include (without limitation) cationic polymers, chitosans, or PEI (polyethylenimine), etc.

Such beta-glucan based delivery system may be formulated for oral delivery, where the orally delivered beta-glucan/miniRNA constructs may be engulfed by macrophages or other related phagocytic cells, which may in turn release the miniRNA constructs in selected in vivo sites. Alternatively or in addition, the miniRNA may changes the expression of certain macrophage target genes.

The optimal protocol for uptake of oligonucleotides will depend upon a number of factors, the most crucial being the type of cells that are being used. Other factors that are important in uptake include, but are not limited to, the nature and concentration of the oligonucleotide, the confluence of the cells, the type of culture the cells are in (e.g., a suspension culture or plated) and the type of media in which the cells are grown.

Encapsulating Agents

Encapsulating agents entrap oligonucleotides within vesicles. In another embodiment of the invention, an oligonucleotide may be associated with a carrier or vehicle, e.g., liposomes or micelles, although other carriers could be used, as would be appreciated by one skilled in the art. Liposomes are vesicles made of a lipid bilayer having a structure similar to biological membranes. Such carriers are used to facilitate the cellular uptake or targeting of the oligonucleotide, or improve the oligonucleotides pharmacokinetic or toxicological properties.

For example, the oligonucleotides of the present invention may also be administered encapsulated in liposomes, pharmaceutical compositions wherein the active ingredient is contained either dispersed or variously present in corpuscles consisting of aqueous concentric layers adherent to lipidic layers. The oligonucleotides, depending upon solubility, may be present both in the aqueous layer and in the lipidic layer, or in what is generally termed a liposomic suspension. The hydrophobic layer, generally but not exclusively, comprises phopholipids such as lecithin and sphingomyelin, steroids such as cholesterol, more or less ionic surfactants such as diacetylphosphate, stearylamine, or phosphatidic acid, or other materials of a hydrophobic nature. The diameters of the liposomes generally range from about 15 nm to about 5 microns.

The use of liposomes as drug delivery vehicles offers several advantages. Liposomes increase intracellular stability, increase uptake efficiency and improve biological activity. Liposomes are hollow spherical vesicles composed of lipids arranged in a similar fashion as those lipids which make up the cell membrane. They have an internal aqueous space for entrapping water soluble compounds and range in size from 0.05 to several microns in diameter. Several studies have shown that liposomes can deliver nucleic acids to cells and that the nucleic acids remain biologically active. For example, a lipid delivery vehicle originally designed as a research tool, such as Lipofectin or LIPOFECTAMINE™ 2000, can deliver intact nucleic acid molecules to cells.

Specific advantages of using liposomes include the following: they are non-toxic and biodegradable in composition; they display long circulation half-lives; and recognition molecules can be readily attached to their surface for targeting to tissues. Finally, cost-effective manufacture of liposome-based pharmaceuticals, either in a liquid suspension or lyophilized product, has demonstrated the viability of this technology as an acceptable drug delivery system.

In some aspects, formulations associated with the invention might be selected for a class of naturally occurring or chemically synthesized or modified saturated and unsaturated fatty acid residues. Fatty acids might exist in a form of triglycerides, diglycerides or individual fatty acids. In another embodiment, the use of well-validated mixtures of fatty acids and/or fat emulsions currently used in pharmacology for parenteral nutrition may be utilized.

Liposome based formulations are widely used for oligonucleotide delivery. However, most of commercially available lipid or liposome formulations contain at least one positively charged lipid (cationic lipids). The presence of this positively charged lipid is believed to be essential for obtaining a high degree of oligonucleotide loading and for enhancing liposome fusogenic properties. Several methods have been performed and published to identify optimal positively charged lipid chemistries. However, the commercially available liposome formulations containing cationic lipids are characterized by a high level of toxicity. In vivo limited therapeutic indexes have revealed that liposome formulations containing positive charged lipids are associated with toxicity (i.e. elevation in liver enzymes) at concentrations only slightly higher than concentration required to achieve RNA silencing.

New liposome formulations, lacking the toxicity of the prior art liposomes have been developed according to the invention. These new liposome formulations are neutral fat-based formulations for the efficient delivery of oligonucleotides, and in particular for the delivery of the RNA molecules of the invention. The compositions are referred to as neutral nanotransporters because they enable quantitative oligonucleotide incorporation into non-charged lipids mixtures. The lack of toxic levels of cationic lipids in the neutral nanotransporter compositions of the invention is an important feature.

The neutral nanotransporters compositions enable efficient loading of oligonucleotide into neutral fat formulation. The composition includes an oligonucleotide that is modified in a manner such that the hydrophobicity of the molecule is increased (for example a hydrophobic molecule is attached (covalently or no-covalently) to a hydrophobic molecule on the oligonucleotide terminus or a non-terminal nucleotide, base, sugar, or backbone), the modified oligonucleotide being mixed with a neutral fat formulation (for example containing at least 25% of cholesterol and 25% of DOPC or analogs thereof). A cargo molecule, such as another lipid can also be included in the composition. This composition, where part of the formulation is build into the oligonucleotide itself, enables efficient encapsulation of oligonucleotide in neutral lipid particles.

One of several unexpected observations associated with the invention was that the oligonucleotides of the invention could effectively be incorporated in a lipid mixture that was free of cationic lipids and that such a composition could effectively deliver the therapeutic oligonucleotide to a cell in a manner that it is functional. Another unexpected observation was the high level of activity observed when the fatty mixture is composed of a phosphatidylcholine base fatty acid and a sterol such as a cholesterol. For instance, one preferred formulation of neutral fatty mixture is composed of at least 20% of DOPC or DSPC and at least 20% of sterol such as cholesterol. Even as low as 1:5 lipid to oligonucleotide ratio was shown to be sufficient to get complete encapsulation of the oligonucleotide in a non charged formulation. The prior art demonstrated only a 1-5% oligonucleotide encapsulation with non-charged formulations, which is not sufficient to get to a desired amount of in vivo efficacy. Compared to the prior art using neutral lipids the level of oligonucleotide delivery to a cell was quite unexpected.

Stable particles ranging in size from 50 to 140 nm were formed upon complexing of hydrophobic oligonucleotides with preferred formulations. It is interesting to mention that the formulation by itself typically does not form small particles, but rather, forms agglomerates, which are transformed into stable 50-120 nm particles upon addition of the hydrophobic modified oligonucleotide.

The neutral nanotransporter compositions of the invention include a hydrophobic modified polynucleotide, a neutral fatty mixture, and optionally a cargo molecule. A “hydrophobic modified polynucleotide” as used herein is a polynucleotide of the invention (i.e. sd-rxRNA) that has at least one modification that renders the polynucleotide more hydrophobic than the polynucleotide was prior to modification. The modification may be achieved by attaching (covalently or non-covalently) a hydrophobic molecule to the polynucleotide. In some instances the hydrophobic molecule is or includes a lipophilic group.

The term “lipophilic group” means a group that has a higher affinity for lipids than its affinity for water. Examples of lipophilic groups include, but are not limited to, cholesterol, a cholesteryl or modified cholesteryl residue, adamantine, dihydrotesterone, long chain alkyl, long chain alkenyl, long chain alkynyl, olely-lithocholic, cholenic, oleoyl-cholenic, palmityl, heptadecyl, myrisityl, bile acids, cholic acid or taurocholic acid, deoxycholate, oleyl litocholic acid, oleoyl cholenic acid, glycolipids, phospholipids, sphingolipids, isoprenoids, such as steroids, vitamins, such as vitamin E, fatty acids either saturated or unsaturated, fatty acid esters, such as triglycerides, pyrenes, porphyrines, Texaphyrine, adamantane, acridines, biotin, coumarin, fluorescein, rhodamine, Texas-Red, digoxygenin, dimethoxytrityl, t-butyldimethylsilyl, t-butyldiphenylsilyl, cyanine dyes (e.g. Cy3 or Cy5), Hoechst 33258 dye, psoralen, or to ibuprofen. The cholesterol moiety may be reduced (e.g. as in cholestan) or may be substituted (e.g. by halogen). A combination of different lipophilic groups in one molecule is also possible.

The hydrophobic molecule may be attached at various positions of the polynucleotide. As described above, the hydrophobic molecule may be linked to the terminal residue of the polynucleotide such as the 3′ of 5′-end of the polynucleotide. Alternatively, it may be linked to an internal nucleotide or a nucleotide on a branch of the polynucleotide. The hydrophobic molecule may be attached, for instance to a 2′-position of the nucleotide. The hydrophobic molecule may also be linked to the heterocyclic base, the sugar or the backbone of a nucleotide of the polynucleotide.

The hydrophobic molecule may be connected to the polynucleotide by a linker moiety. Optionally the linker moiety is a non-nucleotidic linker moiety. Non-nucleotidic linkers are e.g. abasic residues (dSpacer), oligoethyleneglycol, such as triethyleneglycol (spacer 9) or hexaethylenegylcol (spacer 18), or alkane-diol, such as butanediol. The spacer units are preferably linked by phosphodiester or phosphorothioate bonds. The linker units may appear just once in the molecule or may be incorporated several times, e.g. via phosphodiester, phosphorothioate, methylphosphonate, or amide linkages.

Typical conjugation protocols involve the synthesis of polynucleotides bearing an aminolinker at one or more positions of the sequence, however, a linker is not required. The amino group is then reacted with the molecule being conjugated using appropriate coupling or activating reagents. The conjugation reaction may be performed either with the polynucleotide still bound to a solid support or following cleavage of the polynucleotide in solution phase. Purification of the modified polynucleotide by HPLC typically results in a pure material.

In some embodiments the hydrophobic molecule is a sterol type conjugate, a PhytoSterol conjugate, cholesterol conjugate, sterol type conjugate with altered side chain length, fatty acid conjugate, any other hydrophobic group conjugate, and/or hydrophobic modifications of the internal nucleoside, which provide sufficient hydrophobicity to be incorporated into micelles.

For purposes of the present invention, the term “sterols”, refers or steroid alcohols are a subgroup of steroids with a hydroxyl group at the 3-position of the A-ring. They are amphipathic lipids synthesized from acetyl-coenzyme A via the HMG-CoA reductase pathway. The overall molecule is quite flat. The hydroxyl group on the A ring is polar. The rest of the aliphatic chain is non-polar. Usually sterols are considered to have an 8 carbon chain at position 17.

For purposes of the present invention, the term “sterol type molecules”, refers to steroid alcohols, which are similar in structure to sterols. The main difference is the structure of the ring and number of carbons in a position 21 attached side chain.

For purposes of the present invention, the term “PhytoSterols” (also called plant sterols) are a group of steroid alcohols, phytochemicals naturally occurring in plants. There are more then 200 different known PhytoSterols

For purposes of the present invention, the term “Sterol side chain” refers to a chemical composition of a side chain attached at the position 17 of sterol-type molecule. In a standard definition sterols are limited to a 4 ring structure carrying a 8 carbon chain at position 17. In this invention, the sterol type molecules with side chain longer and shorter than conventional are described. The side chain may branched or contain double back bones.

Thus, sterols useful in the invention, for example, include cholesterols, as well as unique sterols in which position 17 has attached side chain of 2-7 or longer then 9 carbons. In a particular embodiment, the length of the polycarbon tail is varied between 5 and 9 carbons. FIG. 9 demonstrates that there is a correlation between plasma clearance, liver uptake and the length of the polycarbon chain. Such conjugates may have significantly better in vivo efficacy, in particular delivery to liver. These types of molecules are expected to work at concentrations 5 to 9 fold lower then oligonucleotides conjugated to conventional cholesterols.

Alternatively the polynucleotide may be bound to a protein, peptide or positively charged chemical that functions as the hydrophobic molecule. The proteins may be selected from the group consisting of protamine, dsRNA binding domain, and arginine rich peptides. Exemplary positively charged chemicals include spermine, spermidine, cadaverine, and putrescine.

In another embodiment hydrophobic molecule conjugates may demonstrate even higher efficacy when it is combined with optimal chemical modification patterns of the polynucleotide (as described herein in detail), containing but not limited to hydrophobic modifications, phosphorothioate modifications, and 2′ ribo modifications.

In another embodiment the sterol type molecule may be a naturally occurring PhytoSterols such as those shown in FIG. 8. The polycarbon chain may be longer than 9 and may be linear, branched and/or contain double bonds. Some PhytoSterol containing polynucleotide conjugates may be significantly more potent and active in delivery of polynucleotides to various tissues. Some PhytoSterols may demonstrate tissue preference and thus be used as a way to delivery RNAi specifically to particular tissues.

The hydrophobic modified polynucleotide is mixed with a neutral fatty mixture to form a micelle. The neutral fatty acid mixture is a mixture of fats that has a net neutral or slightly net negative charge at or around physiological pH that can form a micelle with the hydrophobic modified polynucleotide. For purposes of the present invention, the term “micelle” refers to a small nanoparticle formed by a mixture of non charged fatty acids and phospholipids. The neutral fatty mixture may include cationic lipids as long as they are present in an amount that does not cause toxicity. In preferred embodiments the neutral fatty mixture is free of cationic lipids. A mixture that is free of cationic lipids is one that has less than 1% and preferably 0% of the total lipid being cationic lipid. The term “cationic lipid” includes lipids and synthetic lipids having a net positive charge at or around physiological pH. The term “anionic lipid” includes lipids and synthetic lipids having a net negative charge at or around physiological pH.

The neutral fats bind to the oligonucleotides of the invention by a strong but non-covalent attraction (e.g., an electrostatic, van der Waals, pi-stacking, etc. interaction).

The neutral fat mixture may include formulations selected from a class of naturally occurring or chemically synthesized or modified saturated and unsaturated fatty acid residues. Fatty acids might exist in a form of triglycerides, diglycerides or individual fatty acids. In another embodiment the use of well-validated mixtures of fatty acids and/or fat emulsions currently used in pharmacology for parenteral nutrition may be utilized.

The neutral fatty mixture is preferably a mixture of a choline based fatty acid and a sterol. Choline based fatty acids include for instance, synthetic phosphocholine derivatives such as DDPC, DLPC, DMPC, DPPC, DSPC, DOPC, POPC, and DEPC. DOPC (chemical registry number 4235-95-4) is dioleoylphosphatidylcholine (also known as dielaidoylphosphatidylcholine, dioleoyl-PC, dioleoylphosphocholine, dioleoyl-sn-glycero-3-phosphocholine, dioleylphosphatidylcholine). DSPC (chemical registry number 816-94-4) is distearoylphosphatidylcholine (also known as 1,2-Distearoyl-sn-Glycero-3-phosphocholine).

The sterol in the neutral fatty mixture may be for instance cholesterol. The neutral fatty mixture may be made up completely of a choline based fatty acid and a sterol or it may optionally include a cargo molecule. For instance, the neutral fatty mixture may have at least 20% or 25% fatty acid and 20% or 25% sterol.

For purposes of the present invention, the term “Fatty acids” relates to conventional description of fatty acid. They may exist as individual entities or in a form of two- and triglycerides. For purposes of the present invention, the term “fat emulsions” refers to safe fat formulations given intravenously to subjects who are unable to get enough fat in their diet. It is an emulsion of soy bean oil (or other naturally occurring oils) and egg phospholipids. Fat emulsions are being used for formulation of some insoluble anesthetics. In this disclosure, fat emulsions might be part of commercially available preparations like Intralipid, Liposyn, Nutrilipid, modified commercial preparations, where they are enriched with particular fatty acids or fully de novo-formulated combinations of fatty acids and phospholipids.

In one embodiment, the cells to be contacted with an oligonucleotide composition of the invention are contacted with a mixture comprising the oligonucleotide and a mixture comprising a lipid, e.g., one of the lipids or lipid compositions described supra for between about 12 hours to about 24 hours. In another embodiment, the cells to be contacted with an oligonucleotide composition are contacted with a mixture comprising the oligonucleotide and a mixture comprising a lipid, e.g., one of the lipids or lipid compositions described supra for between about 1 and about five days. In one embodiment, the cells are contacted with a mixture comprising a lipid and the oligonucleotide for between about three days to as long as about 30 days. In another embodiment, a mixture comprising a lipid is left in contact with the cells for at least about five to about 20 days. In another embodiment, a mixture comprising a lipid is left in contact with the cells for at least about seven to about 15 days.

50%-60% of the formulation can optionally be any other lipid or molecule. Such a lipid or molecule is referred to herein as a cargo lipid or cargo molecule. Cargo molecules include but are not limited to intralipid, small molecules, fusogenic peptides or lipids or other small molecules might be added to alter cellular uptake, endosomal release or tissue distribution properties. The ability to tolerate cargo molecules is important for modulation of properties of these particles, if such properties are desirable. For instance the presence of some tissue specific metabolites might drastically alter tissue distribution profiles. For example use of Intralipid type formulation enriched in shorter or longer fatty chains with various degrees of saturation affects tissue distribution profiles of these type of formulations (and their loads).

An example of a cargo lipid useful according to the invention is a fusogenic lipid. For instance, the zwiterionic lipid DOPE (chemical registry number 4004-5-1, 1,2-Dioleoyl-sn-Glycero-3-phosphoethanolamine) is a preferred cargo lipid.

Intralipid may be comprised of the following composition: 1 000 mL contain: purified soybean oil 90 g, purified egg phospholipids 12 g, glycerol anhydrous 22 g, water for injection q.s. ad 1 000 mL. pH is adjusted with sodium hydroxide to pH approximately 8. Energy content/L: 4.6 MJ (190 kcal). Osmolality (approx.): 300 mOsm/kg water. In another embodiment fat emulsion is Liposyn that contains 5% safflower oil, 5% soybean oil, up to 1.2% egg phosphatides added as an emulsifier and 2.5% glycerin in water for injection. It may also contain sodium hydroxide for pH adjustment. pH 8.0 (6.0-9.0). Liposyn has an osmolarity of 276 m Osmol/liter (actual).

Variation in the identity, amounts and ratios of cargo lipids affects the cellular uptake and tissue distribution characteristics of these compounds. For example, the length of lipid tails and level of saturability will affect differential uptake to liver, lung, fat and cardiomyocytes. Addition of special hydrophobic molecules like vitamins or different forms of sterols can favor distribution to special tissues which are involved in the metabolism of particular compounds. Complexes are formed at different oligonucleotide concentrations, with higher concentrations favoring more efficient complex formation (FIGS. 21-22).

In another embodiment, the fat emulsion is based on a mixture of lipids. Such lipids may include natural compounds, chemically synthesized compounds, purified fatty acids or any other lipids. In yet another embodiment the composition of fat emulsion is entirely artificial. In a particular embodiment, the fat emulsion is more then 70% linoleic acid. In yet another particular embodiment the fat emulsion is at least 1% of cardiolipin. Linoleic acid (LA) is an unsaturated omega-6 fatty acid. It is a colorless liquid made of a carboxylic acid with an 18-carbon chain and two cis double bonds.

In yet another embodiment of the present invention, the alteration of the composition of the fat emulsion is used as a way to alter tissue distribution of hydrophobicly modified polynucleotides. This methodology provides for the specific delivery of the polynucleotides to particular tissues (FIG. 12).

In another embodiment the fat emulsions of the cargo molecule contain more then 70% of Linoleic acid (C18H3202) and/or cardiolipin are used for specifically delivering RNAi to heart muscle.

Fat emulsions, like intralipid have been used before as a delivery formulation for some non-water soluble drugs (such as Propofol, re-formulated as Diprivan). Unique features of the present invention include (a) the concept of combining modified polynucleotides with the hydrophobic compound(s), so it can be incorporated in the fat micelles and (b) mixing it with the fat emulsions to provide a reversible carrier. After injection into a blood stream, micelles usually bind to serum proteins, including albumin, HDL, LDL and other. This binding is reversible and eventually the fat is absorbed by cells. The polynucleotide, incorporated as a part of the micelle will then be delivered closely to the surface of the cells. After that cellular uptake might be happening though variable mechanisms, including but not limited to sterol type delivery.

Complexing Agents

Complexing agents bind to the oligonucleotides of the invention by a strong but non-covalent attraction (e.g., an electrostatic, van der Waals, pi-stacking, etc. interaction). In one embodiment, oligonucleotides of the invention can be complexed with a complexing agent to increase cellular uptake of oligonucleotides. An example of a complexing agent includes cationic lipids. Cationic lipids can be used to deliver oligonucleotides to cells. However, as discussed above, formulations free in cationic lipids are preferred in some embodiments.

The term “cationic lipid” includes lipids and synthetic lipids having both polar and non-polar domains and which are capable of being positively charged at or around physiological pH and which bind to polyanions, such as nucleic acids, and facilitate the delivery of nucleic acids into cells. In general cationic lipids include saturated and unsaturated alkyl and alicyclic ethers and esters of amines, amides, or derivatives thereof. Straight-chain and branched alkyl and alkenyl groups of cationic lipids can contain, e.g., from 1 to about 25 carbon atoms. Preferred straight chain or branched alkyl or alkene groups have six or more carbon atoms. Alicyclic groups include cholesterol and other steroid groups. Cationic lipids can be prepared with a variety of counterions (anions) including, e.g., Cl⁻, Br⁻, I⁻, F⁻, acetate, trifluoroacetate, sulfate, nitrite, and nitrate.

Examples of cationic lipids include polyethylenimine, polyamidoamine (PAMAM) starburst dendrimers, Lipofectin (a combination of DOTMA and DOPE), Lipofectase, LIPOFECTAMINE™ (e.g., LIPOFECTAMINE™ 2000), DOPE, Cytofectin (Gilead Sciences, Foster City, Calif.), and Eufectins (JBL, San Luis Obispo, Calif.). Exemplary cationic liposomes can be made from N-[1-(2,3-dioleoloxy)-propyl]-N,N,N-trimethylammonium chloride (DOTMA), N-[1-(2,3-dioleoloxy)-propyl]-N,N,N-trimethylammonium methylsulfate (DOTAP), 3β-[N—(N′,N′-dimethylaminoethane)carbamoyl]cholesterol (DC-Chol), 2,3,-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate (DOSPA), 1,2-dimyristyloxypropyl-3-dimethyl-hydroxyethyl ammonium bromide; and dimethyldioctadecylammonium bromide (DDAB). The cationic lipid N-(1-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTMA), for example, was found to increase 1000-fold the antisense effect of a phosphorothioate oligonucleotide. (Vlassov et al., 1994, Biochimica et Biophysica Acta 1197:95-108). Oligonucleotides can also be complexed with, e.g., poly (L-lysine) or avidin and lipids may, or may not, be included in this mixture, e.g., steryl-poly (L-lysine).

Cationic lipids have been used in the art to deliver oligonucleotides to cells (see, e.g., U.S. Pat. Nos. 5,855,910; 5,851,548; 5,830,430; 5,780,053; 5,767,099; Lewis et al. 1996. Proc. Natl. Acad. Sci. USA 93:3176; Hope et al. 1998. Molecular Membrane Biology 15:1). Other lipid compositions which can be used to facilitate uptake of the instant oligonucleotides can be used in connection with the claimed methods. In addition to those listed supra, other lipid compositions are also known in the art and include, e.g., those taught in U.S. Pat. No. 4,235,871; U.S. Pat. Nos. 4,501,728; 4,837,028; 4,737,323.

In one embodiment lipid compositions can further comprise agents, e.g., viral proteins to enhance lipid-mediated transfections of oligonucleotides (Kamata, et al., 1994. Nucl. Acids. Res. 22:536). In another embodiment, oligonucleotides are contacted with cells as part of a composition comprising an oligonucleotide, a peptide, and a lipid as taught, e.g., in U.S. Pat. No. 5,736,392. Improved lipids have also been described which are serum resistant (Lewis, et al., 1996. Proc. Natl. Acad Sci. 93:3176). Cationic lipids and other complexing agents act to increase the number of oligonucleotides carried into the cell through endocytosis.

In another embodiment N-substituted glycine oligonucleotides (peptoids) can be used to optimize uptake of oligonucleotides. Peptoids have been used to create cationic lipid-like compounds for transfection (Murphy, et al., 1998. Proc. Natl. Acad Sci. 95:1517). Peptoids can be synthesized using standard methods (e.g., Zuckermann, R. N., et al. 1992. J. Am. Chem. Soc. 114:10646; Zuckermann, R. N., et al. 1992. Int. J. Peptide Protein Res. 40:497). Combinations of cationic lipids and peptoids, liptoids, can also be used to optimize uptake of the subject oligonucleotides (Hunag, et al., 1998. Chemistry and Biology. 5:345). Liptoids can be synthesized by elaborating peptoid oligonucleotides and coupling the amino terminal submonomer to a lipid via its amino group (Hunag, et al., 1998. Chemistry and Biology. 5:345).

It is known in the art that positively charged amino acids can be used for creating highly active cationic lipids (Lewis et al. 1996. Proc. Natl. Acad. Sci. USA. 93:3176). In one embodiment, a composition for delivering oligonucleotides of the invention comprises a number of arginine, lysine, histidine or ornithine residues linked to a lipophilic moiety (see e.g., U.S. Pat. No. 5,777,153).

In another embodiment, a composition for delivering oligonucleotides of the invention comprises a peptide having from between about one to about four basic residues. These basic residues can be located, e.g., on the amino terminal, C-terminal, or internal region of the peptide. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine (can also be considered non-polar), asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalaninc, methionine, tryptophan), beta-branched side chains (e.g., threoninc, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Apart from the basic amino acids, a majority or all of the other residues of the peptide can be selected from the non-basic amino acids, e.g., amino acids other than lysine, arginine, or histidine. Preferably a preponderance of neutral amino acids with long neutral side chains are used.

In one embodiment, a composition for delivering oligonucleotides of the invention comprises a natural or synthetic polypeptide having one or more gamma carboxyglutamic acid residues, or γ-Gla residues. These gamma carboxyglutamic acid residues may enable the polypeptide to bind to each other and to membrane surfaces. In other words, a polypeptide having a series of γ-Gla may be used as a general delivery modality that helps an RNAi construct to stick to whatever membrane to which it comes in contact. This may at least slow RNAi constructs from being cleared from the blood stream and enhance their chance of homing to the target.

The gamma carboxyglutamic acid residues may exist in natural proteins (for example, prothrombin has 10 γ-Gla residues). Alternatively, they can be introduced into the purified, recombinantly produced, or chemically synthesized polypeptides by carboxylation using, for example, a vitamin K-dependent carboxylase. The gamma carboxyglutamic acid residues may be consecutive or non-consecutive, and the total number and location of such gamma carboxyglutamic acid residues in the polypeptide can be regulated/fine tuned to achieve different levels of “stickiness” of the polypeptide.

In one embodiment, the cells to be contacted with an oligonucleotide composition of the invention are contacted with a mixture comprising the oligonucleotide and a mixture comprising a lipid, e.g., one of the lipids or lipid compositions described supra for between about 12 hours to about 24 hours. In another embodiment, the cells to be contacted with an oligonucleotide composition are contacted with a mixture comprising the oligonucleotide and a mixture comprising a lipid, e.g., one of the lipids or lipid compositions described supra for between about 1 and about five days. In one embodiment, the cells are contacted with a mixture comprising a lipid and the oligonucleotide for between about three days to as long as about 30 days. In another embodiment, a mixture comprising a lipid is left in contact with the cells for at least about five to about 20 days. In another embodiment, a mixture comprising a lipid is left in contact with the cells for at least about seven to about 15 days.

For example, in one embodiment, an oligonucleotide composition can be contacted with cells in the presence of a lipid such as cytofectin CS or GSV (available from Glen Research; Sterling, Va.), GS3815, GS2888 for prolonged incubation periods as described herein.

In one embodiment, the incubation of the cells with the mixture comprising a lipid and an oligonucleotide composition does not reduce the viability of the cells. Preferably, after the transfection period the cells are substantially viable. In one embodiment, after transfection, the cells are between at least about 70% and at least about 100% viable. In another embodiment, the cells are between at least about 80% and at least about 95% viable. In yet another embodiment, the cells are between at least about 85% and at least about 90% viable.

In one embodiment, oligonucleotides are modified by attaching a peptide sequence that transports the oligonucleotide into a cell, referred to herein as a “transporting peptide.” In one embodiment, the composition includes an oligonucleotide which is complementary to a target nucleic acid molecule encoding the protein, and a covalently attached transporting peptide.

The language “transporting peptide” includes an amino acid sequence that facilitates the transport of an oligonucleotide into a cell. Exemplary peptides which facilitate the transport of the moieties to which they are linked into cells are known in the art, and include, e.g., HIV TAT transcription factor, lactoferrin, Herpes VP22 protein, and fibroblast growth factor 2 (Pooga et al. 1998. Nature Biotechnology. 16:857; and Derossi et al. 1998. Trends in Cell Biology. 8:84; Elliott and O'Hare. 1997. Cell 88:223).

Oligonucleotides can be attached to the transporting peptide using known techniques, e.g., (Prochiantz, A. 1996. Curr. Opin. Neurobiol. 6:629; Derossi et al. 1998. Trends Cell Biol. 8:84; Troy et al. 1996. J. Neurosci. 16:253), Vives et al. 1997. J. Biol. Chem. 272:16010). For example, in one embodiment, oligonucleotides bearing an activated thiol group are linked via that thiol group to a cysteine present in a transport peptide (e.g., to the cysteine present in the β turn between the second and the third helix of the antennapedia homeodomain as taught, e.g., in Derossi et al. 1998. Trends Cell Biol. 8:84; Prochiantz. 1996. Current Opinion in Neurobiol. 6:629; Allinquant et al. 1995. J Cell Biol. 128:919). In another embodiment, a Boc-Cys-(Npys)OH group can be coupled to the transport peptide as the last (N-terminal) amino acid and an oligonucleotide bearing an SH group can be coupled to the peptide (Troy et al. 1996. J. Neurosci. 16:253).

In one embodiment, a linking group can be attached to a nucleomonomer and the transporting peptide can be covalently attached to the linker. In one embodiment, a linker can function as both an attachment site for a transporting peptide and can provide stability against nucleases. Examples of suitable linkers include substituted or unsubstituted C₁-C₂₀ alkyl chains, C₂-C₂₀ alkenyl chains, C₂-C₂₀ alkynyl chains, peptides, and heteroatoms (e.g., S, O, NH, etc.). Other exemplary linkers include bifunctional crosslinking agents such as sulfosuccinimidyl-4-(maleimidophenyl)-butyrate (SMPB) (see, e.g., Smith et al. Biochem J 1991. 276: 417-2).

In one embodiment, oligonucleotides of the invention are synthesized as molecular conjugates which utilize receptor-mediated endocytotic mechanisms for delivering genes into cells (see, e.g., Bunnell et al. 1992. Somatic Cell and Molecular Genetics. 18:559, and the references cited therein).

Targeting Agents

The delivery of oligonucleotides can also be improved by targeting the oligonucleotides to a cellular receptor. The targeting moieties can be conjugated to the oligonucleotides or attached to a carrier group (i.e., poly(L-lysine) or liposomes) linked to the oligonucleotides. This method is well suited to cells that display specific receptor-mediated endocytosis.

For instance, oligonucleotide conjugates to 6-phosphomannosylated proteins are internalized 20-fold more efficiently by cells expressing mannose 6-phosphate specific receptors than free oligonucleotides. The oligonucleotides may also be coupled to a ligand for a cellular receptor using a biodegradable linker. In another example, the delivery construct is mannosylated streptavidin which forms a tight complex with biotinylated oligonucleotides. Mannosylated streptavidin was found to increase 20-fold the internalization of biotinylated oligonucleotides. (Vlassov et al. 1994. Biochimica et Biophysica Acta 1197:95-108).

In addition specific ligands can be conjugated to the polylysine component of polylysine-based delivery systems. For example, transferrin-polylysine, adenovirus-polylysine, and influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides-polylysine conjugates greatly enhance receptor-mediated DNA delivery in eucaryotic cells. Mannosylated glycoprotein conjugated to poly(L-lysine) in aveolar macrophages has been employed to enhance the cellular uptake of oligonucleotides. Liang et al. 1999. Pharmazie 54:559-566.

Because malignant cells have an increased need for essential nutrients such as folic acid and transferrin, these nutrients can be used to target oligonucleotides to cancerous cells. For example, when folic acid is linked to poly(L-lysine) enhanced oligonucleotide uptake is seen in promyelocytic leukaemia (HL-60) cells and human melanoma (M-14) cells. Ginobbi et al. 1997. Anticancer Res. 17:29. In another example, liposomes coated with maleylated bovine serum albumin, folic acid, or ferric protoporphyrin IX, show enhanced cellular uptake of oligonucleotides in murine macrophages, KB cells, and 2.2.15 human hepatoma cells. Liang et al. 1999. Pharmazie 54:559-566.

Liposomes naturally accumulate in the liver, spleen, and reticuloendothelial system (so-called, passive targeting). By coupling liposomes to various ligands such as antibodies are protein A, they can be actively targeted to specific cell populations. For example, protein A-bearing liposomes may be pretreated with H-2K specific antibodies which are targeted to the mouse major histocompatibility complex-encoded H-2K protein expressed on L cells. (Vlassov et al. 1994. Biochimica et Biophysica Acta 1197:95-108).

Other in vitro and/or in vivo delivery of RNAi reagents are known in the art, and can be used to deliver the subject RNAi constructs. See, for example, U.S. patent application publications 20080152661, 20080112916, 20080107694, 20080038296, 20070231392, 20060240093, 20060178327, 20060008910, 20050265957, 20050064595, 20050042227, 20050037496, 20050026286, 20040162235, 20040072785, 20040063654, 20030157030, WO 2008/036825, WO04/065601, and AU2004206255B2, just to name a few (all incorporated by reference).

Administration

The optimal course of administration or delivery of the oligonucleotides may vary depending upon the desired result and/or on the subject to be treated. As used herein “administration” refers to contacting cells with oligonucleotides and can be performed in vitro or in vivo. The dosage of oligonucleotides may be adjusted to optimally reduce expression of a protein translated from a target nucleic acid molecule, e.g., as measured by a readout of RNA stability or by a therapeutic response, without undue experimentation.

For example, expression of the protein encoded by the nucleic acid target can be measured to determine whether or not the dosage regimen needs to be adjusted accordingly. In addition, an increase or decrease in RNA or protein levels in a cell or produced by a cell can be measured using any art recognized technique. By determining whether transcription has been decreased, the effectiveness of the oligonucleotide in inducing the cleavage of a target RNA can be determined.

Any of the above-described oligonucleotide compositions can be used alone or in conjunction with a pharmaceutically acceptable carrier. As used herein, “pharmaceutically acceptable carrier” includes appropriate solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, it can be used in the therapeutic compositions. Supplementary active ingredients can also be incorporated into the compositions.

Oligonucleotides may be incorporated into liposomes or liposomes modified with polyethylene glycol or admixed with cationic lipids for parenteral administration. Incorporation of additional substances into the liposome, for example, antibodies reactive against membrane proteins found on specific target cells, can help target the oligonucleotides to specific cell types.

Moreover, the present invention provides for administering the subject oligonucleotides with an osmotic pump providing continuous infusion of such oligonucleotides, for example, as described in Rataiczak et al. (1992 Proc. Natl. Acad. Sci. USA 89:11823-11827). Such osmotic pumps are commercially available, e.g., from Alzet Inc. (Palo Alto, Calif.). Topical administration and parenteral administration in a cationic lipid carrier are preferred.

With respect to in vivo applications, the formulations of the present invention can be administered to a patient in a variety of forms adapted to the chosen route of administration, e.g., parenterally, orally, or intraperitoneally. Parenteral administration, which is preferred, includes administration by the following routes: intravenous; intramuscular; interstitially; intraarterially; subcutaneous; intra ocular; intrasynovial; trans epithelial, including transdermal; pulmonary via inhalation; ophthalmic; sublingual and buccal; topically, including ophthalmic; dermal; ocular; rectal; and nasal inhalation via insufflation.

Pharmaceutical preparations for parenteral administration include aqueous solutions of the active compounds in water-soluble or water-dispersible form. In addition, suspensions of the active compounds as appropriate oily injection suspensions may be administered. Suitable lipophilic solvents or vehicles include fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example, ethyl oleate or triglycerides. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension include, for example, sodium carboxymethyl cellulose, sorbitol, or dextran, optionally, the suspension may also contain stabilizers. The oligonucleotides of the invention can be formulated in liquid solutions, preferably in physiologically compatible buffers such as Hank's solution or Ringer's solution. In addition, the oligonucleotides may be formulated in solid form and redissolved or suspended immediately prior to use. Lyophilized forms are also included in the invention.

Pharmaceutical preparations for topical administration include transdermal patches, ointments, lotions, creams, gels, drops, sprays, suppositories, liquids and powders. In addition, conventional pharmaceutical carriers, aqueous, powder or oily bases, or thickeners may be used in pharmaceutical preparations for topical administration.

Pharmaceutical preparations for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets. In addition, thickeners, flavoring agents, diluents, emulsifiers, dispersing aids, or binders may be used in pharmaceutical preparations for oral administration.

For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are known in the art, and include, for example, for transmucosal administration bile salts and fusidic acid derivatives, and detergents. Transmucosal administration may be through nasal sprays or using suppositories. For oral administration, the oligonucleotides are formulated into conventional oral administration forms such as capsules, tablets, and tonics. For topical administration, the oligonucleotides of the invention are formulated into ointments, salves, gels, or creams as known in the art.

Drug delivery vehicles can be chosen e.g., for in vitro, for systemic, or for topical administration. These vehicles can be designed to serve as a slow release reservoir or to deliver their contents directly to the target cell. An advantage of using some direct delivery drug vehicles is that multiple molecules are delivered per uptake. Such vehicles have been shown to increase the circulation half-life of drugs that would otherwise be rapidly cleared from the blood stream. Some examples of such specialized drug delivery vehicles which fall into this category are liposomes, hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres.

The described oligonucleotides may be administered systemically to a subject. Systemic absorption refers to the entry of drugs into the blood stream followed by distribution throughout the entire body. Administration routes which lead to systemic absorption include: intravenous, subcutaneous, intraperitoneal, and intranasal. Each of these administration routes delivers the oligonucleotide to accessible diseased cells. Following subcutaneous administration, the therapeutic agent drains into local lymph nodes and proceeds through the lymphatic network into the circulation. The rate of entry into the circulation has been shown to be a function of molecular weight or size. The use of a liposome or other drug carrier localizes the oligonucleotide at the lymph node. The oligonucleotide can be modified to diffuse into the cell, or the liposome can directly participate in the delivery of either the unmodified or modified oligonucleotide into the cell.

The chosen method of delivery will result in entry into cells. Preferred delivery methods include liposomes (10-400 nm), hydrogels, controlled-release polymers, and other pharmaceutically applicable vehicles, and microinjection or electroporation (for ex vivo treatments).

The pharmaceutical preparations of the present invention may be prepared and formulated as emulsions. Emulsions are usually heterogeneous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1 m in diameter. The emulsions of the present invention may contain excipients such as emulsifiers, stabilizers, dyes, fats, oils, waxes, fatty acids, fatty alcohols, fatty esters, humectants, hydrophilic colloids, preservatives, and anti-oxidants may also be present in emulsions as needed. These excipients may be present as a solution in either the aqueous phase, oily phase or itself as a separate phase.

Examples of naturally occurring emulsifiers that may be used in emulsion formulations of the present invention include lanolin, beeswax, phosphatides, lecithin and acacia. Finely divided solids have also been used as good emulsifiers especially in combination with surfactants and in viscous preparations. Examples of finely divided solids that may be used as emulsifiers include polar inorganic solids, such as heavy metal hydroxides, nonswelling clays such as bentonite, attapulgite, hectorite, kaolin, montmorillonite, colloidal aluminum silicate and colloidal magnesium aluminum silicate, pigments and nonpolar solids such as carbon or glyceryl tristearate.

Examples of preservatives that may be included in the emulsion formulations include methyl paraben, propyl paraben, quaternary ammonium salts, benzalkonium chloride, esters of p-hydroxybenzoic acid, and boric acid. Examples of antioxidants that may be included in the emulsion formulations include free radical scavengers such as tocopherols, alkyl gallates, butylated hydroxyanisole, butylated hydroxytoluene, or reducing agents such as ascorbic acid and sodium metabisulfite, and antioxidant synergists such as citric acid, tartaric acid, and lecithin.

In one embodiment, the compositions of oligonucleotides are formulated as microemulsions. A microemulsion is a system of water, oil and amphiphile which is a single optically isotropic and thermodynamically stable liquid solution. Typically microemulsions are prepared by first dispersing an oil in an aqueous surfactant solution and then adding a sufficient amount of a 4th component, generally an intermediate chain-length alcohol to form a transparent system.

Surfactants that may be used in the preparation of microemulsions include, but are not limited to, ionic surfactants, non-ionic surfactants, Brij 96, polyoxyethylene oleyl ethers, polyglycerol fatty acid esters, tetraglycerol monolaurate (ML310), tetraglycerol monooleate (MO310), hexaglycerol monooleate (PO310), hexaglycerol pentaoleate (PO500), decaglycerol monocaprate (MCA750), decaglycerol monooleate (MO750), decaglycerol sequioleate (S0750), decaglycerol decaoleate (DA0750), alone or in combination with cosurfactants. The cosurfactant, usually a short-chain alcohol such as ethanol, 1-propanol, and 1-butanol, serves to increase the interfacial fluidity by penetrating into the surfactant film and consequently creating a disordered film because of the void space generated among surfactant molecules.

Microemulsions may, however, be prepared without the use of cosurfactants and alcohol-free self-emulsifying microemulsion systems are known in the art. The aqueous phase may typically be, but is not limited to, water, an aqueous solution of the drug, glycerol, PEG300, PEG400, polyglycerols, propylene glycols, and derivatives of ethylene glycol. The oil phase may include, but is not limited to, materials such as Captex 300, Captex 355, Capmul MCM, fatty acid esters, medium chain (C₈-C₁₂) mono, di, and tri-glycerides, polyoxyethylated glyceryl fatty acid esters, fatty alcohols, polyglycolized glycerides, saturated polyglycolized C₈-C₁₀ glycerides, vegetable oils and silicone oil.

Microemulsions are particularly of interest from the standpoint of drug solubilization and the enhanced absorption of drugs. Lipid based microemulsions (both oil/water and water/oil) have been proposed to enhance the oral bioavailability of drugs.

Microemulsions offer improved drug solubilization, protection of drug from enzymatic hydrolysis, possible enhancement of drug absorption due to surfactant-induced alterations in membrane fluidity and permeability, ease of preparation, ease of oral administration over solid dosage forms, improved clinical potency, and decreased toxicity (Constantinides et al., Pharmaceutical Research, 1994, 11:1385; Ho et al., J. Pharm. Sci., 1996, 85:138-143). Microemulsions have also been effective in the transdermal delivery of active components in both cosmetic and pharmaceutical applications. It is expected that the microemulsion compositions and formulations of the present invention will facilitate the increased systemic absorption of oligonucleotides from the gastrointestinal tract, as well as improve the local cellular uptake of oligonucleotides within the gastrointestinal tract, vagina, buccal cavity and other areas of administration.

In an embodiment, the present invention employs various penetration enhancers to affect the efficient delivery of nucleic acids, particularly oligonucleotides, to the skin of animals. Even non-lipophilic drugs may cross cell membranes if the membrane to be crossed is treated with a penetration enhancer. In addition to increasing the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also act to enhance the permeability of lipophilic drugs.

Five categories of penetration enhancers that may be used in the present invention include: surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants. Other agents may be utilized to enhance the penetration of the administered oligonucleotides include: glycols such as ethylene glycol and propylene glycol, pyrrols such as 2-15 pyrrol, azones, and terpenes such as limonene, and menthone.

The oligonucleotides, especially in lipid formulations, can also be administered by coating a medical device, for example, a catheter, such as an angioplasty balloon catheter, with a cationic lipid formulation. Coating may be achieved, for example, by dipping the medical device into a lipid formulation or a mixture of a lipid formulation and a suitable solvent, for example, an aqueous-based buffer, an aqueous solvent, ethanol, methylene chloride, chloroform and the like. An amount of the formulation will naturally adhere to the surface of the device which is subsequently administered to a patient, as appropriate. Alternatively, a lyophilized mixture of a lipid formulation may be specifically bound to the surface of the device. Such binding techniques are described, for example, in K. Ishihara et al., Journal of Biomedical Materials Research, Vol. 27, pp. 1309-1314 (1993), the disclosures of which are incorporated herein by reference in their entirety.

The useful dosage to be administered and the particular mode of administration will vary depending upon such factors as the cell type, or for in vivo use, the age, weight and the particular animal and region thereof to be treated, the particular oligonucleotide and delivery method used, the therapeutic or diagnostic use contemplated, and the form of the formulation, for example, suspension, emulsion, micelle or liposome, as will be readily apparent to those skilled in the art. Typically, dosage is administered at lower levels and increased until the desired effect is achieved. When lipids are used to deliver the oligonucleotides, the amount of lipid compound that is administered can vary and generally depends upon the amount of oligonucleotide agent being administered. For example, the weight ratio of lipid compound to oligonucleotide agent is preferably from about 1:1 to about 15:1, with a weight ratio of about 5:1 to about 10:1 being more preferred. Generally, the amount of cationic lipid compound which is administered will vary from between about 0.1 milligram (mg) to about 1 gram (g). By way of general guidance, typically between about 0.1 mg and about 10 mg of the particular oligonucleotide agent, and about 1 mg to about 100 mg of the lipid compositions, each per kilogram of patient body weight, is administered, although higher and lower amounts can be used.

The agents of the invention are administered to subjects or contacted with cells in a biologically compatible form suitable for pharmaceutical administration. By “biologically compatible form suitable for administration” is meant that the oligonucleotide is administered in a form in which any toxic effects are outweighed by the therapeutic effects of the oligonucleotide. In one embodiment, oligonucleotides can be administered to subjects. Examples of subjects include mammals, e.g., humans and other primates; cows, pigs, horses, and farming (agricultural) animals; dogs, cats, and other domesticated pets; mice, rats, and transgenic non-human animals.

Administration of an active amount of an oligonucleotide of the present invention is defined as an amount effective, at dosages and for periods of time necessary to achieve the desired result. For example, an active amount of an oligonucleotide may vary according to factors such as the type of cell, the oligonucleotide used, and for in vivo uses the disease state, age, sex, and weight of the individual, and the ability of the oligonucleotide to elicit a desired response in the individual. Establishment of therapeutic levels of oligonucleotides within the cell is dependent upon the rates of uptake and efflux or degradation. Decreasing the degree of degradation prolongs the intracellular half-life of the oligonucleotide. Thus, chemically-modified oligonucleotides, e.g., with modification of the phosphate backbone, may require different dosing.

The exact dosage of an oligonucleotide and number of doses administered will depend upon the data generated experimentally and in clinical trials. Several factors such as the desired effect, the delivery vehicle, disease indication, and the route of administration, will affect the dosage. Dosages can be readily determined by one of ordinary skill in the art and formulated into the subject pharmaceutical compositions. Preferably, the duration of treatment will extend at least through the course of the disease symptoms.

Dosage regime may be adjusted to provide the optimum therapeutic response. For example, the oligonucleotide may be repeatedly administered, e.g., several doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation. One of ordinary skill in the art will readily be able to determine appropriate doses and schedules of administration of the subject oligonucleotides, whether the oligonucleotides are to be administered to cells or to subjects.

Physical methods of introducing nucleic acids include injection of a solution containing the nucleic acid, bombardment by particles covered by the nucleic acid, soaking the cell or organism in a solution of the nucleic acid, or electroporation of cell membranes in the presence of the nucleic acid. A viral construct packaged into a viral particle would accomplish both efficient introduction of an expression construct into the cell and transcription of nucleic acid encoded by the expression construct. Other methods known in the art for introducing nucleic acids to cells may be used, such as lipid-mediated carrier transport, chemical-mediated transport, such as calcium phosphate, and the like. Thus the nucleic acid may be introduced along with components that perform one or more of the following activities: enhance nucleic acid uptake by the cell, inhibit annealing of single strands, stabilize the single strands, or other-wise increase inhibition of the target gene.

Nucleic acid may be directly introduced into the cell (i.e., intracellularly); or introduced extracellularly into a cavity, interstitial space, into the circulation of an organism, introduced orally, or may be introduced by bathing a cell or organism in a solution containing the nucleic acid. Vascular or extravascular circulation, the blood or lymph system, and the cerebrospinal fluid are sites where the nucleic acid may be introduced.

The cell with the target gene may be derived from or contained in any organism. The organism may a plant, animal, protozoan, bacterium, virus, or fungus. The plant may be a monocot, dicot or gymnosperm; the animal may be a vertebrate or invertebrate. Preferred microbes are those used in agriculture or by industry, and those that are pathogenic for plants or animals.

Alternatively, vectors, e.g., transgenes encoding a siRNA of the invention can be engineered into a host cell or transgenic animal using art recognized techniques.

A further preferred use for the agents of the present invention (or vectors or transgenes encoding same) is a functional analysis to be carried out in eukaryotic cells, or eukaryotic non-human organisms, preferably mammalian cells or organisms and most preferably human cells, e.g. cell lines such as HeLa or 293 or rodents, e.g. rats and mice. By administering a suitable priming agent/RNAi agent which is sufficiently complementary to a target mRNA sequence to direct target-specific RNA interference, a specific knockout or knockdown phenotype can be obtained in a target cell, e.g. in cell culture or in a target organism.

Thus, a further subject matter of the invention is a eukaryotic cell or a eukaryotic non-human organism exhibiting a target gene-specific knockout or knockdown phenotype comprising a fully or at least partially deficient expression of at least one endogenous target gene wherein said cell or organism is transfected with at least one vector comprising DNA encoding an RNAi agent capable of inhibiting the expression of the target gene. It should be noted that the present invention allows a target-specific knockout or knockdown of several different endogenous genes due to the specificity of the RNAi agent.

Gene-specific knockout or knockdown phenotypes of cells or non-human organisms, particularly of human cells or non-human mammals may be used in analytic to procedures, e.g. in the functional and/or phenotypical analysis of complex physiological processes such as analysis of gene expression profiles and/or proteomes. Preferably the analysis is carried out by high throughput methods using oligonucleotide based chips.

Assays of Oligonucleotide Stability

In some embodiments, the oligonucleotides of the invention are stabilized, i.e., substantially resistant to endonuclease and exonuclease degradation. An oligonucleotide is defined as being substantially resistant to nucleases when it is at least about 3-fold more resistant to attack by an endogenous cellular nuclease, and is highly nuclease resistant when it is at least about 6-fold more resistant than a corresponding oligonucleotide. This can be demonstrated by showing that the oligonucleotides of the invention are substantially resistant to nucleases using techniques which are known in the art.

One way in which substantial stability can be demonstrated is by showing that the oligonucleotides of the invention function when delivered to a cell, e.g., that they reduce transcription or translation of target nucleic acid molecules, e.g., by measuring protein levels or by measuring cleavage of mRNA. Assays which measure the stability of target RNA can be performed at about 24 hours post-transfection (e.g., using Northern blot techniques, RNase Protection Assays, or QC-PCR assays as known in the art). Alternatively, levels of the target protein can be measured. Preferably, in addition to testing the RNA or protein levels of interest, the RNA or protein levels of a control, non-targeted gene will be measured (e.g., actin, or preferably a control with sequence similarity to the target) as a specificity control. RNA or protein measurements can be made using any art-recognized technique. Preferably, measurements will be made beginning at about 16-24 hours post transfection. (M. Y. Chiang, et al. 1991. J Biol Chem. 266:18162-71; T. Fisher, et al. 1993. Nucleic Acids Research. 21 3857).

The ability of an oligonucleotide composition of the invention to inhibit protein synthesis can be measured using techniques which are known in the art, for example, by detecting an inhibition in gene transcription or protein synthesis. For example, Nuclease S mapping can be performed. In another example, Northern blot analysis can be used to measure the presence of RNA encoding a particular protein. For example, total RNA can be prepared over a cesium chloride cushion (see, e.g., Ausebel et al., 1987. Current Protocols in Molecular Biology (Greene & Wiley, New York)). Northern blots can then be made using the RNA and probed (see, e.g., Id.). In another example, the level of the specific mRNA produced by the target protein can be measured, e.g., using PCR. In yet another example, Western blots can be used to measure the amount of target protein present. In still another embodiment, a phenotype influenced by the amount of the protein can be detected. Techniques for performing Western blots are well known in the art, see, e.g., Chen et al. J. Biol. Chem. 271:28259.

In another example, the promoter sequence of a target gene can be linked to a reporter gene and reporter gene transcription (e.g., as described in more detail below) can be monitored. Alternatively, oligonucleotide compositions that do not target a promoter can be identified by fusing a portion of the target nucleic acid molecule with a reporter gene so that the reporter gene is transcribed. By monitoring a change in the expression of the reporter gene in the presence of the oligonucleotide composition, it is possible to determine the effectiveness of the oligonucleotide composition in inhibiting the expression of the reporter gene. For example, in one embodiment, an effective oligonucleotide composition will reduce the expression of the reporter gene.

A “reporter gene” is a nucleic acid that expresses a detectable gene product, which may be RNA or protein. Detection of mRNA expression may be accomplished by Northern blotting and detection of protein may be accomplished by staining with antibodies specific to the protein. Preferred reporter genes produce a readily detectable product. A reporter gene may be operably linked with a regulatory DNA sequence such that detection of the reporter gene product provides a measure of the transcriptional activity of the regulatory sequence. In preferred embodiments, the gene product of the reporter gene is detected by an intrinsic activity associated with that product. For instance, the reporter gene may encode a gene product that, by enzymatic activity, gives rise to a detectable signal based on color, fluorescence, or luminescence. Examples of reporter genes include, but are not limited to, those coding for chloramphenicol acetyl transferase (CAT), luciferase, beta-galactosidase, and alkaline phosphatase.

One skilled in the art would readily recognize numerous reporter genes suitable for use in the present invention. These include, but are not limited to, chloramphenicol acetyltransferase (CAT), luciferase, human growth hormone (hGH), and beta-galactosidase. Examples of such reporter genes can be found in F. A. Ausubel et al., Eds., Current Protocols in Molecular Biology, John Wiley & Sons, New York, (1989). Any gene that encodes a detectable product, e.g., any product having detectable enzymatic activity or against which a specific antibody can be raised, can be used as a reporter gene in the present methods.

One reporter gene system is the firefly luciferase reporter system. (Gould, S. J., and Subramani, S. 1988. Anal. Biochem., 7:404-408 incorporated herein by reference). The luciferase assay is fast and sensitive. In this assay, a lysate of the test cell is prepared and combined with ATP and the substrate luciferin. The encoded enzyme luciferase catalyzes a rapid, ATP dependent oxidation of the substrate to generate a light-emitting product. The total light output is measured and is proportional to the amount of luciferase present over a wide range of enzyme concentrations.

CAT is another frequently used reporter gene system; a major advantage of this system is that it has been an extensively validated and is widely accepted as a measure of promoter activity. (Gorman C. M., Moffat, L. F., and Howard, B. H. 1982. Mol. Cell. Biol., 2:1044-1051). In this system, test cells are transfected with CAT expression vectors and incubated with the candidate substance within 2-3 days of the initial transfection. Thereafter, cell extracts are prepared. The extracts are incubated with acetyl CoA and radioactive chloramphenicol. Following the incubation, acetylated chloramphenicol is separated from nonacetylated form by thin layer chromatography. In this assay, the degree of acetylation reflects the CAT gene activity with the particular promoter.

Another suitable reporter gene system is based on immunologic detection of hGH. This system is also quick and easy to use. (Selden, R., Burke-Howie, K. Rowe, M. E., Goodman, H. M., and Moore, D. D. (1986), Mol. Cell, Biol., 6:3173-3179 incorporated herein by reference). The hGH system is advantageous in that the expressed hGH polypeptide is assayed in the media, rather than in a cell extract. Thus, this system does not require the destruction of the test cells. It will be appreciated that the principle of this reporter gene system is not limited to hGH but rather adapted for use with any polypeptide for which an antibody of acceptable specificity is available or can be prepared.

In one embodiment, nuclease stability of a double-stranded oligonucleotide of the invention is measured and compared to a control, e.g., an RNAi molecule typically used in the art (e.g., a duplex oligonucleotide of less than 25 nucleotides in length and comprising 2 nucleotide base overhangs) or an unmodified RNA duplex with blunt ends.

The target RNA cleavage reaction achieved using the siRNAs of the invention is highly sequence specific. Sequence identity may determined by sequence comparison and alignment algorithms known in the art. To determine the percent identity of two nucleic acid sequences (or of two amino acid sequences), the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the first sequence or second sequence for optimal alignment). A preferred, non-limiting example of a local alignment algorithm utilized for the comparison of sequences is the algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 87:2264-68, modified as in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-77. Such an algorithm is incorporated into the BLAST programs (version 2.0) of Altschul, et al. (1990) J. Mol. Biol. 215:403-10. Greater than 90% sequence identity, e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or even 100% sequence identity, between the siRNA and the portion of the target gene is preferred. Alternatively, the siRNA may be defined functionally as a nucleotide sequence (or oligonucleotide sequence) that is capable of hybridizing with a portion of the target gene transcript. Examples of stringency conditions for polynucleotide hybridization are provided in Sambrook, J., E. F. Fritsch, and T. Maniatis, 1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., chapters 9 and 11, and Current Protocols in Molecular Biology, 1995, F. M. Ausubel et al., eds., John Wiley & Sons, Inc., sections 2.10 and 6.3-6.4, incorporated herein by reference.

Therapeutic Use

By inhibiting the expression of a gene, the oligonucleotide compositions of the present invention can be used to treat any disease involving the expression of a protein. Examples of diseases that can be treated by oligonucleotide compositions, just to illustrate, include: cancer, retinopathies, autoimmune diseases, inflammatory diseases (i.e., ICAM-1 related disorders, Psoriasis, Ulcerative Colitus, Crohn's disease), viral diseases (i.e., HIV, Hepatitis C), miRNA disorders, and cardiovascular diseases.

In one embodiment, in vitro treatment of cells with oligonucleotides can be used for ex vivo therapy of cells removed from a subject (e.g., for treatment of leukemia or viral infection) or for treatment of cells which did not originate in the subject, but are to be administered to the subject (e.g., to eliminate transplantation antigen expression on cells to be transplanted into a subject). In addition, in vitro treatment of cells can be used in non-therapeutic settings, e.g., to evaluate gene function, to study gene regulation and protein synthesis or to evaluate improvements made to oligonucleotides designed to modulate gene expression or protein synthesis. In vivo treatment of cells can be useful in certain clinical settings where it is desirable to inhibit the expression of a protein. There are numerous medical conditions for which antisense therapy is reported to be suitable (see, e.g., U.S. Pat. No. 5,830,653) as well as respiratory syncytial virus infection (WO 95/22,553) influenza virus (WO 94/23,028), and malignancies (WO 94/08,003). Other examples of clinical uses of antisense sequences are reviewed, e.g., in Glaser. 1996. Genetic Engineering News 16:1. Exemplary targets for cleavage by oligonucleotides include, e.g., protein kinase Ca, ICAM-1, c-raf kinase, p53, c-myb, and the bcr/abl fusion gene found in chronic myelogenous leukemia.

The subject nucleic acids can be used in RNAi-based therapy in any animal having RNAi pathway, such as human, non-human primate, non-human mammal, non-human vertebrates, rodents (mice, rats, hamsters, rabbits, etc.), domestic livestock animals, pets (cats, dogs, etc.), Xenopus, fish, insects (Drosophila, etc.), and worms (C. elegans), etc.

The invention provides methods for preventing in a subject, a disease or condition associated with an aberrant or unwanted target gene expression or activity, by administering to the subject a therapeutic agent (e.g., a RNAi agent or vector or transgene encoding same). If appropriate, subjects are first treated with a priming agent so as to be more responsive to the subsequent RNAi therapy. Subjects at risk for a disease which is caused or contributed to by aberrant or unwanted target gene expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the target gene aberrancy, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending on the type of target gene aberrancy, for example, a target gene, target gene agonist or target gene antagonist agent can be used for treating the subject.

In another aspect, the invention pertains to methods of modulating target gene expression, protein expression or activity for therapeutic purposes. Accordingly, in an exemplary embodiment, the modulatory method of the invention involves contacting a cell capable of expressing target gene with a therapeutic agent of the invention that is specific for the target gene or protein (e.g., is specific for the mRNA encoded by said gene or specifying the amino acid sequence of said protein) such that expression or one or more of the activities of target protein is modulated. These modulatory methods can be performed in vitro (e.g., by culturing the cell with the agent), in vivo (e.g., by administering the agent to a subject), or ex vivo. Typically, subjects are first treated with a priming agent so as to be more responsive to the subsequent RNAi therapy. As such, the present invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant or unwanted expression or activity of a target gene polypeptide or nucleic acid molecule. Inhibition of target gene activity is desirable in situations in which target gene is abnormally unregulated and/or in which decreased target gene activity is likely to have a beneficial effect.

The therapeutic agents of the invention can be administered to individuals to treat (prophylactically or therapeutically) disorders associated with aberrant or unwanted target gene activity. In conjunction with such treatment, pharmacogenomics (i.e., the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, a physician or clinician may consider applying knowledge obtained in relevant pharmacogenomics studies in determining whether to administer a therapeutic agent as well as tailoring the dosage and/or therapeutic regimen of treatment with a therapeutic agent. Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See, for example, Eichelbaum, M. et al. (1996) Clin. Exp. Pharmacol. Physiol. 23(10-11): 983-985 and Linder, M. W. et al. (1997) Clin. Chem. 43(2):254-266

RNAi in Skin Indications

Nucleic acid molecules, or compositions comprising nucleic acid molecules, described herein may in some embodiments be administered to pre-treat, treat or prevent compromised skin. As used herein “compromised skin” refers to skin which exhibits characteristics distinct from normal skin. Compromised skin may occur in association with a dermatological condition. Several non-limiting examples of dermatological conditions include rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris. In some instances, compromised skin may comprise a wound and/or scar tissue. In some instances, methods and compositions associated with the invention may be used to promote wound healing, prevention, reduction or inhibition of scarring, and/or promotion of re-epithelialisation of wounds.

A subject can be pre-treated or treated prophylactically with a molecule associated with the invention, prior to the skin of the subject becoming compromised. As used herein “pre-treatment” or “prophylactic treatment” refers to administering a nucleic acid to the skin prior to the skin becoming compromised. For example, a subject could be pre-treated 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 24 hours, 48 hours, or more than 48 hours prior to the skin becoming compromised. In other embodiments, a subject can be treated with a molecule associated with the invention immediately before the skin becomes compromised and/or simultaneous to the skin becoming compromised and/or after the skin has been compromised. In some embodiments, the skin is compromised through a medical procedure such as surgery, including elective surgery. In certain embodiments methods and compositions may be applied to areas of the skin that are believed to be at risk of becoming compromised. It should be appreciated that one of ordinary skill in the art would be able to optimize timing of administration using no more than routine experimentation.

In some aspects, methods associated with the invention can be applied to promote healing of compromised skin. Administration can occur at any time up until the compromised skin has healed, even if the compromised skin has already partially healed. The timing of administration can depend on several factors including the nature of the compromised skin, the degree of damage within the compromised skin, and the size of the compromised area. In some embodiments administration may occur immediately after the skin is compromised, or 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 48 hours, or more than 48 hours after the skin has been compromised. Methods and compositions of the invention may be administered one or more times as necessary. For example, in some embodiments, compositions may be administered daily or twice daily. In some instances, compositions may be administered both before and after formation of compromised skin.

Compositions associated with the invention may be administered by any suitable route. In some embodiments, administration occurs locally at an area of compromised skin. For example, compositions may be administered by intradermal injection. Compositions for intradermal injection may include injectable solutions. Intradermal injection may in some embodiments occur around the are of compromised skin or at a site where the skin is likely to become compromised. In some embodiments, compositions may also be administered in a topical form, such as in a cream or ointment. In some embodiments, administration of compositions described herein comprises part of an initial treatment or pre-treatment of compromised skin, while in other embodiments, administration of such compositions comprises follow-up care for an area of compromised skin.

The appropriate amount of a composition or medicament to be applied can depend on many different factors and can be determined by one of ordinary skill in the art through routine experimentation. Several non-limiting factors that might be considered include biological activity and bioavailability of the agent, nature of the agent, mode of administration, half-life, and characteristics of the subject to be treated.

In some aspects, nucleic acid molecules associated with the invention may also be used in treatment and/or prevention of fibrotic disorders, including pulmonary fibrosis, liver cirrhosis, scleroderma and glomerulonephritis, lung fibrosis, liver fibrosis, skin fibrosis, muscle fibrosis, radiation fibrosis, kidney fibrosis, proliferative vitreoretinopathy and uterine fibrosis.

A therapeutically effective amount of a nucleic acid molecule described herein may in some embodiments be an amount sufficient to prevent the formation of compromised skin and/or improve the condition of compromised skin. In some embodiments, improvement of the condition of compromised skin may correspond to promotion of wound healing and/or inhibition of scarring and/or promotion of epithelial regeneration. The extent of prevention of formation of compromised skin and/or improvement to the condition of compromised skin may in some instances be determined by, for example, a doctor or clinician.

The ability of nucleic acid molecules associated with the invention to prevent the formation of compromised skin and/or improve the condition of compromised skin may in some instances be measured with reference to properties exhibited by the skin. In some instances, these properties may include rate of epithelialisation and/or decreased size of an area of compromised skin compared to control skin at comparable time points.

As used herein, prevention of formation of compromised skin, for example prior to a surgical procedure, and/or improvement of the condition of compromised skin, for example after a surgical procedure, can encompass any increase in the rate of healing in the compromised skin as compared with the rate of healing occurring in a control sample. In some instances, the condition of compromised skin may be assessed with respect to either comparison of the rate of re-epithelialisation achieved in treated and control skin, or comparison of the relative areas of treated and control areas of compromised skin at comparable time points. In some aspects, a molecule that prevents formation of compromised skin or promotes healing of compromised skin may be a molecule that, upon administration, causes the area of compromised skin to exhibit an increased rate of re-epithelialisation and/or a reduction of the size of compromised skin compared to a control at comparable time points. In some embodiments, the healing of compromised skin may give rise to a rate of healing that is 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% greater than the rate occurring in controls.

In some aspects, subjects to be treated by methods and compositions associated with the invention may be subjects who will undergo, are undergoing or have undergone a medical procedure such as a surgery. In some embodiments, the subject may be prone to defective, delayed or otherwise impaired re-epithelialisation, such as dermal wounds in the aged. Other non-limiting examples of conditions or disorders in which wound healing is associated with delayed or otherwise impaired re-epithelialisation include patients suffering from diabetes, patients with polypharmacy, post-menopausal women, patients susceptible to pressure injuries, patients with venous disease, clinically obese patients, patients receiving chemotherapy, patients receiving radiotherapy, patients receiving steroid treatment, and immuno-compromised patients. In some instances, defective re-epithelialisation response can contributes to infections at the wound site, and to the formation of chronic wounds such as ulcers.

In some embodiments, methods associated with the invention may promote the re-epithelialisation of compromised skin in chronic wounds, such as ulcers, and may also inhibit scarring associated with wound healing. In other embodiments, methods associated with the invention are applied to prevention or treatment of compromised skin in acute wounds in patients predisposed to impaired wound healing developing into chronic wounds. In other aspects, methods associated with the invention are applied to promote accelerated healing of compromised skin while preventing, reducing or inhibiting scarring for use in general clinical contexts. In some aspects, this can involve the treatment of surgical incisions and application of such methods may result in the prevention, reduction or inhibition of scarring that may otherwise occur on such healing. Such treatment may result in the scars being less noticeable and exhibiting regeneration of a more normal skin structure. In other embodiments, the compromised skin that is treated is not compromised skin that is caused by a surgical incision. The compromised skin may be subject to continued care and continued application of medicaments to encourage re-epithelialisation and healing.

In some aspects, methods associated with the invention may also be used in the treatment of compromised skin associated with grafting procedures. This can involve treatment at a graft donor site and/or at a graft recipient site. Grafts can in some embodiments involve skin, artificial skin, or skin substitutes. Methods associated with the invention can also be used for promoting epithelial regeneration. As used herein, promotion of epithelial regeneration encompasses any increase in the rate of epithelial regeneration as compared to the regeneration occurring in a control-treated or untreated epithelium. The rate of epithelial regeneration attained can in some instances be compared with that taking place in control-treated or untreated epithelia using any suitable model of epithelial regeneration known in the art. Promotion of epithelial regeneration may be of use to induce effective re-epithelialisation in contexts in which the re-epithelialisation response is impaired, inhibited, retarded or otherwise defective. Promotion of epithelial regeneration may be also effected to accelerate the rate of defective or normal epithelial regeneration responses in patients suffering from epithelial damage.

Some instances where re-epithelialisation response may be defective include conditions such as pemphigus, Hailey-Hailey disease (familial benign pemphigus), toxic epidermal necrolysis (TEN)/Lyell's syndrome, epidermolysis bullosa, cutaneous leishmaniasis and actinic keratosis. Defective re-epithelialisation of the lungs may be associated with idiopathic pulmonary fibrosis (IPF) or interstitial lung disease. Defective re-epithelialisation of the eye may be associated with conditions such as partial limbal stem cell deficiency or corneal erosions. Defective re-epithelialisation of the gastrointestinal tract or colon may be associated with conditions such as chronic anal fissures (fissure in ano), ulcerative colitis or Crohn's disease, and other inflammatory bowel disorders.

In some aspects, methods associated with the invention are used to prevent, reduce or otherwise inhibit compromised skin associated with scarring. This can be applied to any site within the body and any tissue or organ, including the skin, eye, nerves, tendons, ligaments, muscle, and oral cavity (including the lips and palate), as well as internal organs (such as the liver, heart, brain, abdominal cavity, pelvic cavity, thoracic cavity, guts and reproductive tissue). In the skin, treatment may change the morphology and organization of collagen fibers and may result in making the scars less visible and blend in with the surrounding skin. As used herein, prevention, reduction or inhibition of scarring encompasses any degree of prevention, reduction or inhibition in scarring as compared to the level of scarring occurring in a control-treated or untreated wound.

Prevention, reduction or inhibition of compromised skin, such as compromised skin associated with dermal scarring, can be assessed and/or measured with reference to microscopic and/or macroscopic characteristics. Macroscopic characteristics may include color, height, surface texture and stiffness of the skin. In some instances, prevention, reduction or inhibition of compromised skin may be demonstrated when the color, height, surface texture and stiffness of the skin resembles that of normal skin more closely after treatment than does a control that is untreated. Microscopic assessment of compromised skin may involve examining characteristics such as thickness and/or orientation and/or composition of the extracellular matrix (ECM) fibers, and cellularity of the compromised skin. In some instances, prevention, reduction or inhibition of compromised skin may be demonstrated when the thickness and/or orientation and/or composition of the extracellular matrix (ECM) fibers, and/or cellularity of the compromised skin resembles that of normal skin more closely after treatment than does a control that is untreated.

In some aspects, methods associated with the invention are used for cosmetic purposes, at least in part to contribute to improving the cosmetic appearance of compromised skin. In some embodiments, methods associated with the invention may be used to prevent, reduce or inhibit compromised skin such as scarring of wounds covering joints of the body. In other embodiments, methods associated with the invention may be used to promote accelerated wound healing and/or prevent, reduce or inhibit scarring of wounds at increased risk of forming a contractile scar, and/or of wounds located at sites of high skin tension.

In some embodiments, methods associated with the invention can be applied to promoting healing of compromised skin in instances where there is an increased risk of pathological scar formation, such as hypertrophic scars and keloids, which may have more pronounced deleterious effects than normal scarring. In some embodiments, methods described herein for promoting accelerated healing of compromised skin and/or preventing, reducing or inhibiting scarring are applied to compromised skin produced by surgical revision of pathological scars.

Aspects of the invention can be applied to compromised skin caused by burn injuries. Healing in response to burn injuries can lead to adverse scarring, including the formation of hypertrophic scars. Methods associated with the invention can be applied to treatment of all injuries involving damage to an epithelial layer, such as injuries to the skin in which the epidermis is damaged. Other non-limiting examples of injuries to epithelial tissue include injuries involving the respiratory epithelia, digestive epithelia or epithelia surrounding internal tissues or organs.

Target Genes

It should be appreciated that based on the RNAi molecules designed and disclosed herein, one of ordinary skill in the art would be able to design such RNAi molecules to target a variety of different genes depending on the context and intended use. For purposes of pre-treating, treating, or preventing compromised skin and/or promoting wound healing and/or preventing, reducing or inhibiting scarring, one of ordinary skill in the art would appreciate that a variety of suitable target genes could be identified based at least in part on the known or predicted functions of the genes, and/or the known or predicted expression patterns of the genes. Several non-limiting examples of genes that could be targeted by RNAi molecules for pre-treating, treating, or preventing compromised skin and/or promoting wound healing and/or preventing, reducing or inhibiting scarring include genes that encode for the following proteins: Transforming growth factor β (TGFβ1, TGFβ2, TGFβ3), Osteopontin, Connective tissue growth factor (CTGF), Platelet-derived growth factor (PDGF), Hypoxia inducible factor-1α (HIF1α), Collagen I and/or III, Prolyl 4-hydroxylase (P4H), Procollagen C-protease (PCP), Matrix metalloproteinase 2, 9 (MMP2, 9), Integrins, Connexin, Histamine H1 receptor, Tissue transglutaminase, Mammalian target of rapamycin (mTOR), HoxB13, VEGF, IL-6, SMAD proteins, Ribosomal protein S6 kinases (RSP6) and Cyclooxygenase-2 (COX-2).

Transforming growth factor β proteins, for which three isoforms exist in mammals (TGFβ1, TGFβ2, TGFβ3), are secreted proteins belonging to a superfamily of growth factors involved in the regulation of many cellular processes including proliferation, migration, apoptosis, adhesion, differentiation, inflammation, immuno-suppression and expression of extracellular proteins. These proteins are produced by a wide range of cell types including epithelial, endothelial, hematopoietic, neuronal, and connective tissue cells. Representative Genbank accession numbers providing DNA and protein sequence information for human TGFβ1, TGFβ2 and TGFβ3 are BT007245, BC096235, and X14149, respectively. Within the TGFβ family, TGFβ1 and TGFβ2 but not TGFβ3 represent suitable targets. The alteration in the ratio of TGFβ variants will promote better wound healing and will prevent excessive scar formation. Osteopontin (OPN), also known as Secreted phosphoprotein 1 (SPP1), Bone Sinaloprotein 1 (BSP-1), and early T-lymphocyte activation (ETA-1) is a secreted glycoprotein protein that binds to hydroxyapatite. OPN has been implicated in a variety of biological processes including bone remodeling, immune functions, chemotaxis, cell activation and apoptosis. Osteopontin is produced by a variety of cell types including fibroblasts, preosteoblasts, osteoblasts, osteocytes, odontoblasts, bone marrow cells, hypertrophic chondrocytes, dendritic cells, macrophages, smooth muscle, skeletal muscle myoblasts, endothelial cells, and extraosseous (non-bone) cells in the inner ear, brain, kidney, deciduum, and placenta. Representative Genbank accession number providing DNA and protein sequence information for human Osteopontin are NM_000582.2 and X13694.

Connective tissue growth factor (CTGF), also known as Hypertrophic chondrocyte-specific protein 24, is a secreted heparin-binding protein that has been implicated in wound healing and scleroderma. Connective tissue growth factor is active in many cell types including fibroblasts, myofibroblasts, endothelial and epithelial cells. Representative Genbank accession number providing DNA and protein sequence information for human CTGF are NM_001901.2 and M92934.

The Platelet-derived growth factor (PDGF) family of proteins, including several isoforms, are secreted mitogens. PDGF proteins are implicated in wound healing, at least in part, because they are released from platelets following wounding. Representative Genbank accession numbers providing DNA and protein sequence information for human PDGF genes and proteins include X03795 (PDGFA), X02811 (PDGFB), AF091434 (PDGFC), AB033832 (PDGFD).

Hypoxia inducible factor-1α (HIF1α), is a transcription factor involved in cellular response to hypoxia. HIF1α is implicated in cellular processes such as embryonic vascularization, tumor angiogenesis and pathophysiology of ischemic disease. A representative Genbank accession number providing DNA and protein sequence information for human HIF1α is U22431.

Collagen proteins are the most abundant mammalian proteins and are found in tissues such as skin, tendon, vascular, ligature, organs, and bone. Collagen I proteins (such as COL1A1 and COL1A2) are detected in scar tissue during wound healing, and are expressed in the skin. Collagen III proteins (including COL3A1) are detected in connective tissue in wounds (granulation tissue), and are also expressed in skin. Representative Genbank accession numbers providing DNA and protein sequence information for human Collagen proteins include: Z74615 (COL1A1), J03464 (COL1A2) and X14420 (COL3A1).

Prolyl 4-hydroxylase (P4H), is involved in production of collagen and in oxygen sensing. A representative Genbank accession number providing DNA and protein sequence information for human P4H is AY198406.

Procollagen C-protease (PCP) is another target.

Matrix metalloproteinase 2, 9 (MMP2, 9) belong to the metzincin metalloproteinase superfamily and are zinc-dependent endopeptidases. These proteins are implicated in a variety of cellular processes including tissue repair. Representative Genbank accession numbers providing DNA and protein sequence information for human MMP proteins are M55593 (MMP2) and J05070 (MMP9).

Integrins are a family of proteins involved in interaction and communication between a cell and the extracellular matrix. Vertebrates contain a variety of integrins including α₁β₁, α₂β₁, α₄β₁, α₅β₁, α₆β₁, α_Lβ₂, α_Mβ₂, α_11bβ₃, α_vβ₃, α_vβ₅, α_vβ₆, α₆β₄.

Connexins are a family of vertebrate transmembrane proteins that form gap junctions. Several examples of Connexins, with the accompanying gene name shown in brackets, include Cx23 (GJE1), Cx25 (GJB7), Cx26 (GJB2), Cx29 (GJE1), Cx30 (GJB6), Cx30.2 (GJC3), Cx30.3 (GJB4), Cx31 (GJB3), Cx31.1 (GJB5), Cx31.9 (GJC1/GJD3), Cx32 (GJB1), Cx33 (GJA6), Cx36 (GJD2/GJA9), Cx37 (GJA4), Cx39 (GJD4), Cx40 (GJA5), Cx40.1 (GJD4), Cx43 (GJA1), Cx45 (GJC1/GJA7), Cx46 (GJA3), Cx47 (GJC2/GJA12), Cx50 (GJA8), Cx59 (GJA10), and Cx62 (GJA10).

Histamine H1 receptor (HRH1) is a metabotropic G-protein-coupled receptor involved in the phospholipase C and phosphatidylinositol (PIP2) signaling pathways. A representative Genbank accession number providing DNA and protein sequence information for human HRH1 is Z34897.

Tissue transglutaminase, also called Protein-glutamine gamma-glutamyltransferase 2, is involved in protein crosslinking and is implicated is biological processes such as apoptosis, cellular differentiation and matrix stabilization. A representative Genbank accession number providing DNA and protein sequence information for human Tissue transglutaminase is M55153.

Mammalian target of rapamycin (mTOR), also known as Serine/threonine-protein kinase mTOR and FK506 binding protein 12-rapamycin associated protein 1 (FRAP1), is involved in regulating cell growth and survival, cell motility, transcription and translation. A representative Genbank accession number providing DNA and protein sequence information for human mTOR is L34075.

HoxB13 belongs to the family of Homeobox proteins and has been linked to functions such as cutaneous regeneration and fetal skin development. A representative Genbank accession number providing DNA and protein sequence information for human HoxB13 is U57052.

Vascular endothelial growth factor (VEGF) proteins are growth factors that bind to tyrosine kinase receptors and are implicated in multiple disorders such as cancer, age-related macular degeneration, rheumatoid arthritis and diabetic retinopathy. Members of this protein family include VEGF-A, VEGF-B, VEGF-C and VEGF-D. Representative Genbank accession numbers providing DNA and protein sequence information for human VEGF proteins are M32977 (VEGF-A), U43368 (VEGF-B), X94216 (VEGF-C), and D89630 (VEGF-D).

Interleukin-6 (IL-6) is a cytokine involved in stimulating immune response to tissue damage. A representative Genbank accession number providing DNA and protein sequence information for human IL-6 is X04430.

SMAD proteins (SMAD1-7, 9) are a family of transcription factors involved in regulation of TGFβ signaling. Representative Genbank accession numbers providing DNA and protein sequence information for human SMAD proteins are U59912 (SMAD1), U59911 (SMAD2), U68019 (SMAD3), U44378 (SMAD4), U59913 (SMAD5), U59914 (SMAD6), AF015261 (SMAD7), and BC011559 (SMAD9).

Ribosomal protein S6 kinases (RSK6) represent a family of serine/threonine kinases involved in activation of the transcription factor CREB. A representative Genbank accession number providing DNA and protein sequence information for human Ribosomal protein S6 kinase alpha-6 is AF184965.

Cyclooxygenase-2 (COX-2), also called Prostaglandin G/H synthase 2 (PTGS2), is involved in lipid metabolism and biosynthesis of prostanoids and is implicated in inflammatory disorders such as rheumatoid arthritis. A representative Genbank accession number providing DNA and protein sequence information for human COX-2 is AY462100.

EXAMPLES

Example 1: Inhibition of Gene Expression Using Minimum Length Trigger RNAs

Transfection of Minimum Length Trigger (mlt) RNA

mltRNA constructs were chemically synthesized (Integrated DNA Technologies, Coralville, Iowa) and transfected into HEK293 cells (ATCC, Manassas, Va.) using the Lipofectamine RNAiMAX (Invitrogen, Carlsbad, Calif.) reagent according to manufacturer's instructions. In brief, RNA was diluted to a 12× concentration and then combined with a 12× concentration of Lipofectamine RNAiMAX to complex. The RNA and transfection reagent were allowed to complex at room temperature for 20 minutes and make a 6× concentration. While complexing, HEK293 cells were washed, trypsinized and counted. The cells were diluted to a concentration recommended by the manufacturer and previously described conditions which was at 1×10⁵ cells/mi. When RNA had completed complexing with the RNAiMAX transfection reagent, 20ul of the complexes were added to the appropriate well of the 96-well plate in triplicate. Cells were added to each well (100ul volume) to make the final cell count per well at 1×10⁴ cells/well. The volume of cells diluted the 6× concentration of complex to IX which was equal to a concentration noted (between 10-0.05 nM). Cells were incubated for 24 or 48 hours under normal growth conditions.

After 24 or 48 hour incubation cells were lysed and gene silencing activity was measured using the QuantiGene assay (Panomics, Freemont, Calif.) which employs bDNA hybridization technology. The assay was carried out according to manufacturer's instructions.

ΔG Calculation

ΔG was calculated using Mfold, available through the Mfold internet site (http://mfold.bioinfo.rpi.edu/cgi-bin/rna-form1.cgi). Methods for calculating ΔG are described in, and are incorporated by reference from, the following references: Zuker, M. (2003) Nucleic Acids Res., 31(13):3406-15; Mathews, D. H., Sabina, J., Zuker, M. and Turner, D. H. (1999) J. Mol. Biol. 288:911-940; Mathews, D. H., Disney, M. D., Childs, J. L., Schroeder, S. J., Zuker, M., and Turner, D. H. (2004) Proc. Natl. Acad. Sci. 101:7287-7292; Duan, S., Mathews, D. H., and Turner, D. H. (2006) Biochemistry 45:9819-9832; Wuchty, S., Fontana, W., Hofacker, I. L., and Schuster, P. (1999) Biopolymers 49:145-165.

Example 2: Optimization of Sd-rxRNA^nano Molecules for Gene Silencing

Asymmetric double stranded RNAi molecules, with minimal double stranded regions, were developed herein and are highly effective at gene silencing. These molecules can contain a variety of chemical modifications on the sense and/or anti-sense strands, and can be conjugated to sterol-like compounds such as cholesterol.

FIGS. 1-3 present schematics of RNAi molecules associated with the invention. In the asymmetric molecules, which contain a sense and anti-sense strand, either of the strands can be the longer strand. Either strand can also contain a single-stranded region. There can also be mismatches between the sense and anti-sense strand, as indicated in FIG. 1D. Preferably, one end of the double-stranded molecule is either blunt-ended or contains a short overhang such as an overhang of one nucleotide. FIG. 2 indicates types of chemical modifications applied to the sense and anti-sense strands including 2′F, 2′OMe, hydrophobic modifications and phosphorothioate modifications. Preferably, the single stranded region of the molecule contains multiple phosphorothioate modifications. Hydrophobicity of molecules can be increased using such compounds as 4-pyridyl at 5-U, 2-pyridyl at 5-U, isobutyl at 5-U and indolyl at 5-U (FIG. 2). Proteins or peptides such as protamine (or other Arg rich peptides), spermidine or other similar chemical structures can also be used to block duplex charge and facilitate cellular entry (FIG. 3). Increased hydrophobicity can be achieved through either covalent or non-covalent modifications. Several positively charged chemicals, which might be used for polynucleotide charge blockage are depicted in FIG. 4.

Chemical modifications of polynucleotides, such as the guide strand in a duplex molecule, can facilitate RISC entry. FIG. 5 depicts single stranded polynucleotides, representing a guide strand in a duplex molecule, with a variety of chemical modifications including 2′d, 2′OMe, 2′F, hydrophobic modifications, phosphorothioate modifications, and attachment of conjugates such as “X” in FIG. 5, where X can be a small molecule with high affinity to a PAZ domain, or sterol-type entity. Similarly, FIG. 6 depicts single stranded polynucleotides, representing a passenger strand in a duplex molecule, with proposed structural and chemical compositions of RISC substrate inhibitors. Combinations of chemical modifications can ensure efficient uptake and efficient binding to preloaded RISC complexes.

FIG. 7 depicts structures of polynucleotides with sterol-type molecules attached, where R represents a polycarbonic tail of 9 carbons or longer. FIG. 8 presents examples of naturally occurring phytosterols with a polycarbon chain longer than 8 attached at position 17. More than 250 different types of phytosterols are known. FIG. 9 presents examples of sterol-like structures with variations in the sizes of the polycarbon chains attached at position 17. FIG. 91 presents further examples of sterol-type molecules that can be used as a hydrophobic entity in place of cholesterol. FIG. 92 presents further examples of hydrophobic molecules that might be used as hydrophobic entities in place of cholesterol. Optimization of such characteristics can improve uptake properties of the RNAi molecules. FIG. 10 presents data adapted from Martins et al. (J Lipid Research), showing that the percentage of liver uptake and plasma clearance of lipid emulsions containing sterol-type molecules is directly affected by the size of the attached polycarbon chain at position 17. FIG. 11 depicts a micelle formed from a mixture of polynucleotides attached to hydrophobic conjugates and fatty acids. FIG. 12 describes how alteration in lipid composition can affect pharmacokinetic behavior and tissue distribution of hydrophobically modified and/or hydrophobically conjugated polynucleotides. In particular, the use of lipid mixtures that are enriched in linoleic acid and cardiolipin results in preferential uptake by cardiomyocites.

FIG. 13 depicts examples of RNAi constructs and controls designed to target MAP4K4 expression. FIGS. 14 and 15 reveal that RNAi constructs with minimal duplex regions (such as duplex regions of approximately 13 nucleotides) are effective in mediating RNA silencing in cell culture. Parameters associated with these RNA molecules are shown in FIG. 16. FIG. 17 depicts examples of RNAi constructs and controls designed to target SOD1 expression. FIGS. 18 and 19 reveal the results of gene silencing experiments using these RNAi molecules to target SOD1 in cells. FIG. 20 presents a schematic indicating that RNA molecules with double stranded regions that are less than 10 nucleotides are not cleaved by Dicer, and FIG. 21 presents a schematic of a hypothetical RNAi model for RNA induced gene silencing.

The RNA molecules described herein were subject to a variety of chemical modifications on the sense and antisense strands, and the effects of such modifications were observed. RNAi molecules were synthesized and optimized through testing of a variety of modifications. In first generation optimization, the sense (passenger) and anti-sense (guide) strands of the sd-rxRNA^nano molecules were modified for example through incorporation of C and U 2′OMe modifications, 2′F modifications, phosphorothioate modifications, phosphorylation, and conjugation of cholesterol. Molecules were tested for inhibition of MAP4K4 expression in cells including HeLa, primary mouse hepatocytes and primary human hepatocytes through both lipid-mediated and passive uptake transfection.

FIG. 22 reveals that chemical modifications can enhance gene silencing. In particular, modifying the guide strand with 2′F UC modifications, and with a stretch of phosphorothioate modifications, combined with complete CU O′Me modification of the passenger strands, resulted in molecules that were highly effective in gene silencing. The effect of chemical modification on in vitro efficacy in un-assisted delivery in HeLa cells was also examined. FIG. 23 reveals that compounds lacking any of 2′F, 2′OMe, a stretch of phosphorothioate modifications, or cholesterol conjugates, were completely inactive in passive uptake. A combination of all 4 types of chemical modifications, for example in compound 12386, was found to be highly effective in gene silencing. FIG. 24 also shows the effectiveness of compound 12386 in gene silencing.

Optimization of the length of the oligonucleotide was also investigated. FIGS. 25 and 26 reveal that oligonucleotides with a length of 21 nucleotides were more effective than oligonucleotides with a length of 25 nucleotides, indicating that reduction in the size of an RNA molecule can improve efficiency, potentially by assisting in its uptake. Screening was also conducted to optimize the size of the duplex region of double stranded RNA molecules. FIG. 88 reveals that compounds with duplexes of 10 nucleotides were effective in inducing gene silencing. Positioning of the sense strand relative to the guide strand can also be critical for silencing gene expression (FIG. 89). In this assay, a blunt end was found to be most effective. 3′ overhangs were tolerated, but 5′ overhangs resulted in a complete loss of functionality. The guide strand can be effective in gene silencing when hybridized to a sense strand of varying lengths (FIG. 90). In this assay presented in FIG. 90, the compounds were introduced into HeLa cells via lipid mediated transfection.

The importance of phosphorothioate content of the RNA molecule for unassisted delivery was also investigated. FIG. 27 presents the results of a systematic screen that identified that the presence of at least 2-12 phosphorothioates in the guide strand as being highly advantageous for achieving uptake, with 4-8 being the preferred number. FIG. 27 also shows that presence or absence of phosphorothioate modifications in the sense strand did not alter efficacy.

FIGS. 28-29 reveal the effects of passive uptake of RNA compounds on gene silencing in primary mouse hepatocytes. nanoRNA molecules were found to be highly effective, especially at a concentration of 1 μM (FIG. 28). FIGS. 30 and 31 reveal that the RNA compounds associated with the invention were also effective in gene silencing following passive uptake in primary human hepatocytes. The cellular localization of the RNA molecules associated with the invention was examined and compared to the localization of Chol-siRNA (Alnylam) molecules, as shown in FIGS. 32 and 33.

A summary of 1^st generation sd-rxRNA molecules is presented in FIG. 21. Chemical modifications were introduced into the RNA molecules, at least in part, to increase potency, such as through optimization of nucleotide length and phosphorothioate content, to reduce toxicity, such as through replacing 2′F modifications on the guide strand with other modifications, to improve delivery such as by adding or conjugating the RNA molecules to linker and sterol modalities, and to improve the ease of manufacturing the RNA molecules. FIG. 35 presents schematic depictions of some of the chemical modifications that were screened in 1^st generation molecules. Parameters that were optimized for the guide strand included nucleotide length (e.g., 19, 21 and 25 nucleotides), phosphorothioate content (e.g., 0-18 phosphorothioate linkages) and replacement of 2′F groups with 2′OMe and 5 Me C or riboThymidine. Parameters that were optimized for the sense strand included nucleotide length (e.g., 11, 13 and 19 nucleotides), phosphorothioate content (e.g., 0-4 phosphorothioate linkages), and 2′OMe modifications. FIG. 36 summarizes parameters that were screened. For example, the nucleotide length and the phosphorothioate tail length were modified and screened for optimization, as were the additions of 2′OMe C and U modifications. Guide strand length and the length of the phosphorothioate modified stretch of nucleotides were found to influence efficacy (FIGS. 37-38). Phosphorothioate modifications were tolerated in the guide strand and were found to influence passive uptake (FIGS. 39-42).

FIG. 43 presents a schematic revealing guide strand chemical modifications that were screened. FIGS. 44 and 45 reveal that 2′OMe modifications were tolerated in the 3′ end of the guide strand. In particular, 2′OMe modifications in positions 1 and 11-18 were well tolerated. The 2′OMe modifications in the seed area were tolerated but resulted in slight reduction of efficacy. Ribo-modifications in the seed were also well tolerated. These data indicate that the molecules associated with the invention offer the significant advantage of having reduced or no 2′F modification content. This is advantageous because 2′F modifications are thought to generate toxicity in vivo. In some instances, a complete substitution of 2′F modifications with 2′OMe was found to lead to some reduction in potency. However, the 2′ OMe substituted molecules were still very active. A molecule with 50% reduction in 2′F content (including at positions 11, 16-18 which were changed to 2′OMe modifications), was found to have comparable efficacy to a compound with complete 2′F C and U modification. 2′OMe modification in position was found in some instances to reduce efficacy, although this can be at least partially compensated by 2′OMe modification in position 1 (with chemical phosphate). In some instances, 5 Me C and/or ribothymidine substitution for 2′F modifications led to a reduction in passive uptake efficacy, but increased potency in lipid mediated transfections compared to 2′F modifications. Optimization results for lipid mediated transfection were not necessarily the same as for passive uptake.

Modifications to the sense strand were also developed and tested, as depicted in FIG. 46. FIG. 47 reveals that in some instances, a sense strand length between 10-15 bases was found to be optimal. For the molecules tested in FIG. 47, an increase in the sense strand length resulted in reduction of passive uptake, however an increase in sense strand length may be tolerated for some compounds. FIG. 47 also reveals that LNA modification of the sense strand demonstrated similar efficacy to non-LNA containing compounds. In general, the addition of LNA or other thermodynamically stabilizing compounds has been found to be beneficial, in some instances resulting in converting non-functional sequences to functional sequences. FIG. 48 also presents data on sense strand length optimization, while FIG. 49 shows that phosphorothioate modification of the sense strand is not required for passive uptake.

Based on the above-described optimization experiments, 2^nd generation RNA molecules were developed. As shown in FIG. 50, these molecules contained reduced phosphorothioate modification content and reduced 2′F modification content, relative to 1^st generation RNA molecules. Significantly, these RNA molecules exhibit spontaneous cellular uptake and efficacy without a delivery vehicle (FIG. 51). These molecules can achieve self-delivery (i.e., with no transfection reagent) and following self-delivery can exhibit nanomolar activity in cell culture. These molecules can also be delivered using lipid-mediated transfection, and exhibit picomolar activity levels following transfection. Significantly, these molecules exhibit highly efficient uptake, 95% by most cells in cell culture, and are stable for more than three days in the presence of 100% human serum. These molecules are also highly specific and exhibit little or no immune induction. FIGS. 52 and 53 reveal the significance of chemical modifications and the configurations of such modifications in influencing the properties of the RNA molecules associated with the invention.

Linker chemistry was also tested in conjunction with the RNA molecules associated with the invention. As depicted in FIG. 54, 2^nd generation RNA molecules were synthesized with sterol-type molecules attached through TEG and amino caproic acid linkers. Both linkers showed identical potency. This functionality of the RNA molecules, independent of linker chemistry offers additional advantages in terms of scale up and synthesis and demonstrates that the mechanism of function of these RNA molecules is very different from other previously described RNA molecules.

Stability of the chemically modified sd-rxRNA molecules described herein in human serum is shown in FIG. 55 in comparison to unmodified RNA. The duplex molecules were incubated in 75% serum at 37° C. for the indicated periods of time. The level of degradation was determined by running the samples on non-denaturing gels and staining with SYBGR.

FIGS. 56 and 57 present data on cellular uptake of the sd-rxRNA molecules. FIG. 56 shows that minimizing the length of the RNA molecule is importance for cellular uptake, while FIG. 57 presents data showing target gene silencing after spontaneous cellular uptake in mouse PEC-derived macrophages. FIG. 58 demonstrates spontaneous uptake and target gene silencing in primary cells. FIG. 59 shows the results of delivery of sd-rxRNA molecules associated with the invention to RPE cells with no formulation. Imaging with Hoechst and DY547 reveals the clear presence of a signal representing the RNA molecule in the sd-rxRNA sample, while no signal is detectable in the other samples including the samples competing a competing conjugate, an rxRNA, and an untransfected control. FIG. 60 reveals silencing of target gene expression in RPE cells treated with sd-rxRNA molecules associated with the invention following 24-48 hours without any transfection formulation.

FIG. 61 shows further optimization of the chemical/structural composition of sd-rxRNA compounds. In some instances, preferred properties included an antisense strand that was 17-21 nucleotides long, a sense strand that was 10-15 nucleotides long, phosphorothioate modification of 2-12 nucleotides within the single stranded region of the molecule, preferentially phosphorothioate modification of 6-8 nucleotides within the single stranded region, and 2′OMe modification at the majority of positions within the sense strand, with or without phosphorothioate modification. Any linker chemistry can be used to attach the hydrophobic moiety, such as cholesterol, to the 3′ end of the sense strand. Version GIIb molecules, as shown in FIG. 61, have no 2′F modifications. Significantly, there is was no impact on efficacy in these molecules.

FIG. 62 demonstrates the superior performance of sd-rxRNA compounds compared to compounds published by Wolfrum et. al. Nature Biotech, 2007. Both generation I and II compounds (GI and GIIa) developed herein show great efficacy in reducing target gene expression. By contrast, when the chemistry described in Wolfrum et al. (all oligos contain cholesterol conjugated to the 3′ end of the sense strand) was applied to the same sequence in a context of conventional siRNA (19 bp duplex with two overhang) the compound was practically inactive. These data emphasize the significance of the combination of chemical modifications and assymetrical molecules described herein, producing highly effective RNA compounds.

FIG. 63 shows localization of sd-rxRNA molecules developed herein compared to localization of other RNA molecules such as those described in Soutschek et al. (2004) Nature, 432:173. sd-rxRNA molecules accumulate inside the cells whereas competing conjugate RNAs accumulate on the surface of cells. Significantly, FIG. 64 shows that sd-rxRNA molecules, but not competitor molecules such as those described in Soutschek et al. are internalized within minutes. FIG. 65 compares localization of sd-rxRNA molecules compared to regular siRNA-cholesterol, as described in Soutschek et al. A signal representing the RNA molecule is clearly detected for the sd-rxRNA molecule in tissue culture RPE cells, following local delivery to compromised skin, and following systemic delivery where uptake to the liver is seen. In each case, no signal is detected for the regular siRNA-cholesterol molecule. The sd-rxRNA molecule thus has drastically better cellular and tissue uptake characteristics when compared to conventional cholesterol conjugated siRNAs such as those described in Soutschek et al. The level of uptake is at least order of magnitude higher and is due at least in part to the unique combination of chemistries and conjugated structure. Superior delivery of sd-rxRNA relative to previously described RNA molecules is also demonstrated in FIGS. 66 and 67.

Based on the analysis of 2^nd generation RNA molecules associated with the invention, a screen was performed to identify functional molecules for targeting the SPP1/PPIB gene. As revealed in FIG. 68, several effective molecules were identified, with 14131 being the most effective. The compounds were added to A-549 cells and then the level of SPP1/PPIB ratio was determined by B-DNA after 48 hours.

FIG. 69 reveals efficient cellular uptake of sd-rxRNA within minutes of exposure. This is a unique characteristics of these molecules, not observed with any other RNAi compounds. Compounds described in Soutschek et al. were used as negative controls. FIG. 70 reveals that the uptake and gene silencing of the sd-rxRNA is effective in multiple different cell types including SH-SY5Y neuroblastoma derived cells, ARPE-19 (retinal pigment epithelium) cells, primary hepatocytes, and primary macrophages. In each case silencing was confirmed by looking at target gene expression by a Branched DNA assay.

FIG. 70 reveals that sd-rxRNA is active in the presence or absence of serum. While a slight reduction in efficacy (2-5 fold) was observed in the presence of serum, this small reduction in efficacy in the presence of serum differentiate the sd-rxRNA molecules from previously described molecules which exhibited a larger reduction in efficacy in the presence of serum. This demonstrated level of efficacy in the presence of serum creates a foundation for in vivo efficacy.

FIG. 72 reveals efficient tissue penetration and cellular uptake upon single intradermal injection. This data indicates the potential of the sd-rxRNA compounds described herein for silencing genes in any dermatology applications, and also represents a model for local delivery of sd-rxRNA compounds. FIG. 73 also demonstrates efficient cellular uptake and in vivo silencing with sd-rxRNA following intradermal injection. Silencing is determined as the level of MAP4K4 knockdown in several individual biopsies taken from the site of injection as compared to biopsies taken from a site injected with a negative control. FIG. 74 reveals that sd-rxRNA compounds has improved blood clearance and induced effective gene silencing in vivo in the liver upon systemic administration. In comparison to the RNA molecules described by Soutschek et al., the level of liver uptake at identical dose level is at least 50 fold higher with the sd-rxRNA molecules. The uptake results in productive silencing. sd-rxRNA compounds are also characterized by improved blood clearance kinetics.

The effect of 5-Methly C modifications was also examined. FIG. 75 demonstrates that the presence of 5-Methyl C in an RNAi molecule resulted in increased potency in lipid mediated transfection. This suggests that hydrophobic modification of Cs and Us in an RNAi molecule can be beneficial. These types of modifications can also be used in the context 2′ ribose modified bases to ensure optimal stability and efficacy. FIG. 76 presents data showing that incorporation of 5-Methyl C and/or ribothymidine in the guide strand can in some instances reduce efficacy.

FIG. 77 reveals that sd-rxRNA molecules are more effective than competitor molecules such as molecules described in Soutschek et al., in systemic delivery to the liver. A signal representing the RNA molecule is clearly visible in the sample containing sd-rxRNA, while no signal representing the RNA molecule is visible in the sample containing the competitor RNA molecule.

The addition of hydrophobic conjugates to the sd-rxRNA molecules was also explored (FIGS. 78-83). FIG. 78 presents schematics demonstrating 5-uridyl modifications with improved hydrophobicity characteristics. Incorporation of such modifications into sd-rxRNA compounds can increase cellular and tissue uptake properties. FIG. 78B presents a new type of RNAi compound modification which can be applied to compounds to improve cellular uptake and pharmacokinetic behavior. Significantly, this type of modification, when applied to sd-rxRNA compounds, may contribute to making such compounds orally available. FIG. 79 presents schematics revealing the structures of synthesized modified sterol-type molecules, where the length and structure of the C17 attached tail is modified. Without wishing to be bound by any theory, the length of the C17 attached tail may contribute to improving in vitro and in vivo efficacy of sd-rxRNA compounds.

FIG. 80 presents a schematic demonstrating the lithocholic acid route to long side chain cholesterols. FIG. 81 presents a schematic demonstrating a route to 5-uridyl phosphoramidite synthesis. FIG. 82 presents a schematic demonstrating synthesis of tri-functional hydroxyprolinol linker for 3′-cholesterol attachment. FIG. 83 presents a schematic demonstrating synthesis of solid support for the manufacture of a shorter asymmetric RNAi compound strand.

A screen was conducted to identify compounds that could effectively silence expression of SPP1 (Osteopontin). Compounds targeting SPP1 were added to A549 cells (using passive transfection), and the level of SPP1 expression was evaluated at 48 hours. Several novel compounds effective in SPP1 silencing were identified. Compounds that were effective in silencing of SPP1 included 14116, 14121, 14131, 14134, 14139, 14149, and 14152 (FIGS. 84-86). The most potent compound in this assay was 14131 (FIG. 84). The efficacy of these sd-rxRNA compounds in silencing SPP1 expression was independently validated (FIG. 85).

A similar screen was conducted to identify compounds that could effectively silence expression of CTGF (FIGS. 86-87). Compounds that were effective in silencing of CTGF included 14017, 14013, 14016, 14022, 14025, 14027.

Methods

Transfection of Sd-rxRNA^nano

Lipid Mediated Transfection

sd-rxRNA^nano constructs were chemically synthesized (Dharmacon, Lafayette, Colo.) and transfected into HEK293 cells (ATCC, Manassas, Va.) using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, Calif.) according to the manufacturer's instructions. In brief, RNA was diluted to a 12× concentration in Opti-MEM®1 Reduced Serum Media (Invitrogen, Carlsbad, Calif.) and then combined with a 12× concentration of Lipofectamine RNAiMAX. The RNA and transfection reagent were allowed to complex at room temperature for 20 minutes and make a 6× concentration. While complexing, HEK293 cells were washed, trypsinized and counted. The cells were diluted to a concentration recommended by the manufacturer and previously described of 1×10⁵cells/ml. When RNA had completed complexing with the RNAiMAX transfection reagent, 20 ul of the complexes were added to the appropriate well of the 96-well plate in triplicate. Cells were added to each well (100 ul volume) to make the final cell count per well 1×10⁴ cells/well. The volume of cells diluted the 6× concentration of complex to 1× (between 10-0.05 nM). Cells were incubated for 24 or 48 hours under normal growth conditions. After 24 or 48 hour incubation, cells were lysed and gene silencing activity was measured using the QuantiGene assay (Panomics, Freemont, Calif.) which employs bDNA hybridization technology. The assay was carried out according to manufacturer's instructions.

Passive Uptake Transfection

sd-rxRNA^nano constructs were chemically synthesized (Dharmacon, Lafayette, Colo.). 24 hours prior to transfection, HeLa cells (ATCC, Manassas, Va.) were plated at 1×10⁴ cells/well in a 96 well plate under normal growth conditions (DMEM, 10% FBS and 1% Penicillin and Streptomycin). Prior to transfection of HeLa cells, sd-rxRNA^nano were diluted to a final concentration of 0.01 uM to 1 uM in Accell siRNA Delivery Media (Dharmacon, Lafayette, Colo.). Normal growth media was aspirated off cells and 100 uL of Accell Delivery media containing the appropriate concentration of sd-rxRNAnano was applied to the cells. 48 hours post transfection, delivery media was aspirated off the cells and normal growth media was applied to cells for an additional 24 hours.

After 48 or 72 hour incubation, cells were lysed and gene silencing activity was measured using the QuantiGene assay (Panomics, Freemont, Calif.) according to manufacturer's instructions.

TABLE 1
	Oligo	Accession		Gene
ID Number	Number	number	Gene Name	Symbol
APOB-10167-	12138	NM_000384	Apolipoprotein B (including Ag(x) antigen)	APOB
20-12138
APOB-10167-	12139	NM_000384	Apolipoprotein B (including Ag(x) antigen)	APOB
20-12139
MAP4K4-2931-	12266	NM_004834	Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4	MAP4K4
13-12266			(MAP4K4), transcript variant 1
MAP4K4-2931-	12293	NM_004834	Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4	MAP4K4
16-12293			(MAP4K4), transcript variant 1
MAP4K4-2931-	12383	NM_004834	Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4	MAP4K4
16-12383			(MAP4K4), transcript variant 1
MAP4K4-2931-	12384	NM_004834	Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4	MAP4K4
16-12384			(MAP4K4), transcript variant 1
MAP4K4-2931-	12385	NM_004834	Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4	MAP4K4
16-12385			(MAP4K4), transcript variant 1
MAP4K4-2931-	12386	NM_004834	Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4	MAP4K4
16-12386			(MAP4K4), transcript variant 1
MAP4K4-2931-	12387	NM_004834	Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4	MAP4K4
16-12387			(MAP4K4), transcript variant 1
MAP4K4-2931-	12388	NM_004834	Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4	MAP4K4
15-12388			(MAP4K4), transcript variant 1
MAP4K4-2931-	12432	NM_004834	Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4	MAP4K4
13-12432			(MAP4K4), transcript variant 1
MAP4K4-2931-	12266.2	NM_004834	Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4	MAP4K4
13-12266.2			(MAP4K4), transcript variant 1
APOB--21-	12434	NM_000384	Apolipoprotein B (including Ag(x) antigen)	APOB
12434
APOB--21-	12435	NM_000384	Apolipoprotein B (including Ag(x) antigen)	APOB
12435
MAP4K4-2931-	12451	NM_004834	Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4	MAP4K4
16-12451			(MAP4K4), transcript variant 1
MAP4K4-2931-	12452	NM_004834	Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4	MAP4K4
16-12452			(MAP4K4), transcript variant 1
MAP4K4-2931-	12453	NM_004834	Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4	MAP4K4
16-12453			(MAP4K4), transcript variant 1
MAP4K4-2931-	12454	NM_004834	Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4	MAP4K4
17-12454			(MAP4K4), transcript variant 1
MAP4K4-2931-	12455	NM_004834	Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4	MAP4K4
17-12455			(MAP4K4), transcript variant 1
MAP4K4-2931-	12456	NM_004834	Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4	MAP4K4
19-12456			(MAP4K4), transcript variant 1
--27-12480	12480
--27-12481	12481
APOB-10167-	12505	NM_000384	Apolipoprotein B (including Ag(x) antigen)	APOB
21-12505
APOB-10167-	12506	NM_000384	Apolipoprotein B (including Ag(x) antigen)	APOB
21-12506
MAP4K4-2931-	12539	NM_004834	Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4	MAP4K4
16-12539			(MAP4K4), transcript variant 1
APOB-10167-	12505.2	NM_000384	Apolipoprotein B (including Ag(x) antigen)	APOB
21-12505.2
APOB-10167-	12506.2	NM_000384	Apolipoprotein B (including Ag(x) antigen)	APOB
21-12506.2
MAP4K4--13-	12565			MAP4K4
12565
MAP4K4-2931-	12386.2	NM_004834	Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4	MAP4K4
16-12386.2			(MAP4K4), transcript variant 1
MAP4K4-2931-	12815	NM_004834	Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4	MAP4K4
13-12815			(MAP4K4), transcript variant 1
APOB--13-	12957	NM_000384	Apolipoprotein B (including Ag(x) antigen)	APOB
12957
MAP4K4--16-	12983		Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4	MAP4K4
12983			(MAP4K4), transcript variant 1
MAP4K4--16-	12984		Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4	MAP4K4
12984			(MAP4K4), transcript variant 1
MAP4K4--16-	12985		Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4	MAP4K4
12985			(MAP4K4), transcript variant 1
MAP4K4--16-	12986		Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4	MAP4K4
12986			(MAP4K4), transcript variant 1
MAP4K4--16-	12987		Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4	MAP4K4
12987			(MAP4K4), transcript variant 1
MAP4K4--16-	12988		Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4	MAP4K4
12988			(MAP4K4), transcript variant 1
MAP4K4--16-	12989		Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4	MAP4K4
12989			(MAP4K4), transcript variant 1
MAP4K4--16-	12990		Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4	MAP4K4
12990			(MAP4K4), transcript variant 1
MAP4K4--16-	12991		Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4	MAP4K4
12991			(MAP4K4), transcript variant 1
MAP4K4--16-	12992		Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4	MAP4K4
12992			(MAP4K4), transcript variant 1
MAP4K4--16-	12993		Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4	MAP4K4
12993			(MAP4K4), transcript variant 1
MAP4K4--16-	12994		Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4	MAP4K4
12994			(MAP4K4), transcript variant 1
MAP4K4--16-	12995		Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4	MAP4K4
12995			(MAP4K4), transcript variant 1
MAP4K4-2931-	13012	NM_004834	Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4	MAP4K4
19-13012			(MAP4K4), transcript variant 1
MAP4K4-2931-	13016	NM_004834	Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4	MAP4K4
19-13016			(MAP4K4), transcript variant 1
PPIB--13-	13021	NM_000942	Peptidylprolyl Isomerase B (cyclophilin B)	PPIB
13021
pGL3-1172-	13038	U47296	Cloning vector pGL3-Control	pGL3
13-13038
pGL3-1172-	13040	U47296	Cloning vector pGL3-Control	pGL3
13-13040
--16-13047	13047
SOD1-530-13-	13090	NM_000454	Superoxide Dismutase 1, soluble (amyotrophic lateral	SOD1
13090			sclerosis 1 (adult))
SOD1-523-13-	13091	NM_000454	Superoxide Dismutase 1, soluble (amyotrophic lateral	SOD1
13091			sclerosis 1 (adult))
SOD1-535-13-	13092	NM_000454	Superoxide Dismutase 1, soluble (amyotrophic lateral	SOD1
13092			sclerosis 1 (adult))
SOD1-536-13-	13093	NM_000454	Superoxide Dismutase 1, soluble (amyotrophic lateral	SOD1
13093			sclerosis 1 (adult))
SOD1-396-13-	13094	NM_000454	Superoxide Dismutase 1, soluble (amyotrophic lateral	SOD1
13094			sclerosis 1 (adult))
SOD1-385-13-	13095	NM_000454	Superoxide Dismutase 1, soluble (amyotrophic lateral	SOD1
13095			sclerosis 1 (adult))
SOD1-195-13-	13096	NM_000454	Superoxide Dismutase 1, soluble (amyotrophic lateral	SOD1
13096			sclerosis 1 (adult))
APOB-4314-	13115	NM_000384	Apolipoprotein B (including Ag(x) antigen)	APOB
13-13115
APOB-3384-	13116	NM_000384	Apolipoprotein B (including Ag(x) antigen)	APOB
13-13116
APOB-3547-	13117	NM_000384	Apolipoprotein B (including Ag(x) antigen)	APOB
13-13117
APOB-4318-	13118	NM_000384	Apolipoprotein B (including Ag(x) antigen)	APOB
13-13118
APOB-3741-	13119	NM_000384	Apolipoprotein B (including Ag(x) antigen)	APOB
13-13119
PPIB--16-	13136	NM_000942	Peptidylprolyl Isomerase B (cyclophilin B)	PPIB
13136
APOB-4314-	13154	NM_000384	Apolipoprotein B (including Ag(x) antigen)	APOB
15-13154
APOB-3547-	13155	NM_000384	Apolipoprotein B (including Ag(x) antigen)	APOB
15-13155
APOB-4318-	13157	NM_000384	Apolipoprotein B (including Ag(x) antigen)	APOB
15-13157
APOB-3741-	13158	NM_000384	Apolipoprotein B (including Ag(x) antigen)	APOB
15-13158
APOB--13-	13159	NM_000384	Apolipoprotein B (including Ag(x) antigen)	APOB
13159
APOB--15-	13160	NM_000384	Apolipoprotein B (including Ag(x) antigen)	APOB
13160
SOD1-530-16-	13163	NM_000454	Superoxide Dismutase 1, soluble (amyotrophic lateral	SOD1
13163			sclerosis 1 (adult))
SOD1-523-16-	13164	NM_000454	Superoxide Dismutase 1, soluble (amyotrophic lateral	SOD1
13164			sclerosis 1 (adult))
SOD1-535-16-	13165	NM_000454	Superoxide Dismutase 1, soluble (amyotrophic lateral	SOD1
13165			sclerosis 1 (adult))
SOD1-536-16-	13166	NM_000454	Superoxide Dismutase 1, soluble (amyotrophic lateral	SOD1
13166			sclerosis 1 (adult))
SOD1-396-16-	13167	NM_000454	Superoxide Dismutase 1, soluble (amyotrophic lateral	SOD1
13167			sclerosis 1 (adult))
SOD1-385-16-	13168	NM_000454	Superoxide Dismutase 1, soluble (amyotrophic lateral	SOD1
13168			sclerosis 1 (adult))
SOD1-195-16-	13169	NM_000454	Superoxide Dismutase 1, soluble (amyotrophic lateral	SOD1
13169			sclerosis 1 (adult))
pGL3-1172-	13170	U47296	Cloning vector pGL3-Control	pGL3
16-13170
pGL3-1172-	13171	U47296	Cloning vector pGL3-Control	pGL3
16-13171
MAP4k4-2931-	13189	NM_004834	Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4	MAP4k4
19-13189			(MAP4K4), transcript variant 1
CTGF-1222-	13190	NM_001901.2	connective tissue growth factor	CTGF
13-13190
CTGF-813-13-	13192	NM_001901.2	connective tissue growth factor	CTGF
13192
CTGF-747-13-	13194	NM_001901.2	connective tissue growth factor	CTGF
13194
CTGF-817-13-	13196	NM_001901.2	connective tissue growth factor	CTGF
13196
CTGF-1174-	13198	NM_001901.2	connective tissue growth factor	CTGF
13-13198
CTGF-1005-	13200	NM_001901.2	connective tissue growth factor	CTGF
13-13200
CTGF-814-13-	13202	NM_001901.2	connective tissue growth factor	CTGF
13202
CTGF-816-13-	13204	NM_001901.2	connective tissue growth factor	CTGF
13204
CTGF-1001-	13206	NM_001901.2	connective tissue growth factor	CTGF
13-13206
CTGF-1173-	13208	NM_001901.2	connective tissue growth factor	CTGF
13-13208
CTGF-749-13-	13210	NM_001901.2	connective tissue growth factor	CTGF
13210
CTGF-792-13-	13212	NM_001901.2	connective tissue growth factor	CTGF
13212
CTGF-1162-	13214	NM_001901.2	connective tissue growth factor	CTGF
13-13214
CTGF-811-13-	13216	NM_001901.2	connective tissue growth factor	CTGF
13216
CTGF-797-13-	13218	NM_001901.2	connective tissue growth factor	CTGF
13218
CTGF-1175-	13220	NM_001901.2	connective tissue growth factor	CTGF
13-13220
CTGF-1172-	13222	NM_001901.2	connective tissue growth factor	CTGF
13-13222
CTGF-1177-	13224	NM_001901.2	connective tissue growth factor	CTGF
13-13224
CTGF-1176-	13226	NM_001901.2	connective tissue growth factor	CTGF
13-13226
CTGF-812-13-	13228	NM_001901.2	connective tissue growth factor	CTGF
13228
CTGF-745-13-	13230	NM_001901.2	connective tissue growth factor	CTGF
13230
CTGF-1230-	13232	NM_001901.2	connective tissue growth factor	CTGF
13-13232
CTGF-920-13-	13234	NM_001901.2	connective tissue growth factor	CTGF
13234
CTGF-679-13-	13236	NM_001901.2	connective tissue growth factor	CTGF
13236
CTGF-992-13-	13238	NM_001901.2	connective tissue growth factor	CTGF
13238
CTGF-1045-	13240	NM_001901.2	connective tissue growth factor	CTGF
13-13240
CTGF-1231-	13242	NM_001901.2	connective tissue growth factor	CTGF
13-13242
CTGF-991-13-	13244	NM_001901.2	connective tissue growth factor	CTGF
13244
CTGF-998-13-	13246	NM_001901.2	connective tissue growth factor	CTGF
13246
CTGF-1049-	13248	NM_001901.2	connective tissue growth factor	CTGF
13-13248
CTGF-1044-	13250	NM_001901.2	connective tissue growth factor	CTGF
13-13250
CTGF-1327-	13252	NM_001901.2	connective tissue growth factor	CTGF
13-13252
CTGF-1196-	13254	NM_001901.2	connective tissue growth factor	CTGF
13-13254
CTGF-562-13-	13256	NM_001901.2	connective tissue growth factor	CTGF
13256
CTGF-752-13-	13258	NM_001901.2	connective tissue growth factor	CTGF
13258
CTGF-994-13-	13260	NM_001901.2	connective tissue growth factor	CTGF
13260
CTGF-1040-	13262	NM_001901.2	connective tissue growth factor	CTGF
13-13262
CTGF-1984-	13264	NM_001901.2	connective tissue growth factor	CTGF
13-13264
CTGF-2195-	13266	NM_001901.2	connective tissue growth factor	CTGF
13-13266
CTGF-2043-	13268	NM_001901.2	connective tissue growth factor	CTGF
13-13268
CTGF-1892-	13270	NM_001901.2	connective tissue growth factor	CTGF
13-13270
CTGF-1567-	13272	NM_001901.2	connective tissue growth factor	CTGF
13-13272
CTGF-1780-	13274	NM_001901.2	connective tissue growth factor	CTGF
13-13274
CTGF-2162-	13276	NM_001901.2	connective tissue growth factor	CTGF
13-13276
CTGF-1034-	13278	NM_001901.2	connective tissue growth factor	CTGF
13-13278
CTGF-2264-	13280	NM_001901.2	connective tissue growth factor	CTGF
13-13280
CTGF-1032-	13282	NM_001901.2	connective tissue growth factor	CTGF
13-13282
CTGF-1535-	13284	NM_001901.2	connective tissue growth factor	CTGF
13-13284
CTGF-1694-	13286	NM_001901.2	connective tissue growth factor	CTGF
13-13286
CTGF-1588-	13288	NM_001901.2	connective tissue growth factor	CTGF
13-13288
CTGF-928-13-	13290	NM_001901.2	connective tissue growth factor	CTGF
13290
CTGF-1133-	13292	NM_001901.2	connective tissue growth factor	CTGF
13-13292
CTGF-912-13-	13294	NM_001901.2	connective tissue growth factor	CTGF
13294
CTGF-753-13-	13296	NM_001901.2	connective tissue growth factor	CTGF
13296
CTGF-918-13-	13298	NM_001901.2	connective tissue growth factor	CTGF
13298
CTGF-744-13-	13300	NM_001901.2	connective tissue growth factor	CTGF
13300
CTGF-466-13-	13302	NM_001901.2	connective tissue growth factor	CTGF
13302
CTGF-917-13-	13304	NM_001901.2	connective tissue growth factor	CTGF
13304
CTGF-1038-	13306	NM_001901.2	connective tissue growth factor	CTGF
13-13306
CTGF-1048-	13308	NM_001901.2	connective tissue growth factor	CTGF
13-13308
CTGF-1235-	13310	NM_001901.2	connective tissue growth factor	CTGF
13-13310
CTGF-868-13-	13312	NM_001901.2	connective tissue growth factor	CTGF
13312
CTGF-1131-	13314	NM_001901.2	connective tissue growth factor	CTGF
13-13314
CTGF-1043-	13316	NM_001901.2	connective tissue growth factor	CTGF
13-13316
CTGF-751-13-	13318	NM_001901.2	connective tissue growth factor	CTGF
13318
CTGF-1227-	13320	NM_001901.2	connective tissue growth factor	CTGF
13-13320
CTGF-867-13-	13322	NM_001901.2	connective tissue growth factor	CTGF
13322
CTGF-1128-	13324	NM_001901.2	connective tissue growth factor	CTGF
13-13324
CTGF-756-13-	13326	NM_001901.2	connective tissue growth factor	CTGF
13326
CTGF-1234-	13328	NM_001901.2	connective tissue growth factor	CTGF
13-13328
CTGF-916-13-	13330	NM_001901.2	connective tissue growth factor	CTGF
13330
CTGF-925-13-	13332	NM_001901.2	connective tissue growth factor	CTGF
13332
CTGF-1225-	13334	NM_001901.2	connective tissue growth factor	CTGF
13-13334
CTGF-445-13-	13336	NM_001901.2	connective tissue growth factor	CTGF
13336
CTGF-446-13-	13338	NM_001901.2	connective tissue growth factor	CTGF
13338
CTGF-913-13-	13340	NM_001901.2	connective tissue growth factor	CTGF
13340
CTGF-997-13-	13342	NM_001901.2	connective tissue growth factor	CTGF
13342
CTGF-277-13-	13344	NM_001901.2	connective tissue growth factor	CTGF
13344
CTGF-1052-	13346	NM_001901.2	connective tissue growth factor	CTGF
13-13346
CTGF-887-13-	13348	NM_001901.2	connective tissue growth factor	CTGF
13348
CTGF-914-13-	13350	NM_001901.2	connective tissue growth factor	CTGF
13350
CTGF-1039-	13352	NM_001901.2	connective tissue growth factor	CTGF
13-13352
CTGF-754-13-	13354	NM_001901.2	connective tissue growth factor	CTGF
13354
CTGF-1130-	13356	NM_001901.2	connective tissue growth factor	CTGF
13-13356
CTGF-919-13-	13358	NM_001901.2	connective tissue growth factor	CTGF
13358
CTGF-922-13-	13360	NM_001901.2	connective tissue growth factor	CTGF
13360
CTGF-746-13-	13362	NM_001901.2	connective tissue growth factor	CTGF
13362
CTGF-993-13-	13364	NM_001901.2	connective tissue growth factor	CTGF
13364
CTGF-825-13-	13366	NM_001901.2	connective tissue growth factor	CTGF
13366
CTGF-926-13-	13368	NM_001901.2	connective tissue growth factor	CTGF
13368
CTGF-923-13-	13370	NM_001901.2	connective tissue growth factor	CTGF
13370
CTGF-866-13-	13372	NM_001901.2	connective tissue growth factor	CTGF
13372
CTGF-563-13-	13374	NM_001901.2	connective tissue growth factor	CTGF
13374
CTGF-823-13-	13376	NM_001901.2	connective tissue growth factor	CTGF
13376
CTGF-1233-	13378	NM_001901.2	connective tissue growth factor	CTGF
13-13378
CTGF-924-13-	13380	NM_001901.2	connective tissue growth factor	CTGF
13380
CTGF-921-13-	13382	NM_001901.2	connective tissue growth factor	CTGF
13382
CTGF-443-13-	13384	NM_001901.2	connective tissue growth factor	CTGF
13384
CTGF-1041-	13386	NM_001901.2	connective tissue growth factor	CTGF
13-13386
CTGF-1042-	13388	NM_001901.2	connective tissue growth factor	CTGF
13-13388
CTGF-755-13-	13390	NM_001901.2	connective tissue growth factor	CTGF
13390
CTGF-467-13-	13392	NM_001901.2	connective tissue growth factor	CTGF
13392
CTGF-995-13-	13394	NM_001901.2	connective tissue growth factor	CTGF
13394
CTGF-927-13-	13396	NM_001901.2	connective tissue growth factor	CTGF
13396
SPP1-1025-	13398	NM_000582.2	Osteopontin	SPP1
13-13398
SPP1-1049-	13400	NM_000582.2	Osteopontin	SPP1
13-13400
SPP1-1051-	13402	NM_000582.2	Osteopontin	SPP1
13-13402
SPP1-1048-	13404	NM_000582.2	Osteopontin	SPP1
13-13404
SPP1-1050-	13406	NM_000582.2	Osteopontin	SPP1
13-13406
SPP1-1047-	13408	NM_000582.2	Osteopontin	SPP1
13-13408
SPP1-800-13-	13410	NM_000582.2	Osteopontin	SPP1
13410
SPP1-492-13-	13412	NM_000582.2	Osteopontin	SPP1
13412
SPP1-612-13-	13414	NM_000582.2	Osteopontin	SPP1
13414
SPP1-481-13-	13416	NM_000582.2	Osteopontin	SPP1
13416
SPP1-614-13-	13418	NM_000582.2	Osteopontin	SPP1
13418
SPP1-951-13-	13420	NM_000582.2	Osteopontin	SPP1
13420
SPP1-482-13-	13422	NM_000582.2	Osteopontin	SPP1
13422
SPP1-856-13-	13424	NM_000582.2	Osteopontin	SPP1
13424
SPP1-857-13-	13426	NM_000582.2	Osteopontin	SPP1
13426
SPP1-365-13-	13428	NM_000582.2	Osteopontin	SPP1
13428
SPP1-359-13-	13430	NM_000582.2	Osteopontin	SPP1
13430
SPP1-357-13-	13432	NM_000582.2	Osteopontin	SPP1
13432
SPP1-858-13-	13434	NM_000582.2	Osteopontin	SPP1
13434
SPP1-1012-	13436	NM_000582.2	Osteopontin	SPP1
13-13436
SPP1-1014-	13438	NM_000582.2	Osteopontin	SPP1
13-13438
SPP1-356-13-	13440	NM_000582.2	Osteopontin	SPP1
13440
SPP1-368-13-	13442	NM_000582.2	Osteopontin	SPP1
13442
SPP1-1011-	13444	NM_000582.2	Osteopontin	SPP1
13-13444
SPP1-754-13-	13446	NM_000582.2	Osteopontin	SPP1
13446
SPP1-1021-	13448	NM_000582.2	Osteopontin	SPP1
13-13448
SPP1-1330-	13450	NM_000582.2	Osteopontin	SPP1
13-13450
SPP1-346-13-	13452	NM_000582.2	Osteopontin	SPP1
13452
SPP1-869-13-	13454	NM_000582.2	Osteopontin	SPP1
13454
SPP1-701-13-	13456	NM_000582.2	Osteopontin	SPP1
13456
SPP1-896-13-	13458	NM_000582.2	Osteopontin	SPP1
13458
SPP1-1035-	13460	NM_000582.2	Osteopontin	SPP1
13-13460
SPP1-1170-	13462	NM_000582.2	Osteopontin	SPP1
13-13462
SPP1-1282-	13464	NM_000582.2	Osteopontin	SPP1
13-13464
SPP1-1537-	13466	NM_000582.2	Osteopontin	SPP1
13-13466
SPP1-692-13-	13468	NM_000582.2	Osteopontin	SPP1
13468
SPP1-840-13-	13470	NM_000582.2	Osteopontin	SPP1
13470
SPP1-1163-	13472	NM_000582.2	Osteopontin	SPP1
13-13472
SPP1-789-13-	13474	NM_000582.2	Osteopontin	SPP1
13474
SPP1-841-13-	13476	NM_000582.2	Osteopontin	SPP1
13476
SPP1-852-13-	13478	NM_000582.2	Osteopontin	SPP1
13478
SPP1-209-13-	13480	NM_000582.2	Osteopontin	SPP1
13480
SPP1-1276-	13482	NM_000582.2	Osteopontin	SPP1
13-13482
SPP1-137-13-	13484	NM_000582.2	Osteopontin	SPP1
13484
SPP1-711-13-	13486	NM_000582.2	Osteopontin	SPP1
13486
SPP1-582-13-	13488	NM_000582.2	Osteopontin	SPP1
13488
SPP1-839-13-	13490	NM_000582.2	Osteopontin	SPP1
13490
SPP1-1091-	13492	NM_000582.2	Osteopontin	SPP1
13-13492
SPP1-884-13-	13494	NM_000582.2	Osteopontin	SPP1
13494
SPP1-903-13-	13496	NM_000582.2	Osteopontin	SPP1
13496
SPP1-1090-	13498	NM_000582.2	Osteopontin	SPP1
13-13498
SPP1-474-13-	13500	NM_000582.2	Osteopontin	SPP1
13500
SPP1-575-13-	13502	NM_000582.2	Osteopontin	SPP1
13502
SPP1-671-13-	13504	NM_000582.2	Osteopontin	SPP1
13504
SPP1-924-13-	13506	NM_000582.2	Osteopontin	SPP1
13506
SPP1-1185-	13508	NM_000582.2	Osteopontin	SPP1
13-13508
SPP1-1221-	13510	NM_000582.2	Osteopontin	SPP1
13-13510
SPP1-347-13-	13512	NM_000582.2	Osteopontin	SPP1
13512
SPP1-634-13-	13514	NM_000582.2	Osteopontin	SPP1
13514
SPP1-877-13-	13516	NM_000582.2	Osteopontin	SPP1
13516
SPP1-1033-	13518	NM_000582.2	Osteopontin	SPP1
13-13518
SPP1-714-13-	13520	NM_000582.2	Osteopontin	SPP1
13520
SPP1-791-13-	13522	NM_000582.2	Osteopontin	SPP1
13522
SPP1-813-13-	13524	NM_000582.2	Osteopontin	SPP1
13524
SPP1-939-13-	13526	NM_000582.2	Osteopontin	SPP1
13526
SPP1-1161-	13528	NM_000582.2	Osteopontin	SPP1
13-13528
SPP1-1164-	13530	NM_000582.2	Osteopontin	SPP1
13-13530
SPP1-1190-	13532	NM_000582.2	Osteopontin	SPP1
13-13532
SPP1-1333-	13534	NM_000582.2	Osteopontin	SPP1
13-13534
SPP1-537-13-	13536	NM_000582.2	Osteopontin	SPP1
13536
SPP1-684-13-	13538	NM_000582.2	Osteopontin	SPP1
13538
SPP1-707-13-	13540	NM_000582.2	Osteopontin	SPP1
13540
SPP1-799-13-	13542	NM_000582.2	Osteopontin	SPP1
13542
SPP1-853-13-	13544	NM_000582.2	Osteopontin	SPP1
13544
SPP1-888-13-	13546	NM_000582.2	Osteopontin	SPP1
13546
SPP1-1194-	13548	NM_000582.2	Osteopontin	SPP1
13-13548
SPP1-1279-	13550	NM_000582.2	Osteopontin	SPP1
13-13550
SPP1-1300-	13552	NM_000582.2	Osteopontin	SPP1
13-13552
SPP1-1510-	13554	NM_000582.2	Osteopontin	SPP1
13-13554
SPP1-1543-	13556	NM_000582.2	Osteopontin	SPP1
13-13556
SPP1-434-13-	13558	NM_000582.2	Osteopontin	SPP1
13558
SPP1-600-13-	13560	NM_000582.2	Osteopontin	SPP1
13560
SPP1-863-13-	13562	NM_000582.2	Osteopontin	SPP1
13562
SPP1-902-13-	13564	NM_000582.2	Osteopontin	SPP1
13564
SPP1-921-13-	13566	NM_000582.2	Osteopontin	SPP1
13566
SPP1-154-13-	13568	NM_000582.2	Osteopontin	SPP1
13568
SPP1-217-13-	13570	NM_000582.2	Osteopontin	SPP1
13570
SPP1-816-13-	13572	NM_000582.2	Osteopontin	SPP1
13572
SPP1-882-13-	13574	NM_000582.2	Osteopontin	SPP1
13574
SPP1-932-13-	13576	NM_000582.2	Osteopontin	SPP1
13576
SPP1-1509-	13578	NM_000582.2	Osteopontin	SPP1
13-13578
SPP1-157-13-	13580	NM_000582.2	Osteopontin	SPP1
13580
SPP1-350-13-	13582	NM_000582.2	Osteopontin	SPP1
13582
SPP1-511-13-	13584	NM_000582.2	Osteopontin	SPP1
13584
SPP1-605-13-	13586	NM_000582.2	Osteopontin	SPP1
13586
SPP1-811-13-	13588	NM_000582.2	Osteopontin	SPP1
13588
SPP1-892-13-	13590	NM_000582.2	Osteopontin	SPP1
13590
SPP1-922-13-	13592	NM_000582.2	Osteopontin	SPP1
13592
SPP1-1169-	13594	NM_000582.2	Osteopontin	SPP1
13-13594
SPP1-1182-	13596	NM_000582.2	Osteopontin	SPP1
13-13596
SPP1-1539-	13598	NM_000582.2	Osteopontin	SPP1
13-13598
SPP1-1541-	13600	NM_000582.2	Osteopontin	SPP1
13-13600
SPP1-427-13-	13602	NM_000582.2	Osteopontin	SPP1
13602
SPP1-533-13-	13604	NM_000582.2	Osteopontin	SPP1
13604
APOB--13-	13763	NM_000384	Apolipoprotein B (including Ag(x) antigen)	APOB
13763
APOB--13-	13764	NM_000384	Apolipoprotein B (including Ag(x) antigen)	APOB
13764
MAP4K4--16-	13766			MAP4K4
13766
PPIB--13-	13767	NM_000942	peptidylprolyl isomerase B (cyclophilin B)	PPIB
13767
PPIB--15-	13768	NM_000942	peptidylprolyl isomerase B (cyclophilin B)	PPIB
13768
PPIB--17-	13769	NM_000942	peptidylprolyl isomerase B (cyclophilin B)	PPIB
13769
MAP4K4--16-	13939			MAP4K4
13939
APOB-4314-	13940	NM_000384	Apolipoprotein B (including Ag(x) antigen)	APOB
16-13940
APOB-4314-	13941	NM_000384	Apolipoprotein B (including Ag(x) antigen)	APOB
17-13941
APOB--16-	13942	NM_000384	Apolipoprotein B (including Ag(x) antigen)	APOB
13942
APOB--18-	13943	NM_000384	Apolipoprotein B (including Ag(x) antigen)	APOB
13943
APOB--17-	13944	NM_000384	Apolipoprotein B (including Ag(x) antigen)	APOB
13944
APOB--19-	13945	NM_000384	Apolipoprotein B (including Ag(x) antigen)	APOB
13945
APOB-4314-	13946	NM_000384	Apolipoprotein B (including Ag(x) antigen)	APOB
16-13946
APOB-4314-	13947	NM_000384	Apolipoprotein B (including Ag(x) antigen)	APOB
17-13947
APOB--16-	13948	NM_000384	Apolipoprotein B (including Ag(x) antigen)	APOB
13948
APOB--17-	13949	NM_000384	Apolipoprotein B (including Ag(x) antigen)	APOB
13949
APOB--16-	13950	NM_000384	Apolipoprotein B (including Ag(x) antigen)	APOB
13950
APOB--18-	13951	NM_000384	Apolipoprotein B (including Ag(x) antigen)	APOB
13951
APOB--17-	13952	NM_000384	Apolipoprotein B (including Ag(x) antigen)	APOB
13952
APOB--19-	13953	NM_000384	Apolipoprotein B (including Ag(x) antigen)	APOB
13953
MAP4K4--16-	13766.2			MAP4K4
13766.2
CTGF-1222-	13980	NM_001901.2	connective tissue growth factor	CTGF
16-13980
CTGF-813-16-	13981	NM_001901.2	connective tissue growth factor	CTGF
13981
CTGF-747-16-	13982	NM_001901.2	connective tissue growth factor	CTGF
13982
CTGF-817-16-	13983	NM_001901.2	connective tissue growth factor	CTGF
13983
CTGF-1174-	13984	NM_001901.2	connective tissue growth factor	CTGF
16-13984
CTGF-1005-	13985	NM_001901.2	connective tissue growth factor	CTGF
16-13985
CTGF-814-16-	13986	NM_001901.2	connective tissue growth factor	CTGF
13986
CTGF-816-16-	13987	NM_001901.2	connective tissue growth factor	CTGF
13987
CTGF-1001-	13988	NM_001901.2	connective tissue growth factor	CTGF
16-13988
CTGF-1173-	13989	NM_001901.2	connective tissue growth factor	CTGF
16-13989
CTGF-749-16-	13990	NM_001901.2	connective tissue growth factor	CTGF
13990
CTGF-792-16-	13991	NM_001901.2	connective tissue growth factor	CTGF
13991
CTGF-1162-	13992	NM_001901.2	connective tissue growth factor	CTGF
16-13992
CTGF-811-16-	13993	NM_001901.2	connective tissue growth factor	CTGF
13993
CTGF-797-16-	13994	NM_001901.2	connective tissue growth factor	CTGF
13994
CTGF-1175-	13995	NM_001901.2	connective tissue growth factor	CTGF
16-13995
CTGF-1172-	13996	NM_001901.2	connective tissue growth factor	CTGF
16-13996
CTGF-1177-	13997	NM_001901.2	connective tissue growth factor	CTGF
16-13997
CTGF-1176-	13998	NM_001901.2	connective tissue growth factor	CTGF
16-13998
CTGF-812-16-	13999	NM_001901.2	connective tissue growth factor	CTGF
13999
CTGF-745-16-	14000	NM_001901.2	connective tissue growth factor	CTGF
14000
CTGF-1230-	14001	NM_001901.2	connective tissue growth factor	CTGF
16-14001
CTGF-920-16-	14002	NM_001901.2	connective tissue growth factor	CTGF
14002
CTGF-679-16-	14003	NM_001901.2	connective tissue growth factor	CTGF
14003
CTGF-992-16-	14004	NM_001901.2	connective tissue growth factor	CTGF
14004
CTGF-1045-	14005	NM_001901.2	connective tissue growth factor	CTGF
16-14005
CTGF-1231-	14006	NM_001901.2	connective tissue growth factor	CTGF
16-14006
CTGF-991-16-	14007	NM_001901.2	connective tissue growth factor	CTGF
14007
CTGF-998-16-	14008	NM_001901.2	connective tissue growth factor	CTGF
14008
CTGF-1049-	14009	NM_001901.2	connective tissue growth factor	CTGF
16-14009
CTGF-1044-	14010	NM_001901.2	connective tissue growth factor	CTGF
16-14010
CTGF-1327-	14011	NM_001901.2	connective tissue growth factor	CTGF
16-14011
CTGF-1196-	14012	NM_001901.2	connective tissue growth factor	CTGF
16-14012
CTGF-562-16-	14013	NM_001901.2	connective tissue growth factor	CTGF
14013
CTGF-752-16-	14014	NM_001901.2	connective tissue growth factor	CTGF
14014
CTGF-994-16-	14015	NM_001901.2	connective tissue growth factor	CTGF
14015
CTGF-1040-	14016	NM_001901.2	connective tissue growth factor	CTGF
16-14016
CTGF-1984-	14017	NM_001901.2	connective tissue growth factor	CTGF
16-14017
CTGF-2195-	14018	NM_001901.2	connective tissue growth factor	CTGF
16-14018
CTGF-2043-	14019	NM_001901.2	connective tissue growth factor	CTGF
16-14019
CTGF-1892-	14020	NM_001901.2	connective tissue growth factor	CTGF
16-14020
CTGF-1567-	14021	NM_001901.2	connective tissue growth factor	CTGF
16-14021
CTGF-1780-	14022	NM_001901.2	connective tissue growth factor	CTGF
16-14022
CTGF-2162-	14023	NM_001901.2	connective tissue growth factor	CTGF
16-14023
CTGF-1034-	14024	NM_001901.2	connective tissue growth factor	CTGF
16-14024
CTGF-2264-	14025	NM_001901.2	connective tissue growth factor	CTGF
16-14025
CTGF-1032-	14026	NM_001901.2	connective tissue growth factor	CTGF
16-14026
CTGF-1535-	14027	NM_001901.2	connective tissue growth factor	CTGF
16-14027
CTGF-1694-	14028	NM_001901.2	connective tissue growth factor	CTGF
16-14028
CTGF-1588-	14029	NM_001901.2	connective tissue growth factor	CTGF
16-14029
CTGF-928-16-	14030	NM_001901.2	connective tissue growth factor	CTGF
14030
CTGF-1133-	14031	NM_001901.2	connective tissue growth factor	CTGF
16-14031
CTGF-912-16-	14032	NM_001901.2	connective tissue growth factor	CTGF
14032
CTGF-753-16-	14033	NM_001901.2	connective tissue growth factor	CTGF
14033
CTGF-918-16-	14034	NM_001901.2	connective tissue growth factor	CTGF
14034
CTGF-744-16-	14035	NM_001901.2	connective tissue growth factor	CTGF
14035
CTGF-466-16-	14036	NM_001901.2	connective tissue growth factor	CTGF
14036
CTGF-917-16-	14037	NM_001901.2	connective tissue growth factor	CTGF
14037
CTGF-1038-	14038	NM_001901.2	connective tissue growth factor	CTGF
16-14038
CTGF-1048-	14039	NM_001901.2	connective tissue growth factor	CTGF
16-14039
CTGF-1235-	14040	NM_001901.2	connective tissue growth factor	CTGF
16-14040
CTGF-868-16-	14041	NM_001901.2	connective tissue growth factor	CTGF
14041
CTGF-1131-	14042	NM_001901.2	connective tissue growth factor	CTGF
16-14042
CTGF-1043-	14043	NM_001901.2	connective tissue growth factor	CTGF
16-14043
CTGF-751-16-	14044	NM_001901.2	connective tissue growth factor	CTGF
14044
CTGF-1227-	14045	NM_001901.2	connective tissue growth factor	CTGF
16-14045
CTGF-867-16-	14046	NM_001901.2	connective tissue growth factor	CTGF
14046
CTGF-1128-	14047	NM_001901.2	connective tissue growth factor	CTGF
16-14047
CTGF-756-16-	14048	NM_001901.2	connective tissue growth factor	CTGF
14048
CTGF-1234-	14049	NM_001901.2	connective tissue growth factor	CTGF
16-14049
CTGF-916-16-	14050	NM_001901.2	connective tissue growth factor	CTGF
14050
CTGF-925-16-	14051	NM_001901.2	connective tissue growth factor	CTGF
14051
CTGF-1225-	14052	NM_001901.2	connective tissue growth factor	CTGF
16-14052
CTGF-445-16-	14053	NM_001901.2	connective tissue growth factor	CTGF
14053
CTGF-446-16-	14054	NM_001901.2	connective tissue growth factor	CTGF
14054
CTGF-913-16-	14055	NM_001901.2	connective tissue growth factor	CTGF
14055
CTGF-997-16-	14056	NM_001901.2	connective tissue growth factor	CTGF
14056
CTGF-277-16-	14057	NM_001901.2	connective tissue growth factor	CTGF
14057
CTGF-1052-	14058	NM_001901.2	connective tissue growth factor	CTGF
16-14058
CTGF-887-16-	14059	NM_001901.2	connective tissue growth factor	CTGF
14059
CTGF-914-16-	14060	NM_001901.2	connective tissue growth factor	CTGF
14060
CTGF-1039-	14061	NM_001901.2	connective tissue growth factor	CTGF
16-14061
CTGF-754-16-	14062	NM_001901.2	connective tissue growth factor	CTGF
14062
CTGF-1130-	14063	NM_001901.2	connective tissue growth factor	CTGF
16-14063
CTGF-919-16-	14064	NM_001901.2	connective tissue growth factor	CTGF
14064
CTGF-922-16-	14065	NM_001901.2	connective tissue growth factor	CTGF
14065
CTGF-746-16-	14066	NM_001901.2	connective tissue growth factor	CTGF
14066
CTGF-993-16-	14067	NM_001901.2	connective tissue growth factor	CTGF
14067
CTGF-825-16-	14068	NM_001901.2	connective tissue growth factor	CTGF
14068
CTGF-926-16-	14069	NM_001901.2	connective tissue growth factor	CTGF
14069
CTGF-923-16-	14070	NM_001901.2	connective tissue growth factor	CTGF
14070
CTGF-866-16-	14071	NM_001901.2	connective tissue growth factor	CTGF
14071
CTGF-563-16-	14072	NM_001901.2	connective tissue growth factor	CTGF
14072
CTGF-823-16-	14073	NM_001901.2	connective tissue growth factor	CTGF
14073
CTGF-1233-	14074	NM_001901.2	connective tissue growth factor	CTGF
16-14074
CTGF-924-16-	14075	NM_001901.2	connective tissue growth factor	CTGF
14075
CTGF-921-16-	14076	NM_001901.2	connective tissue growth factor	CTGF
14076
CTGF-443-16-	14077	NM_001901.2	connective tissue growth factor	CTGF
14077
CTGF-1041-	14078	NM_001901.2	connective tissue growth factor	CTGF
16-14078
CTGF-1042-	14079	NM_001901.2	connective tissue growth factor	CTGF
16-14079
CTGF-755-16-	14080	NM_001901.2	connective tissue growth factor	CTGF
14080
CTGF-467-16-	14081	NM_001901.2	connective tissue growth factor	CTGF
14081
CTGF-995-16-	14082	NM_001901.2	connective tissue growth factor	CTGF
14082
CTGF-927-16-	14083	NM_001901.2	connective tissue growth factor	CTGF
14083
SPP1-1091-	14131	NM_000582.2	Osteopontin	SPP1
16-14131
PPIB--16-	14188	NM_000942	peptidylprolyl isomerase B (cyclophilin B)	PPIB
14188
PPIB--17-	14189	NM_000942	peptidylprolyl isomerase B (cyclophilin B)	PPIB
14189
PPIB--18-	14190	NM_000942	peptidylprolyl isomerase B (cyclophilin B)	PPIB
14190
pGL3-1172-	14386	U47296	Cloning vector pGL3-Control	pGL3
16-14386
pGL3-1172-	14387	U47296	Cloning vector pGL3-Control	pGL3
16-14387
MAP4K4-2931-	14390	NM_004834	Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4	MAP4K4
25-14390			(MAP4K4), transcript variant 1
miR-122--23-	14391			miR-122
14391
	14084	NM_000582.2	Osteopontin	SPP1
	14085	NM_000582.2	Osteopontin	SPP1
	14086	NM_000582.2	Osteopontin	SPP1
	14087	NM_000582.2	Osteopontin	SPP1
	14088	NM_000582.2	Osteopontin	SPP1
	14089	NM_000582.2	Osteopontin	SPP1
	14090	NM_000582.2	Osteopontin	SPP1
	14091	NM_000582.2	Osteopontin	SPP1
	14092	NM_000582.2	Osteopontin	SPP1
	14093	NM_000582.2	Osteopontin	SPP1
	14094	NM_000582.2	Osteopontin	SPP1
	14095	NM_000582.2	Osteopontin	SPP1
	14096	NM_000582.2	Osteopontin	SPP1
	14097	NM_000582.2	Osteopontin	SPP1
	14098	NM_000582.2	Osteopontin	SPP1
	14099	NM_000582.2	Osteopontin	SPP1
	14100	NM_000582.2	Osteopontin	SPP1
	14101	NM_000582.2	Osteopontin	SPP1
	14102	NM_000582.2	Osteopontin	SPP1
	14103	NM_000582.2	Osteopontin	SPP1
	14104	NM_000582.2	Osteopontin	SPP1
	14105	NM_000582.2	Osteopontin	SPP1
	14106	NM_000582.2	Osteopontin	SPP1
	14107	NM_000582.2	Osteopontin	SPP1
	14108	NM_000582.2	Osteopontin	SPP1
	14109	NM_000582.2	Osteopontin	SPP1
	14110	NM_000582.2	Osteopontin	SPP1
	14111	NM_000582.2	Osteopontin	SPP1
	14112	NM_000582.2	Osteopontin	SPP1
	14113	NM_000582.2	Osteopontin	SPP1
	14114	NM_000582.2	Osteopontin	SPP1
	14115	NM_000582.2	Osteopontin	SPP1
	14116	NM_000582.2	Osteopontin	SPP1
	14117	NM_000582.2	Osteopontin	SPP1
	14118	NM_000582.2	Osteopontin	SPP1
	14119	NM_000582.2	Osteopontin	SPP1
	14120	NM_000582.2	Osteopontin	SPP1
	14121	NM_000582.2	Osteopontin	SPP1
	14122	NM_000582.2	Osteopontin	SPP1
	14123	NM_000582.2	Osteopontin	SPP1
	14124	NM_000582.2	Osteopontin	SPP1
	14125	NM_000582.2	Osteopontin	SPP1
	14126	NM_000582.2	Osteopontin	SPP1
	14127	NM_000582.2	Osteopontin	SPP1
	14128	NM_000582.2	Osteopontin	SPP1
	14129	NM_000582.2	Osteopontin	SPP1
	14130	NM_000582.2	Osteopontin	SPP1
	14132	NM_000582.2	Osteopontin	SPP1
	14133	NM_000582.2	Osteopontin	SPP1
	14134	NM_000582.2	Osteopontin	SPP1
	14135	NM_000582.2	Osteopontin	SPP1
	14136	NM_000582.2	Osteopontin	SPP1
	14137	NM_000582.2	Osteopontin	SPP1
	14138	NM_000582.2	Osteopontin	SPP1
	14139	NM_000582.2	Osteopontin	SPP1
	14140	NM_000582.2	Osteopontin	SPP1
	14141	NM_000582.2	Osteopontin	SPP1
	14142	NM_000582.2	Osteopontin	SPP1
	14143	NM_000582.2	Osteopontin	SPP1
	14144	NM_000582.2	Osteopontin	SPP1
	14145	NM_000582.2	Osteopontin	SPP1
	14146	NM_000582.2	Osteopontin	SPP1
	14147	NM_000582.2	Osteopontin	SPP1
	14148	NM_000582.2	Osteopontin	SPP1
	14149	NM_000582.2	Osteopontin	SPP1
	14150	NM_000582.2	Osteopontin	SPP1
	14151	NM_000582.2	Osteopontin	SPP1
	14152	NM_000582.2	Osteopontin	SPP1
	14153	NM_000582.2	Osteopontin	SPP1
	14154	NM_000582.2	Osteopontin	SPP1
	14155	NM_000582.2	Osteopontin	SPP1
	14156	NM_000582.2	Osteopontin	SPP1
	14157	NM_000582.2	Osteopontin	SPP1
	14158	NM_000582.2	Osteopontin	SPP1
	14159	NM_000582.2	Osteopontin	SPP1
	14160	NM_000582.2	Osteopontin	SPP1
	14161	NM_000582.2	Osteopontin	SPP1
	14162	NM_000582.2	Osteopontin	SPP1
	14163	NM_000582.2	Osteopontin	SPP1
	14164	NM_000582.2	Osteopontin	SPP1
	14165	NM_000582.2	Osteopontin	SPP1
	14166	NM_000582.2	Osteopontin	SPP1
	14167	NM_000582.2	Osteopontin	SPP1
	14168	NM_000582.2	Osteopontin	SPP1
	14169	NM_000582.2	Osteopontin	SPP1
	14170	NM_000582.2	Osteopontin	SPP1
	14171	NM_000582.2	Osteopontin	SPP1
	14172	NM_000582.2	Osteopontin	SPP1
	14173	NM_000582.2	Osteopontin	SPP1
	14174	NM_000582.2	Osteopontin	SPP1
	14175	NM_000582.2	Osteopontin	SPP1
	14176	NM_000582.2	Osteopontin	SPP1
	14177	NM_000582.2	Osteopontin	SPP1
	14178	NM_000582.2	Osteopontin	SPP1
	14179	NM_000582.2	Osteopontin	SPP1
	14180	NM_000582.2	Osteopontin	SPP1
	14181	NM_000582.2	Osteopontin	SPP1
	14182	NM_000582.2	Osteopontin	SPP1
	14183	NM_000582.2	Osteopontin	SPP1
	14184	NM_000582.2	Osteopontin	SPP1
	14185	NM_000582.2	Osteopontin	SPP1
	14186	NM_000582.2	Osteopontin	SPP1
	14187	NM_000582.2	Osteopontin	SPP1

TABLE 2
Antisense backbone, chemistry, and sequence information. o: phosphodiester;
s: phosphorothioate; P: 5′ phosphorylation; 0: 2′-OH; F: 2′-fluoro;
m: 2′ O-methyl; +: LNA modification. Capital letters in the sequence signify
ribonucleotides, lower case letters signify deoxyribonucleotides.
	Oligo				SEQ
ID Number	Number	AntiSense Backbone	AntiSense Chemistry	AntiSense Sequence	ID NO:
APOB-	12138	ooooooooooooooooooo	00000000000000000000m	AUUGGUAUUCAGUGUGAUG	1
10167-20-12138
APOB-	12139	ooooooooooooooooooo	00000000000000000000m	AUUCGUAUUGAGUCUGAUC	2
10167-20-12139
MAP4K4-	12266
2931-13-12266
MAP4K4-	12293	ooooooooooooooooooo	Pf000fffff0f0000fff0	UAGACUUCCACAGAACUCU	3
2931-16-12293
MAP4K4-	12383	ooooooooooooooooooo	0000000000000000000	UAGACUUCCACAGAACUCU	4
2931-16-12383
MAP4K4-	12384	ooooooooooooooooooo	P0000000000000000000	UAGACUUCCACAGAACUCU	5
2931-16-12384
MAP4K4-	12385	ooooooooooooooooooo	Pf000fffff0f0000fff0	UAGACUUCCACAGAACUCU	6
3931-16-12385
MAP4K4-	12386	oooooooooosssssssso	Pf000fffff0f0000fff0	UAGACUUCCACAGAACUCU	7
2931-16-12386
MAP4K4-	12387	oooooooooosssssssso	P0000000000000000000	UAGACUUCCACAGAACUCU	8
2931-16-12387
MAP4K4-	12388	ooooooooooooooooo	00000000000000000	UAGACUUCCACAGAACU	9
2931-15-12388
MAP4K4-	12432
2931-13-12432
MAP4K4-	12266.2
2931-13-12266.2
APOB--	12434	ooooooooooooooooooo	000000000000000000000	AUUGGUAUUCAGUGUGAUG	10
21-12434		oo	m	AC
APOB--	12435	ooooooooooooooooooo	000000000000000000000	AUUCGUAUUGAGUCUGAUC	11
21-12435		oo	m	AC
MAP4K4-	12451	oooooooooosssssssso	Pf000fffff0f0000ffmm	UAGACUUCCACAGAACUCU	12
2931-16-12451
MAP4K4-	12452	oooooooooosssssssso	Pf000fffff0f0000ffmm	UAGACUUCCACAGAACUCU	13
2931-16-12452
MAP4K4-	12453	oooooooooosssssssso	Pf000fffff0f0000ffmm	UAGACUUCCACAGAACUCU	14
2931-16-12453
MAP4K4-	12454	oooooooooooosssssss	Pm000fffff0f0000ffffm	UAGACUUCCACAGAACUCU	15
2931-17-12454		so	m	UC
MAP4K4-	12455	oooooooosssssssssss	Pm000fffff0f0000ffffm	UAGACUUCCACAGAACUCU	16
2931-17-12455		so	m	UC
MAP4K4-	12456	oooooooooooosssssss	Pm000fffff0f0000fffff	UAGACUUCCACAGAACUCU	17
2931-19-12456		ssssso	f00mm	UCAAAG
--27-12480	123480
--27-12481	12481
APOB-	12505	ooooooooooooooooooo	00000000000000000000m	AUUGGUAUUCAGUGUGAUG	18
10167-21-12505		os		AC
APOB-	12506	ooooooooooooooooooo	00000000000000000000m	AUUCGUAUUGAGUCUGAUC	19
10167-21-12506		os		AC
MAP4K4-	12539	ooooooooooossssssss	Pf000fffff0f0000fff0	UAGACUUCCACAGAACUCU	20
2931-16-12539
APOB-	12505.2	ooooooooooooooooooo	00000000000000000000m	AUUGGUAUUCAGUGUGAUG	21
10167-21-12505.2		oo		AC
APOB-	12506.2	ooooooooooooooooooo	00000000000000000000m	AUUCGUAUUGAGUCUGAUC	22
10167-21-12506.2		oo		AC
MAP4K4--	12565
13-12565
MAP4K4-	12386.2	oooooooooosssssssso	Pf000fffff0f0000fff0	UAGACUUCCACAGAACUCU	23
2931-16-12386.2
MAP4K4-	12815
2931-13-12815
APOB--13-12957	12957
MAP4K4--	12983	oooooooooooosssssso	Pm000fffff0m0000mmm0	uagacuuccacagaacucu	24
16-12983
MAP4K4--	12984	oooooooooooossssss	Pm000fffff0m0000mmm0	uagacuuccacagaacucu	25
26-12984
MAP4K4--	12985	oooooooooooosssssso	Pm000fffff0m0000mmm0	uagacuuccacagaacucu	26
16-12985
MAP4K4--	12986	oooooooooosssssssso	Pf000fffff0f0000fff0	UAGACUUCCACAGAACUCU	27
16-12986
MAP4K4--	12987	ooooooooooooossssss	P0000f00ff0m0000m0m0	UagacUUccacagaacUcU	28
16-12987
MAP4K4--	12983	ooooooooooooossssss	P0000f00ff0m0000m0m0	UagacUUccacagaacUcu	29
16-12988
MAP4K4--	12989	ooooooooooooossssss	P0000ff0ff0m0000m0m0	UagacuUccacagaacUcu	30
16-12989
MAP4K4--	12990	ooooooooooooossssss	Pf0000ff000000000m00	uagaCuuCCaCagaaCuCu	31
16-12990
MAP4K4--	12991	ooooooooooooossssss	Pf0000fff00m00000mm0	uagaCuucCacagaaCucu	32
16-12991
MAP4K4--	12992	ooooooooooooossssss	Pf000fffff0000000m00	uagacuuccaCagaaCuCu	33
16-12992
MAP4K4--	12993	ooooooooooooossssss	P0000000000000000000	UagaCUUCCaCagaaCUCU	34
16-12993
MAP4K4--	12994	ooooooooooooossssss	P0000f0f0f0000000m00	UagacUuCcaCagaaCuCu	35
16-12994
MAP4K4--	12995	oooooooooooosssssso	Pf000fffff0000000000	uagacuuccaCagaaCUCU	36
16-12995
MAP4K4--	13012
2931-19-13012
MAP4K4--	13016
2931-19-13016
PPIB--13-13021	13021
pGL3-	13040
1172-13-13040
--16-13047	13047	oooooooooooossssss	Pm000000000m0000mmm0	UAGACUUCCACAGAACUCU	37
SOD1-	13090
530-13-13090
SOD1-	13091
523-13-13091
SOD1-	13092
535-13-13092
SOD1-	13093
536-13-13093
SOD1-	13094
396-13-13094
SOD1-	13095
385-13-13095
SOD1-	13096
195-13-13096
APOB-	13115
4314-13-13115
APOB-	13116
3384-13-13116
APOB-	13117
3547-13-13117
APOB-	13118
4318-13-13118
APOB-	13119
3741-13-13119
PPIB--16-13136	13136	oooooooooooossssss	Pm0fffff0f00mm000mm0	UGUUUUUGUAGCCAAAUCC	38
APOB-	13154
4314-15-13154
APOB-	13155
3547-15-13155
APOB-	13157
4318-15-13157
APOB-	13158
3741-15-13158
APOB--15-13159	13159
APOB--15-13160	13160
SOD1-	13163	oooooooooooosssssso	Pm0ffffffff0mmmmm0m0	UACUUUCUUCAUUUCCACC	39
530-16-13163
SOD1-	13164	oooooooooooosssssso	Pmff0fffff0fmmmm0mm0	UUCAUUUCCACCUUUGCCC	40
532-16-13164
SOD1-	13165	oooooooooooosssssso	Pmfff0f0ffffmmmm0mm0	CUUUGUACUUUCUUCAUUU	41
535-16-13165
SOD1-	13166	oooooooooooosssssso	Pmffff0f0fffmmmmm0m0	UCUUUGUACUUUCUUCAUU	42
536-16-13166
SOD1-	13167	oooooooooooosssssso	Pmf00f00ff0f0mm0mmm0	UCAGCAGUCACAUUGCCCA	43
396-16-13167
SOD1-	13168	oooooooooooosssssso	Pmff0fff000fmmmm00m0	AUUGCCCAAGUCUCCAACA	44
385-16-13168
SOD1-	13169	oooooooooooosssssso	Pmfff0fff0000mm00m00	UUCUGCUCGAAAUUGAUGA	45
195-16-13169
pGL3-	13170	oooooooooooosssssso	Pm00ff0f0ffm0ff00mm0	AAAUCGUAUUUGUCAAUCA	46
1172-16-13170
pGL3-	13171	ooooooooooooossssss	Pm00ff0f0ffm0ff00mm0	AAAUCGUAUUUGUCAAUCA	47
1172-16-13171
MAP4K4-	13189	ooooooooooooooooooo	0000000000000000000	UAGACUUCCACAGAACUCU	48
2931-19-13189
CTGF-	13190
1222-13-13190
CTGF-	13192
813-13-13192
CTGF-	13194
747-13-13194
CTGF-	13196
817-13-13196
CTGF-	13198
1174-13-13198
CTGF-	13200
1005-13-13200
CTGF-	13202
814-13-13202
CTGF-	13204
816-13-13204
CTGF-	13206
1001-13-13206
CTGF-	13208
1173-13-13208
CTGF-	13210
749-13-13210
CTGF-	13212
792-13-13212
CTGF-	13214
1162-13-13214
CTGF-	13216
811-13-13216
CTGF-	13218
797-13-13218
CTGF-	13220
1175-13-13220
CTGF-	13222
1172-13-13200
CTGF-	13224
1177-13-13224
CTGF-	13226
1176-13-13226
CTGF-	13228
812-13-13228
CTGF-	13230
745-13-13230
CTGF-	13232
1230-13-13232
CTGF-	13234
920-13-13234
CTGF-	13236
679-13-13236
CTGF-	13238
992-13-13238
CTGF-	13240
1045-13-13240
CTGF-	13242
1231-13-13242
CTGF-	13244
991-13-13244
CTGF-	13246
998-13-13246
CTGF-	13248
1049-13-13200
CTGF-	13250
1044-13-13250
CTGF-	13252
1327-13-13252
CTGF-	13254
1196-13-13254
CTGF-	13256
562-13-13256
CTGF-	13258
752-13-13258
CTGF-	13260
994-13-13260
CTGF-	13262
1040-13-13262
CTGF-	13264
1984-13-13264
CTGF-	13266
2195-13-13266
CTGF-	13268
2043-13-13268
CTGF-	13270
1892-13-13270
CTGF-	13272
1567-13-13272
CTGF-	13274
1780-13-13274
CTGF-	13276
2162-13-13276
CTGF-	13278
1034-13-13278
CTGF-	13280
2264-13-13280
CTGF-	13282
1032-13-13282
CTGF-	13284
1535-13-13284
CTGF-	13286
1694-13-13286
CTGF-	13288
1588-13-13288
CTGF-	13290
928-13-13290
CTGF-	13292
1133-13-13292
CTGF-	13294
912-13-13294
CTGF-	13296
753-13-13296
CTGF-	13298
918-13-13298
CTGF-	13230
744-13-13230
CTGF-	13202
466-13-13202
CTGF-	13204
917-13-13204
CTGF-	13206
1038-13-13206
CTGF-	13208
1048-13-13208
CTGF-	13310
1235-13-13310
CTGF-	13312
868-13-13312
CTGF-	13314
1131-13-13314
CTGF-	13316
1043-13-13316
CTGF-	13318
751-13-13318
CTGF-	13320
1227-13-13320
CTGF-	13322
867-13-13322
CTGF-	13324
1128-13-13324
CTGF-	13326
756-13-13326
CTGF-	13328
1234-13-13328
CTGF-	13330
916-13-13330
CTGF-	13332
925-13-13332
CTGF-	13334
1225-13-13334
CTGF-	13336
445-13-13336
CTGF-	13338
446-13-13338
CTGF-	13340
913-13-13340
CTGF-	13342
997-13-13342
CTGF-	13344
277-13-13344
CTGF-	13346
1052-13-13346
CTGF-	13348
887-13-13348
CTGF-	13350
914-13-13350
CTGF-	13352
1039-13-13352
CTGF-	13354
754-13-13354
CTGF-	13356
1130-13-13356
CTGF-	13358
919-13-13358
CTGF-	13360
922-13-13360
CTGF-	13362
746-13-13362
CTGF-	13364
993-13-13364
CTGF-	13366
825-13-13366
CTGF-	13368
926-13-13368
CTGF-	13370
923-13-13370
CTGF-	13372
866-13-13372
CTGF-	13374
563-13-13374
CTGF-	13376
823-13-13376
CTGF-	13378
1233-13-13378
CTGF-	13380
924-13-13380
CTGF-	13382
924-13-13382
CTGF-	13384
443-13-13384
CTGF-	13386
1041-13-13386
CTGF-	13388
1042-13-13388
CTGF-	13390
755-13-13390
CTGF-	13392
467-13-13392
CTGF-	13394
995-13-13394
CTGF-	13396
927-13-13396
SPP1-	13398
1025-13-13398
SPP1-	13400
1049-13-13400
SPP1-	13402
1051-13-13402
SPP1-	13404
1048-13-13404
SPP1-	13406
1050-13-13406
SPP1-	13408
1047-13-13408
SPP1-	13410
800-13-13410
SPP1-	13412
492-13-13412
SPP1-	13414
612-13-13414
SPP1-	13416
481-13-13416
SPP1-	13418
614-13-13418
SPP1-	13420
951-13-13420
SPP1-	13422
482-13-13422
SPP1-	13424
856-13-13424
SPP1-	13426
857-13-13426
SPP1-	13428
365-13-13428
SPP1-	13430
359-13-13430
SPP1-	13432
357-13-13432
SPP1-	13434
858-13-13434
SPP1-	13436
1012-13-13436
SPP1-	13438
1014-13-13438
SPP1-	13440
356-13-13440
SPP1-	13442
368-13-13442
SPP1-	13444
1011-13-13444
SPP1-	13446
754-13-13446
SPP1-	13448
1021-13-13448
SPP1-	13450
1330-13-13450
SPP1-	13452
346-13-13452
SPP1-	13454
869-13-13454
SPP1-	13456
701-13-13456
SPP1-	13458
896-13-13458
SPP1-	13460
1035-13-13460
SPP1-	13462
1170-13-13462
SPP1-	13464
1282-13-13464
SPP1-	13466
1537-13-13466
SPP1-	13468
692-13-13468
SPP1-	13470
840-13-13470
SPP1-	13472
1163-13-13472
SPP1-	13474
789-13-13474
SPP1-	13476
841-13-13476
SPP1-	13478
852-13-13478
SPP1-	13480
209-13-13480
SPP1-	13482
1276-13-13482
SPP1-	13484
137-13-13484
SPP1-	13486
711-13-13486
SPP1-	13488
582-13-13488
SPP1-	13490
839-13-13490
SPP1-	13492
1091-13-13492
SPP1-	13494
884-13-13494
SPP1-	13496
903-13-13496
SPP1-	13498
1090-13-13498
SPP1-	13500
474-13-13500
SPP1-	13502
575-13-13502
SPP1-	13504
671-13-13504
SPP1-	13506
924-13-13506
SPP1-	13508
1185-13-13508
SPP1-	13510
1221-13-13510
SPP1-	13512
347-13-13512
SPP1-	13514
634-13-13514
SPP1-	13516
877-13-13516
SPP1-	13518
1033-13-13518
SPP1-	13520
714-13-13520
SPP1-	13522
791-13-13522
SPP1-	13524
813-13-13524
SPP1-	13526
939-13-13526
SPP1-	13528
1161-13-13528
SPP1-	13530
1164-13-13530
SPP1-	13532
1190-13-13532
SPP1-	13534
1333-13-13534
SPP1-	13536
537-13-13536
SPP1-	13538
684-13-13538
SPP1-	13540
707-13-13540
SPP1-	13542
799-13-13542
SPP1-	13544
853-13-13544
SPP1-	13546
888-13-13546
SPP1-	13548
1194-13-13548
SPP1-	13550
1279-13-13550
SPP1-	13552
1300-13-13552
SPP1-	13554
1510-13-13554
SPP1-	13556
1543-13-13556
SPP1-	13558
434-13-13558
SPP1-	13560
600-13-13560
SPP1-	13562
863-13-13562
SPP1-	13564
902-13-13564
SPP1-	13566
921-13-13566
SPP1-	13568
154-13-13568
SPP1-	13570
217-13-13570
SPP1-	13572
816-13-13572
SPP1-	13574
882-13-13574
SPP1-	13576
932-13-13576
SPP1-	13578
1509-13-13578
SPP1-	13580
157-13-13580
SPP1-	13582
350-13-13582
SPP1-	13584
511-13-13584
SPP1-	13586
605-13-13586
SPP1-	13588
811-13-13588
SPP1-	13590
892-13-13590
SPP1-	13592
922-13-13592
SPP1-	13594
1169-13-13594
SPP1-	13596
1182-13-13596
SPP1-	13598
1539-13-13598
SPP1-	13600
1541-13-13600
SPP1-	13602
427-13-13602
SPP1-	13604
533-13-13504
APOB--13-13763	13763
APOB--13-13764	13764
MAP4K4--	13766	oooooooooooosssssso	Pm000fffff0m0000mmm0	UAGACUUCCACAGAACUCU	49
16-13766
PPIB--13-13767	13767
PPIB--15-13768	13768
PPIB-17-13769	13769
MAP4K4--	13939	oooooooooooosssssso	m000f0ffff0m0m00m0m	UAGACAUCCUACACAGCAC	50
16-13939
APOB-	13940	oooooooooooosssssso	Pm0fffffff000mmmmm00	UGUUUCUCCAGAUCCUUGC	51
4314-16-13940
APOB-	13941	oooooooooooosssssso	Pm0fffffff000mmmmm00	UGUUUCUCCAGAUCCUUGC	52
4314-17-13941
APOB--16-13942	13942	oooooooooooosssssso	Pm00f000f000mmm0mmm0	UAGCAGAUGAGUCCAUUUG	53
APOB--18-13943	13943	oooooooooooooooosss	Pm00f000f000mmm0mmm00	UAGCAGAUGAGUCCAUUUG	54
		ssso	000	GAGA
APOB--17-13944	13944	oooooooooooosssssso	Pm00f000f000mmm0mmm0	UAGCAGAUGAGUCCAUUUG	55
APOB--19-13945	13945	oooooooooooooooosss	Pm00f000f000mmm0mmm00	UAGCAGAUGAGUCCAUUUG	56
		ssso	000	GAGA
APOB-	13946	oooooooooooosssssso	Pmf0ff0ffffmmm000mm0	AUGUUGUUUCUCCAGAUCC	57
4314-16-13946
APOB-	13947	oooooooooooosssssso	Pmf0ff0ffffmmm000mm0	AUGUUGUUUCUCCAGAUCC	58
4314-17-13947
APOB--16-14948	13948	oooooooooooosssssso	Pm0fff000000mmmm0m00	UGUUUGAGGGACUCUGUGA	59
APOB--17-13949	13949	oooooooooooosssssso	Pm0fff000000mmmm0m00	UGUUUGAGGGACUCUGUGA	60
APOB--16-13950	13950	oooooooooooosssssso	Pmff00f0fff00m0m00m0	AUUGGUAUUCAGUGUGAUG	61
APOB--18-13951	13951	oooooooooooooooosss	Pmff00f0fff00m0m00m00	AUUGGUAUUCAGUGUGAUG	62
		ssso	m00	ACAC
APOB--17-13952	13952	oooooooooooosssssso	Pmff00f0fff00m0m00m0	AUUGGUAUUCAGUGUGAUG	63
APOB--19-13953	13953	oooooooooooooooosss	Pmff00f0fff00m0m00m00	AUUGGUAUUCAGUGUGAUG	64
		ssso	m00	ACAC
MAP4K4--	13766.2	oooooooooooosssssso	Pm000fffff0m0000mmm0	UAGACUUCCACAGAACUCU	65
16-13766.2
CTGF-	13980	oooooooooooosssssso	Pm0f0ffffffm0m00m0m0	UACAUCUUCCUGUAGUACA	66
1222-16-13980
CTGF-	13981	oooooooooooosssssso	Pm0f0ffff0mmmm0m000	AGGCGCUCCACUCUGUGGU	67
813-16-13981
CTGF-	13982	oooooooooooosssssso	Pm0ffffff00mm0m0000	UGUCUUCCAGUCGGUAAGC	68
747-16-13982
CTGF-	13983	oooooooooooosssssso	Pm00f000f0fmmm0mmmm0	GAACAGGCGCUCCACUCUG	69
817-16-13983
CTGF-	13984	oooooooooooosssssso	Pm00ff0f00f00m000m00	CAGUUGUAAUGGCAGGCAC	70
1174-16-13984
CTGF-	13985	oooooooooooosssssso	Pmff000000mmm000mm0	AGCCAGAAAGCUCAAACUU	71
1005-16-13985
CTGF-	13986	oooooooooooosssssso	Pm000f0ffff0mmmm0m00	CAGGCGCUCCACUCUGUGG	72
814-16-13986
CTGF-	13987	oooooooooooosssssso	Pm0f000f0ffmm0mmmm00	AACAGGCGCUCCACUCUGU	73
816-16-13987
CTGF-	13988	oooooooooooosssssso	Pm0000fff000mmm00m0	AGAAAGCUCAAACUUGAUA	74
1001-16-13988
CTGF-	13989	oooooooooooosssssso	Pmff0f00f00m000m0m0	AGUUGUAAUGGCAGGCACA	75
1173-16-13989
CTGF-	13990	oooooooooooosssssso	Pmf0ffffff00mm00m00	CGUGUCUUCCAGUCGGUAA	76
749-16-13990
CTGF-	13991	oooooooooooosssssso	Pm00ff000f00mm00mmm0	GGACCAGGCAGUUGGCUCU	77
792-16-13991
CTGF-	13992	oooooooooooosssssso	Pm000f0f000mmmm00m00	CAGGCACAGGUCUUGAUGA	78
1162-16-13992
CTGF-	13993	oooooooooooosssssso	Pmf0ffff0ffmm0m00mm0	GCGCUCCACUCUGUGGUCU	79
811-16-13993
CTGF-	13994	oooooooooooosssssso	Pm0fff000ff000m00mm0	GGUCUGGACCAGGCAGUUG	80
797-16-13994
CTGF-	13995	oooooooooooosssssso	Pmf00ff0f00m00m000m0	ACAGUUGUAAUGGCAGGCA	81
1175-16-13995
CTGF-	13996	oooooooooooosssssso	Pmff0f00f00m000m0m00	GUUGUAAUGGCAGGCACAG	82
1172-16-13996
CTGF-	13997	oooooooooooosssssso	Pm00f00ff0f00m00m000	GGACAGUUGUAAUGGCAGG	83
1177-16-13997
CTGF-	13998	oooooooooooosssssso	Pm0f0ffff0fmmm0m00m0	GGCGCUCCACUCUGUGGUC	84
1176-16-13998
CTGF-	13999	oooooooooooosssssso	Pm0f0ffff0fmmm0m00m0	GGCGCUCCACUCUGUGGUC	85
812-16-13999
CTGF-	14000	oooooooooooosssssso	Pmfffff00ff00m000mm0	UCUUCCAGUCGGUAAGCCG	86
745-16-14000
CTGF-	14001	oooooooooooosssssso	Pm0fffff0f0m0mmmmmm0	UGUCUCCGUACAUCUUCCU	87
1230-16-14001
CTGF-	14002	oooooooooooosssssso	Pmffff-f0000mmm00m0	AGCUUCGCAAGGCCUGACC	88
920-16-14002
CTGF-	14003	oooooooooooosssssso	Pm0ffffff0f00m0mmmm0	CACUCCUCGCAGCAUUUCC	89
679-16-14003
CTGF-	14004	oooooooooooosssssso	Pm00fff00f000mmm0000	AAACUUGAUAGGCUUGGAG	90
992-16-14004
CTGF-	14005	oooooooooooosssssso	Pmffff0f0000mmm00mm0	ACUCCACAGAAUUUAGCUC	91
1045-16-14005
CTGF-	14006	oooooooooooosssssso	Pmf0fffff0f0m0mmmmm0	AUGUCUCCGUACAUCUUCC	92
1231-16-14006
CTGF-	14007	oooooooooooosssssso	Pm0fff00f000mmm00000	AACUUGAUAGGCUUGGAGA	93
991-16-14007
CTGF-	14008	oooooooooooosssssso	Pm00fff000fmm00m0000	AAGCUCAAACUUGAUAGGC	94
998-16-14008
CTGF-	14009	oooooooooooosssssso	Pmf0f0ffff0m0000mmm0	ACAUACUCCACAGAAUUUA	95
1049-16-14009
CTGF-	14010	oooooooooooosssssso	Pmfff0f0000mmm00mmm0	CUCCACAGAAUUUAGCUCG	96
1044-16-14010
CTGF-	14011	oooooooooooosssssso	Pm0f0ff0ff0000mm0mm0	UGUGCUACUGAAAUCAUUU	97
1327-16-14011
CTGF-	14012	oooooooooooosssssso	Pm0000f0ff0mm0mmmmm0	AAAGAUGUCAUUGUCUCCG	98
1196-16-14012
CTGF-	14013	oooooooooooosssssso	Pmf0f0ff00f0mmm0m000	GUGCACUGGUACUUGCAGC	99
562-16-14013
CTGF-	14014	oooooooooooosssssso	Pm00f0f0fffmmm00mm00	AAACGUGUCUUCCAGUCGG	100
752-16-14014
CTGF-	14015	oooooooooooosssssso	Pmf000fff00m000mmm00	UCAAACUUGAUAGGCUUGG	101
994-16-14015
CTGF-	14016	oooooooooooosssssso	Pmf0000fff00mmm00m00	ACAGAAUUUAGCUCGGUAU	102
1040-16-14016
CTGF-	14017	oooooooooooosssssso	Pmf0f0ffff0mmm0m00m0	UUACAUUCUACCUAUGGUG	103
1984-16-14017
CTGF-	14018	oooooooooooosssssso	Pm00ff00ff00mM0m0m00	AAACUGAUCAGCUAUAUAG	104
2195-16-14018
CTGF-	14019	oooooooooooosssssso	Pm0fff000f0000mmmmm0	UAUCUGAGCAGAAUUUCCA	105
2043-16-14019
CTGF-	14020	oooooooooooosssssso	Pmf00fff000m00mm0m00	UUAACUUAGAUAACUGUAC	106
1892-16-14020
CTGF-	14021	oooooooooooosssssso	Pm0ff0fff0f0m0000m00	UAUUACUCGUAUAAGAUGC	107
1567-16-14021
CTGF-	14022	oooooooooooosssssso	Pm00ff0fff00mmm00mm0	AAGCUGUCCAGUCUAAUCG	108
1780-16-14022
CTGF-	14023	oooooooooooosssssso	Pm00F00000Fm0mmm0mm0	UAAUAAAGGCCAUUUGUUC	109
2162-16-14023
CTGF-	14024	oooooooooooosssssso	Pmff00fff00m0m0mmmm0	UUUAGCUCGGUAUGUCUUC	110
1034-16-14024
CTGF-	14025	oooooooooooosssssso	Pmf0fffff00m000m0000	ACACUCUCAACAAAUAAAC	111
2264-16-14025
CTGF-	14026	oooooooooooosssssso	Pm00fff00f0m0mmmmm00	UAGCUCGGUAUGUCUUCAU	112
1032-16-14026
CTGF-	14027	oooooooooooosssssso	Pm00fffffff0mm00m0m0	UAACCUUUCUGCUGGUACC	113
1535-16-14027
CTGF-	14028	oooooooooooosssssso	Pmf000000f00mmm00mm0	UUAAGGAACAACUUGACUC	114
1694-16-14028
CTGF-	14029	oooooooooooosssssso	Pmf0f0ffff000m00m000	UUACACUUCAAAUAGCAGG	115
1588-16-14029
CTGF-	14030	oooooooooooosssssso	Pmff000ff00mmmm0m000	UCCAGGUCAGCUUCGCAAG	116
928-16-14030
CTGF-	14031	oooooooooooosssssso	Pmffffff0f00mmmm0mm0	CUUCUUCAUGACCUCGCCG	117
1133-16-14031
CTGF-	14032	oooooooooooosssssso	Pm000fff00fm0m0m0m00	AAGGCCUGACCAUGCACAG	118
912-16-14032
CTGF-	14033	oooooooooooosssssso	Pm000f0f0ffmmmm00mm0	CAAACGUGUCUUCCAGUCG	119
753-16-14033
CTGF-	14034	oooooooooooosssssso	Pmfff0f0000mmm00mm00	CUUCGCAAGGCCUGACCAU	120
918-16-14034
CTGF-	14035	oooooooooooosssssso	pmffff00ff00m000mm00	CUUCCAGUCGGUAAGCCGC	121
744-16-14035
CTGF-	14036	oooooooooooosssssso	Pmf00ffff0f00mm00mm0	CCGAUCUUGCGGUUGGCCG	122
466-16-14036
CTGF-	14037	oooooooooooosssssso	Pmff0f0000fmm00mm0m0	UUCGCAAGGCCUGACCAUG	123
917-16-14037
CTGF-	14038	oooooooooooosssssso	Pm00fff00fmm0m0m00	AGAAUUUAGCUCGGUAUGU	124
1038-16-14038
CTGF-	14039	oooooooooooosssssso	Pm0f0ffff0f0000mmm00	CAUACUCCACAGAAUUUAG	125
1048-16-14039
CTGF-	14040	oooooooooooosssssso	Pm0ff0f0fffmmm0m0m0	UGCCAUGUCUCCGUACAUC	126
1235-16-14040
CTGF-	14041	oooooooooooosssssso	Pm000f0ff0fm0mm00m00	GAGGCGUUGUCAUUGGUAA	127
868-16-14041
CTGF-	14042	oooooooooooosssssso	Pmffff0f00fmmm0mm0m0	UCUUCAUGACCUCGCCGUC	128
1131-16-14042
CTGF-	14043	oooooooooooosssssso	Pmff0f0000fmm00mmm00	UCCACAGAAUUUAGCUCGG	129
1043-16-14043
CTGF-	14044	oooooooooooosssssso	Pm0f0f0ffffmm00mm000	AACGUGUCUUCCAGUCGGU	130
751-16-14044
CTGF-	14045	oooooooooooosssssso	Pmfff0f0f0fmmmmmm0m0	CUCCGUACAUCUUCCUGUA	131
1227-16-14045
CTGF-	14046	oooooooooooosssssso	Pm0f0ff0ff0mm00m000	AGGCGUUGUCAUUGGUAAC	132
867-16-14046
CTGF-	14047	oooooooooooosssssso	Pmf0f00ffff0mm0mm000	UCAUGACCUCGCCGUCAGG	133
1128-16-14047
CTGF-	14048	oooooooooooosssssso	Pm0ff000f0f0mmmmmm00	GGCCAAACGUGUCUUCCAG	134
756-16-14048
CTGF-	14049	oooooooooooosssssso	Pmff0f0ffffmm0m0mm0	GCCAUGUCUCCGUACAUCU	135
1234-16-14049
CTGF-	14050	oooooooooooosssssso	Pmf0f0000ffm00mm0m00	UCGCAAGGCCUGACCAUGC	136
916-16-14050
CTGF-	14051	oooooooooooosssssso	Pm0ff00fffmm0000m0	AGGUCAGCUUCGCAAGGCC	137
925-16-14051
CTGF-	14052	oooooooooooosssssso	Pmf0f0f0fffmmmm0m000	CCGUACAUCUUCCUGUAGU	138
1225-16-14052
CTGF-	14053	oooooooooooosssssso	Pm00ff0000fm0m000000	GAGCCGAAGUCACAGAAGA	139
445-16-14053
CTGF-	14054	oooooooooooosssssso	Pm000ff0000mm0m00000	GGAGCCGAAGUCACAGAAG	140
446-16-14054
CTGF-	14055	oooooooooooosssssso	Pm0000fff00mm0m0m0m0	CAAGGCCUGACCAUGCACA	141
913-16-14055
CTGF-	14056	oooooooooooosssssso	Pmfff000ffm00m000m0	AGCUCAAACUUGAUAGGCU	142
997-16-14056
CTGF-	14057	oooooooooooosssssso	Pmf0f00ffff00mm00m00	CUGCAGUUCUGGCCGACGG	143
277-16-14057
CTGF-	14058	oooooooooooosssssso	Pm0f0f0f0ffmm0m00000	GGUACAUACUCCACAGAAU	144
1052-16-14058
CTGF-	14059	oooooooooooosssssso	Pmf0fffffff00mmm0m00	CUGCUUCUCUAGCCUGCAG	145
887-16-14050
CTGF-	14060	oooooooooooosssssso	Pmf0000fff00mm0m0m00	GCAAGGCCUGACCAUGCAC	146
914-16-14060
CTGF-	14061	oooooooooooosssssso	Pm0000fff00mmm00m0m0	CAGAAUUUAGCUCGGUAUG	147
1039-16-14061
CTGF-	14062	oooooooooooosssssso	Pmf000f0f0fmmmmm00m0	CCAAACGUGUCUUCCAGUC	148
754-16-14062
CTGF-	14063	oooooooooooosssssso	Pmfff0f00ffmmmm0mm0	CUUCAUGACCUCGCCGUCA	149
1130-16-14063
CTGF-	14064	oooooooooooosssssso	Pmffff0f0000mmm00mm0	GCUUCGCAAGGCCUGACCA	150
919-16-14064
CTGF-	14065	oooooooooooosssssso	Pmf00ffff0f0000mmm00	UCAGCUUCGCAAGGCCUGA	151
922-16-14065
CTGF-	14066	oooooooooooosssssso	Pmffffff00fm0m000m0	GUCUUCCAGUCGGUAAGCC	152
746-16-14066
CTGF-	14067	oooooooooooosssssso	Pm000fff00f000mmm000	CAAACUUGAUAGGCUUGGA	153
993-16-14067
CTGF-	14068	oooooooooooosssssso	Pm0ffff0000m000m0m0	AGGUCUUGGAACAGGCGCU	154
825-16-14068
CTGF-	14069	oooooooooooosssssso	Pm000ff00ffmmm00000	CAGGUCAGCUUCGCAAGGC	155
926-16-14069
CTGF-	14070	oooooooooooosssssso	Pmff00ffff0m0000mmm0	GUCAGCUUCGCAAGGCCUG	156
923-16-14070
CTGF-	14071	oooooooooooosssssso	Pm0f0ff0ff0mm00m00m0	GGCGUUGUCAUUGGUAACC	157
866-16-14071
CTGF-	14072	oooooooooooosssssso	Pmf0f0ff00m0mmm0m00	CGUGCACUGGUACUUGCAG	158
563-16-14072
CTGF-	14073	oooooooooooosssssso	Pmffff0000f000m0mmm0	GUCUUGGAACAGGCGCUCC	159
823-16-14073
CTGF-	14074	oooooooooooosssssso	Pmf0f0fffff0m0m0mmm0	CCAUGUCUCCGUACAUCUU	160
1233-16-14074
CTGF-	14075	oooooooooooosssssso	Pm0ff00ffff0m0000mm0	GGUCAGCUUCGCAAGGCCU	161
924-16-14075
CTGF-	14076	oooooooooooosssssso	Pm00ffff0f0000mmm000	CAGCUUCGCAAGGCCUGAC	162
921-16-14076
CTGF-	14077	oooooooooooosssssso	Pmff0000ff0m00000000	GCCGAAGUCACAGAAGAGG	163
443-16-14077
CTGF-	14078	oooooooooooosssssso	Pm0f0000fff00mmm00m0	CACAGAAUUUAGCUCGGUA	164
1041-16-14078
CTGF-	14079	oooooooooooosssssso	Pmf0f0000ffm00mmm000	CCACAGAAUUUAGCUCGGU	165
1042-16-14079
CTGF-	14080	oooooooooooosssssso	Pmff000f0f0mmmmmm000	GCCAAACGUGUCUUCCAGU	166
755-16-14080
CTGF-	14081	oooooooooooosssssso	Pmf0f00ffff0m0mm00m0	GCCGAUCUUGCGGUUGGCC	167
467-16-14081
CTGF-	14082	oooooooooooosssssso	Pmff000fff00m000mmm0	CUCAAACUUGAUAGGCUUG	168
995-16-14082
CTGF-	14083	oooooooooooosssssso	Pmf000ff00fmmm0m0000	CCAGGUCAGCUUCGCAAGG	169
927-16-14083
SPP1-	14131	oooooooooooosssssso	Pmff00ff000m0m0000m0	UUUGACUAAAUGCAAAGUG	170
1091-16-14131
PPIB--16-14188	14188	ooooooooooooossssss	Pm0fffff0f00mm000mm0	UGUUUUUGUAGCCAAAUCC	171
PPIB--17-14189	14189	ooooooooooooossssss	Pm0fffff0f00mm000mm0	UGUUUUUGUAGCCAAAUCC	172
PPIB--18-14190	14190	ooooooooooooossssss	Pm0fffff0f00mm000mm0	UGUUUUUGUAGCCAAAUCC	173
pGL3-	14386	oooooooooooosssssso	Pm00ff0f0ffm0mm00mm0	AAAUCGUAUUUGUCAAUCA	174
1172-16-14386
pGL3-	14387	oooooooooooosssssso	Pm00ff0f0ffm0mm00mm0	AAAUCGUAUUUGUCAAUCA	175
1172-16-14387
MAP4K4-	14390
2931-25-14390
miR-122--	14391
23-14391
	14084	oooooooooooosssssso	Pmff00fff0f000000m00	UCUAAUUCAUGAGAAAUAC	616
	14085	oooooooooooosssssso	Pm00ff00fffm000000m0	UAAUUGACCUCAGAAGAUG	617
	14086	oooooooooooosssssso	Pmff00ff00fmmm000000	UUUAAUUGACCUCAGAAGA	618
	14087	oooooooooooosssssso	Pm0ff00ffff000000m00	AAUUGACCUCAGAAGAUGC	619
	14088	oooooooooooosssssso	Pmf00ff00ffmm0000000	UUAAUUGACCUCAGAAGAU	620
	14089	oooooooooooosssssso	Pmff00ffff000000m0m0	AUUGACCUCAGAAGAUGCA	621
	14090	oooooooooooosssssso	Pmf0fff00ff00mmm0mm0	UCAUCCAGCUGACUCGUUU	622
	14091	oooooooooooosssssso	Pm0fff0ff0000m00m00	AGAUUCAUCAGAAUGGUGA	623
	14092	oooooooooooosssssso	Pm00ffff00fmm0m000m0	UGACCUCAGUCCAUAAACC	624
	14093	oooooooooooosssssso	Pm0f00f0000mmm0mm000	AAUGGUGAGACUCAUCAGA	625
	14094	oooooooooooosssssso	Pmff00fffff00mmm0m000	UUUGACCUCAGUCCAUAAA	626
	14095	oooooooooooosssssso	Pmff0f00ff0m0000mmm0	UUCAUGGCUGUGAAAUUCA	627
	14096	oooooooooooosssssso	Pm00f00f0000mmm0mm00	GAAUGGUGAGACUCAUCAG	628
	14097	oooooooooooosssssso	Pm00ffffff0mmm0m0m00	UGGCUUUCCGCUUAUAUAA	629
	14098	oooooooooooosssssso	Pmf00ffffff0mmm0m0m0	UUGGCUUUCCGCUUAUAUA	630
	14099	oooooooooooosssssso	Pmf0fff0f0f00mm0m000	UCAUCCAUGUGGUCAUGGC	631
	14100	oooooooooooosssssso	Pmf0f00ff0f00mmmmm00	AUGUGGUCAUGGCUUUCGU	632
	14101	oooooooooooosssssso	Pmf00ff0f00mmmmm0mm0	GUGGUCAUGGCUUUCGUUG	633
	14102	oooooooooooosssssso	Pmff00fffffmmmm0m00	AUUGGCUUUCCGCUUAUAU	634
	14103	oooooooooooosssssso	Pm00f0f0000mmmm000m0	AAAUACGAAAUUUCAGGUG	635
	14104	oooooooooooosssssso	Pm000f0f0000mmmm000	AGAAAUACGAAAUUUCAGG	636
	14105	oooooooooooosssssso	Pm00ff0f00fmmmm0mm00	UGGUCAUGGCUUUCGUUGG	637
	14106	oooooooooooosssssso	Pmf0ff0fff0m0m00mm00	AUAUCAUCCAUGUGGUCAU	638
	14107	oooooooooooosssssso	Pm0f0f0000fmmm000m00	AAUACGAAAUUUCAGGUGU	639
	14108	oooooooooooosssssso	Pm0ff000000mm0mmm00	AAUCAGAAGGCGCGUUCAG	640
	10109	oooooooooooosssssso	Pmfff0f000000m0m0000	AUUCAUGAGAAAUACGAAA	641
	14110	oooooooooooosssssso	Pmf0fff0f0000000m000	CUAUUCAUGAGAGAAUAAC	642
	14111	oooooooooooosssssso	Pmfff0ff000mmm0mmm00	UUUCGUUGGACUUACUUGG	643
	14112	oooooooooooosssssso	Pmf0fffff0fm0mm00mm0	UUGCUCUCAUCAUUGGCUU	644
	14113	oooooooooooosssssso	Pmff00fffffmmmmmmm0	UUCAACUCCUCGCUUUCCA	645
	14114	oooooooooooosssssso	Pm00ff0ff00mm0m0mm00	UGACUAUCAAUCACAUCGG	646
	14115	oooooooooooosssssso	Pm0f0f0ff0mmm00mmm0	AGAUGCACUAUCUAAUUCA	647
	14116	oooooooooooosssssso	Pm0f000f0f0m0mmm00m0	AAUAGAUACACAUUCAACC	648
	14117	oooooooooooosssssso	Pmffffff0f0000m000m0	UUCUUCUAUAGAAUGAACA	649
	14118	oooooooooooosssssso	Pm0ff0ff000m00mm0m00	AAUUGCUGGACAACCGUGG	650
	14119	oooooooooooosssssso	Pmf0ffffff0m0m0m0000	UCGCUUUCCAUGUGUGAGG	651
	14120	oooooooooooosssssso	Pm00fff000fm0mmm0m00	UAAUCUGGACUGCUUGUGG	652
	14121	oooooooooooosssssso	Pmf0f0fff00mm00m0000	ACACAUUCAACCAAUAAAC	653
	14122	oooooooooooosssssso	Pmfff0ffff0m00mm0mm0	ACUCGUUUCAUAACUGUCC	654
	14123	oooooooooooosssssso	Pmf00fff000mm0mmm0m0	AUAAUCUGGACUGCUUGUG	655
	14124	oooooooooooosssssso	Pmffff0fff0m0m00mmm0	UUUCCGCUUAUAUAAUCUG	656
	14125	oooooooooooosssssso	Pm0fff00ff00m0m00m00	UGUUUAACUGGUAUGGCAC	657
	14126	oooooooooooosssssso	Pm0f0000f000m0m000m0	UAUAGAAUGAACAUAGACA	658
	14127	oooooooooooosssssso	Pmffffff00fm0m0mmm0	UUUCCUUGGUCGGCGUUUG	659
	14128	oooooooooooosssssso	Pmf0f0f0ff0mmm00mmm0	GUAUGCACCAUUCAACUCC	660
	14129	oooooooooooosssssso	Pmf00ff0ff0m0m0m0mm0	UCGGCCAUCAUAUGUGUCU	661
	14130	oooooooooooosssssso	Pm0fff000ff0mmm0m000	AAUCUGGACUGCUUGUGGC	662
	14132	oooooooooooosssssso	Pmf0ff0000f0mmm0mm00	ACAUCGGAAUGCUCAUUGC	663
	14133	oooooooooooosssssso	Pm00fffff00mm0mm00m0	AAGUUCCUGACUAUCAAUC	664
	14134	oooooooooooosssssso	Pmf00ff000f0m0000m00	UUGACUAAAUGCAAAGUGA	665
	14135	oooooooooooosssssso	Pm0fff0ff000mm00m00	AGACUCAUCAGACUGGUGA	666
	14136	oooooooooooosssssso	Pmf0f0f0f0fmm0mm0m00	UCAUAUGUGUCUACUGUGG	667
	14137	oooooooooooosssssso	Pmf0fffff0fmm0m00m00	AUGUCCUCGUCUGUAGCAU	668
	14138	oooooooooooosssssso	Pm00fff0f00mm00mmmm0	GAAUUCACGGCUGACUUUG	669
	14139	oooooooooooosssssso	Pmf0fffff000mmm000m0	UUAUUUCCAGACUCAAAUA	670
	14140	oooooooooooosssssso	Pm000ff0f000mm000mm0	GAAGCCACAAACUAAACUA	671
	14141	oooooooooooosssssso	Pmffff0ff000mmm0mmm0	CUUUCGUUGGACUUACUUG	672
	14142	oooooooooooosssssso	Pmfff0f0000mmmmmm000	GUCUGCGAAACUUCUUAGA	673
	14143	oooooooooooosssssso	Pm0f0fff0ff0mmmmm0m0	AAUGCUCAUUGCUCUCAUC	674
	14144	oooooooooooosssssso	Pmf0f0ff0ffm00mmm0m0	AUGCACUAUCUAAUUCAUG	675
	14145	oooooooooooosssssso	Pmff0f0f0f0mm0mmm000	CUUGUAUGCACCAUUCAAC	676
	14146	oooooooooooosssssso	Pm00fff0fffm0m00mm00	UGACUCGUUUCAUAACUGU	677
	14147	oooooooooooosssssso	Pmff00f0fffm00mm0mm0	UUCAGCACUCUGGUCAUCC	678
	14118	oooooooooooosssssso	Pm00fff0f00mm0m00000	AAAUUCAUGGCUGUGGAAU	679
	14149	oooooooooooosssssso	Pmf0fff00ff00m000mm0	ACAUUCAACCAAUAAACUG	680
	14150	oooooooooooosssssso	Pm0f0f0fff00mm00m000	UACACAUUCAACCAAUAAA	681
	14151	oooooooooooosssssso	Pmff00ff0ffmmm000mm0	AUUAGUUAUUUCCAGACUC	682
	14152	oooooooooooosssssso	Pmffff0fff0m00000000	UUUCUAUUCAUGAGAGAAU	683
	14153	oooooooooooosssssso	Pmff00ff0ff00m000mm0	UUCGGUUGCUGGCAGGUCC	684
	14154	oooooooooooosssssso	Pm0f0f0f0000m00m0mm0	CAUGUGUGAGGUGAUGUCC	685
	14155	oooooooooooosssssso	Pmf0ff0fff00mmmmmm00	GCACCAUUCAACUCCUCGC	686
	14156	oooooooooooosssssso	Pm0fff00ff00mmm0mmm0	CAUCCAGCUGACUCGUUUC	687
	14157	oooooooooooosssssso	Pmfffff0fff0m0m00mm0	CUUUCCGCUUAUAUAAUCU	688
	14158	oooooooooooosssssso	Pm0ff0f0ff0000m0mmm0	AAUCACAUCGGAAUGCUCA	689
	14159	oooooooooooosssssso	Pmf0f0ff00fm0mmmmm00	ACACAUUAGUUAUUUCCAG	690
	14160	oooooooooooosssssso	Pmfff0f0000m000m0m00	UUCUAUAGAAUGAACAUAG	691
	14161	oooooooooooosssssso	Pm0f00f00f00mmm0m0m0	UACAGUGAUAGUUUGCAUU	692
	14162	oooooooooooosssssso	Pmf000f00ff00m0mm0m0	AUAAGCAAUUGACACCACC	693
	14163	oooooooooooosssssso	Pmff0ff00ff0mm000m00	UUUAUUAAUUGCUGGACAA	694
	14164	oooooooooooosssssso	Pmf0ff0000fmmmm0000	UCAUCAGAGUCGUUCGAGU	695
	14165	oooooooooooosssssso	Pmf000ff0f0mm0mm0mm0	AUAAACCACACUAUCACCU	696
	14166	oooooooooooosssssso	Pmf0ff0ff00mmmmmm0m0	UCAUCAUUGGCUUUCCGCU	697
	14167	oooooooooooosssssso	Pmfffff00fm0mm00mm0	AGUUCCUGACUAUCAAUCA	698
	14168	oooooooooooosssssso	Pmff0f00ff00mmmm0000	UUCACGGCUGACUUUGGAA	699
	14169	oooooooooooosssssso	Pmffff0f00f00m000mm0	UUCUCAUGGUAGUGAGUUU	700
	14170	oooooooooooosssssso	Pm0ff00fff0mmm00mm00	AAUCAGCCUGUUUAACUGG	701
	14171	oooooooooooosssssso	Pm0ffff00f0mmmm00mm0	GGUUUCAGCACUCUGGUCA	702
	14172	oooooooooooosssssso	Pmff0000f0fmm0mm0mm0	AUCGGAAUGCUCAUUGCUC	703
	17173	oooooooooooosssssso	Pm00fF0f0000mmm0m000	UGGCUGUGGAAUUCACGGC	704
	14174	oooooooooooosssssso	Pm000f00ff00m0mm0mm0	UAAGCAAUUGACACCACCA	705
	14175	oooooooooooosssssso	Pm00fffff0f00m00m000	CAAUUCUCAUGGUAGUGAG	706
	14176	oooooooooooosssssso	Pm00fffff0fm000mmm00	UGGCUUUCGUUGGACUUAC	707
	14177	oooooooooooosssssso	Pm0ff00f00fm00mmm0m0	AAUCAGUGACCAGUUCAUC	708
	14178	oooooooooooosssssso	Pmfff0f000mm0m0mm00	AGUCCAUAAACCACACUAU	709
	14179	oooooooooooosssssso	Pm00f0ffff00mm0mmm00	CAGCACUCUGGUCAUCCAG	710
	14180	oooooooooooosssssso	Pm0ff00ff0f0mm0000m0	UAUCAAUCACAUCGGAAUG	711
	14181	oooooooooooosssssso	Pmfff0f00ff00mmmm000	AUUCACGGCUGACUUUGGA	712
	14182	oooooooooooosssssso	Pmf000f0f0f0mmm00mm0	AUAGAUACACAUUCAACCA	713
	14183	oooooooooooosssssso	Pmffff000ffm000m0000	UUUCCAGACUCAAAUAGAU	714
	14184	oooooooooooosssssso	Pmf00ff0ff000m00mm00	UUAAUUGCUGGACAACCGU	715
	14185	oooooooooooosssssso	Pm0ff00ff0fm000m00m0	UAUUAAUUGCUGGACAACC	716
	14186	oooooooooooosssssso	Pmff0fff000mm00m000	AGUCGUUCGAGUCAAUGGA	717
	14187	oooooooooooosssssso	Pmff0ff00f000mmm0m00	GUUGCUGGCAGGUCCGUGG	718

TABLE 3
		OHang
	Oligo	Sense				SEQ
ID Number	Number	Chem.	Sense Backbone	Sense Chemistry	Sense Sequence	ID NO:
APOB-	12138	ch1	ooooooooooooooo	000000000000000000	GUCAUCACACUGAAUACCAAU	176
10167-20-12138			ooooso	00
APOB-	121389	chl	ooooooooooooooo	000000000000000000	GUGAUCAGACUCAAUACGAAU	177
10167-20-12139			ooooso	00
MAP4K4-	12266	chl	oooooooooosso	mm0m00000mmm0	CUGUGGAAGUCUA	178
2931-13-12266
MAP4K4-	12293	chl	oooooooooosso	mm0m00000mmm0	CUGUGGAAGUCUA	179
2931-13-12293
MAP4K4-	12383	chl	ooooooooooooo	mm0m00000mmm0	CUGUGGAAGUCUA	180
2931-16-12383
MAP4K4-	12384	chl	ooooooooooooo	mm0m00000mmm0	CUGUGGAAGUCUA	181
2931-16-12384
MAP4K4-	12385	chl	ooooooooooooo	mm0m00000mmm0	CUGUGGAAGUCUA	182
2931-16-12385
MAP4K4-	12386	chl	oooooooooosso	0mm0m00000mmm0	CUGUGGAAGUCUA	183
2931-16-12386
MAP4K4-	12387	chl	ooooooooooooo	mm0m00000mmm0	CUGUGGAAGUCUA	184
2931-16-12387
MAP4K4-	12388	chl	ooooooooooooo	mm0m00000mmm0	CUGUGGAAGUCUA	185
2931-16-12388
MAP4K4-	12432	chl	ooooooooooooo	DY547mm0m00000mmm0	CUGUGGAAGUCUA	186
2931-13-12432
MAP4K4-	12266.2	chl	oooooooooooss	mm0m00000mmm0	CUGUGGAAGUCUA	187
2931-13-12266.2
APOB--	12434	chl	ooooooooooooooo	000000000000000000	GUCAUCACACUGAAUACCAAU	188
21-12434			ooooso	00
APOB--	12435	chl	ooooooooooooooo	DY5470000000000000	GUGAUCAGACUCAAUACGAAU	189
21-12435			ooooso	0000000
MAP4K4-	12451	chl	oooooooooooss	0mm0m00000mmm0	CUGUGGAAGUCUA	190
2931-16-12451
MAP4K4-	12452	chl	oooooooooooss	mm0m00000mmm0	CUGUGGAAGUCUA	191
2931-16-12452
MAP4K4-	12453	chl	oooooooooooss	mm0m00000mmm0	CUGUGGAAGUCUA	192
2931-16-12453
MAP4K4-	12454	chl	oooooooooooss	0mm0m00000mmm0	CUGUGGAAGUCUA	193
2931-17-12454
MAP4K4-	12455	chl	oooooooooooss	mm0m00000mmm0	CUGUGGAAGUCUA	194
2931-17-12455
MAP4K4-	12456	chl	oooooooooooss	mm0m00000mmm0	CUGUGGAAGUCUA	195
2931-19-12456
--27-12480	12480	chl	ooooooooooooooo	DY547mm0f000f0055f	UCAUAGGUAACCUCUGGUUGA	196
			ooooooooosso	5f00mm00000m000	AAGUGA
--27-12481	12481	chl	ooooooooooooooo	DY547mm05f05000f05	CGGCUACAGGUGCUUAUGAAG	197
			ooooooooosso	ff0m00000000m00	AAAGUA
APOB-	12505	chl	ooooooooooooooo	000000000000000000	GUCAUCACACUGAAUACCAAU	198
10167-21-12505			ooooos	000
APOB-	12506	chl	ooooooooooooooo	000000000000000000	GUGAUCAGACUCAAUACGAAU	199
10167-21-12506			ooooos	000
MAP4K4-	12539	chl	oooooooooooss	DY547mm0m00000mmm0	CUGUGGAAGUCUA	200
2931-16-12539
APOB-	12505.2	chl	ooooooooooooooo	000000000000000000	GUCAUCACACUGAAUACCAAU	201
10167-21-12505.2			ooooso	00
APOB-	12506.2	chl	ooooooooooooooo	000000000000000000	GUGAUCAGACUCAAUACGAAU	202
10167-21-12506.2			ooooso	00
MAP4K4--	12565	Chl	ooooooooooooo	m0m0000m0mmm0	UGUAGGAUGUCUA	203
13-12565
MAP4K4-	12386.2	chl	ooooooooooooo	0mm0m00000mmm0	CUGUGGAAGUCUA	204
2931-16-12386.2
MAP4K4-	12815	chl	ooooooooooooo	m0m0m0m0mk0m0m0m0m	CUGUGGAAGUCUA	205
2931-13-12815				0m0m0m0m0
APOB--	12957	Chl	oooooooooooss	0mmmmmmmmmmmmm	ACUGAAUACCAAU	206
13-12957		TEG
MAP4K4--	12983	chl	oooooooooooss	mm0m00000mmm0	CUGUGGAAGUCUA	207
16-12983
MAP4K4--	12984	Chl	oooooooooooooo	mm0m00000mmm0	CUGUGGAAGUCUA	208
16-12984
MAP4K4--	12985	chl	oooooooooosso	mmmmmmmmmmmmm	CUGUGGAAGUCUA	209
16-12985
MAP4K4--	12986	chl	oooooooooosso	mmmmmmmmmmmmm	CUGUGGAAGUCUA	210
16-12986
MAP4K4--	12987	chl	oooooooooosso	mm0m00000mmm0	CUGUGGAAGUCUA	211
16-12987
MAP4K4--	12988	chl	oooooooooosso	mm0m00000mmm0	CUGUGGAAGUCUA	212
16-12988
MAP4K4--	12989	chl	oooooooooosso	mm0m00000mmm0	CUGUGGAAGUCUA	213
16-12989
MAP4K4--	12990	chl	oooooooooosso	mm0m00000mmm0	CUGUGGAAGUCUA	214
16-12990
MAP4K4--	12991	chl	oooooooooosso	mm0m00000mmm0	CUGUGGAAGUCUA	215
16-12991
MAP4K4--	12992	chl	oooooooooosso	mm0m00000mmm0	CUGUGGAAGUCUA	216
16-12992
MAP4K4--	12993	chl	oooooooooosso	mm0m00000mmm0	CUGUGGAAGUCUA	217
16-12993
MAP4K4--	12994	chl	oooooooooosso	mm0m00000mmm0	CUGUGGAAGUCUA	218
16-12994
MAP4K4--	12995	chl	oooooooooosso	mm0m00000mmm0	CUGUGGAAGUCUA	219
16-12995
MAP4K4-	13012	chl	ooooooooooooooo	000000000000000000	AGAGUUCUGUGGAAGUCUA	220
2931-19-13012			oooo	000
MAP4K4-	13016	chl	ooooooooooooooo	DY5470000000000000	AGAGUUCUGUGGAAGUCUA	221
2931-19-13016			oooo	00000000
PPIB--	13021	Chl	ooooooooooooo	0mmm00mm0m000	AUUUGGCUACAAA	222
13-13021
pGL3-	13038	chl	ooooooooooooo	00m000m0m00mmm	ACAAAUACGAUUU	223
1172-13-13038
pGL3-	13040	chl	ooooooooooooo	DY5470m000m0m00mmm	ACAAAUACGAUUU	224
1172-13-13040
--16-13047	13047	Chl	oooooooooooooo	mm0m00000mmm0	CUGUGGAAGUCUA	225
SOD1-	13090	chl	ooooooooooooo	00m00000000m0	AAUGAAGAAAGUA	226
530-13-13090
SOD1-	13091	chl	ooooooooooooo	000m00000m000	AGGUGGAAAUGAA	227
523-13-13091
SOD1-	13092	chl	ooooooooooooo	000000m0m0000	AGAAAGUACAAAG	228
535-13-13092
SOD1-	13093	chl	ooooooooooooo	00000m0m00000	GAAAGUACAAAGA	229
536-13-13093
SOD1-	13094	chl	ooooooooooooo	0m0m00mm0mm00	AUGUGACUGCUGA	230
596-13-13094
SOD1-	13095	chl	ooooooooooooo	000mmm000m00m	AGACUUGGGCAAU	231
385-13-13095
SOD1-	13096	chl	ooooooooooooo	0mmmm000m0000	AUUUCGAGCAGAA	232
195-13-13096
APOB-	13115	Chl	ooooooooooooo	0mmm0000000m0	AUCUGGAGAAACA	233
4314-13-13115
APOB-	13116	Chl	ooooooooooooo	mm0000m000000	UCAGAACAAGAAA	234
3384-13-13116
APOB-	13117	Chl	ooooooooooooo	00mmm0mmm0mm0	GACUCAUCUGCUA	235
3547-13-13117
APOB-	13118	Chl	ooooooooooooo	0000000m00m0m	GGAGAAACAACAU	236
4318-13-13118
APOB-	13119	Chl	ooooooooooooo	00mmmmmm000m0	AGUCCCUCAAACA	237
3714-13-13119
PPIB--	13136	Chl	oooooooooooooo	00mm0m00000m0	GGCUACAAAAACA	238
16-13136
APOB-	13154	chl	oooooooooooooo	000mmm0000000m0	AGAUCUGGAGAAACA	239
4314-15-13154
APOB-	13155	chl	oooooooooooooo	m000mmm0mmm0mm0	UGGACUCAUCUGCUA	240
3547-15-13155
APOB-	13157	chl	oooooooooooooo	mm0000000m00m0m	CUGGAGAAACAACAU	241
4318-15-13157
APOB-	13158	chl	oooooooooooooo	000mmmmmm000m0	AGAGUCCCUCAAACA	242
3714-15-13158
AP0B--	13159	chl	oooooooooooo	0mm000m0mm00m	ACUGAAUACCAAU	243
13-13159
APOB--	13160	chl	oooooooooooooo	0m0mm000m0mm00m	ACACUGAAUACCAAU	244
15-13160
SOD1-	13163	chl	ooooooooooooo	00m00000000m0	AAUGAAGAAAGUA	245
530-16-13163
SOD1-	13164	chl	ooooooooooooo	000m00000m000	AGGUGGAAAUGAA	246
523-16-13164
SOD1-	13165	chl	ooooooooooooo	000000m0m0000	AGAAAGUACAAAG	247
535-16-13165
SOD1-	13166	chl	ooooooooooooo	00000m0m00000	GAAAGUACAAAGA	248
536-16-13166
SOD1-	13167	chl	ooooooooooooo	0m0m00mm0mm00	AUGUGACUGCUGA	249
396-16-13167
SOD1-	13168	chl	ooooooooooooo	000mmm000m00m	AGACUUGGGCAAU	250
385-16-13168
SOD1-	13169	chl	ooooooooooooo	0mmmm000m0000	AUUUCGAGCAGAA	251
195-16-13169
pGL3-	13170	chl	ooooooooooooo	0m000m0m00mmm	ACAAAUACGAUUU	252
1172-16-13170
pGL3-	13171	chl	ooooooooooooo	DY5470m000m0m00mmm	ACAAAUACGAUUU	253
1172-16-13171
MAP4k4-	13189	chl	ooooooooooooooo	000000000000000000	AGAGUUCUGUGGAAGUCUA	254
2931-19-13189			oooo	000
CTGF-	13190	Chl	ooooooooooooo	0m0000000m0m0	ACAGGAAGAUGUA	255
1222-13-13190
CTGF-	13192	Chl	ooooooooooooo	000m0000m0mmm	GAGUGGAGCGCCU	256
813-13-13192
CTGF-	13194	Chl	ooooooooooooo	m00mm000000m0	CGACUGGAAGACA	257
747-13-13194
CTGF-	13196	Chl	ooooooooooooo	0000m0mmm0mmm	GGAGCGCCUGUUC	258
817-13-13196
CTGF-	13198	Chl	ooooooooooooo	0mm0mm0m00mm0	GCCAUUACAACUG	259
1174-13-13198
CTGF-	13200	Chl	ooooooooooooo	000mmmmmm00mm	GAGCUUUCUGGCU	260
1005-13-13200
CTGF-	13202	Chl	ooooooooooooo	00m0000m0mmm0	AGUGGAGCGCCUG	261
814-13-13202
CTGF-	13204	Chl	ooooooooooooo	m0000m0mmm0mm	UGGAGCGCCUGUU	262
816-13-13204
CTGF-	13206	Chl	ooooooooooooo	0mmm000mmmmmm	GUUUGAGCUUUCU	263
1001-13-13206
CTGF-	13208	Chl	ooooooooooooo	m0mm0mm0m00mm	UGCCAUUACAACU	264
1173-13-13208
CTGF-	13210	Chl	ooooooooooooo	0mm000000m0m0	ACUGGAAGACACG	265
749-13-13210
CTGF-	13212	Chl	ooooooooooooo	00mm0mmm00mmm	AACUGCCUGGUCC	266
792-13-13212
CTGF-	13214	Chl	ooooooooooooo	000mmm0m0mmm0	AGACCUGUGCCUG	267
1162-13-13214
CTGF-	13216	Chl	ooooooooooooo	m0000m0000m0m	CAGAGUGGAGCGC	268
811-13-13216
CTGF-	13218	Chl	ooooooooooooo	mmm00mmm000mm	CCUGGUCCAGACC	269
797-13-13218
CTGF-	13220	Chl	ooooooooooooo	mm0mm0m00mm0m	CCAUUACAACUGU	270
1175-13-13220
CTGF-	13222	Chl	ooooooooooooo	mm0mm0mm0m00m	CUGCCAUUACAAC	271
1172-13-13222
CTGF-	13224	Chl	ooooooooooooo	0mm0m00mm0mmmm	AUUACAACUGUCC	272
1177-13-13224
CTGF-	13226	Chl	ooooooooooooo	m0mm0m00mm0mm	CAUUACAACUGUC	273
1176-13-13226
CTGF-	13228	Chl	ooooooooooooo	0000m0000m0mm	AGAGUGGAGCGCC	274
812-13-13228
CTGF-	13230	Chl	ooooooooooooo	0mm00mm000000	ACCGACUGGAAGA	275
745-13-13230
CTGF-	13232	Chl	ooooooooooooo	0m0m0m00000m0	AUGUACGGAGACA	276
1230-13-13232
CTGF-	13234	Chl	ooooooooooooo	0mmmm0m0000mm	GCCUUGCGAAGCU	277
920-13-13234
CTGF-	13238	Chl	ooooooooooooo	0mm0m000000m0	GCUGCGAGGAGUG	278
679-13-13238
CTGF-	13238	Chl	ooooooooooooo	0mmm0mm000mmm	GCCUAUCAAGUUU	279
992-13-13238
CTGF-	13240	Chl	ooooooooooooo	00mmmm0m0000m	AAUUCUGUGGAGU	280
1045-13-13240
CTGF-	13242	Chl	ooooooooooooo	m0m0m00000m0m	UGUACGGAGACAU	281
1231-13-13242
CTGF-	13244	Chl	ooooooooooooo	00mmm0mm000mm	AGCCUAUCAAGUU	282
991-13-13244
CTGF-	13246	Chl	ooooooooooooo	m000mmm000mmm	CAAGUUUGAGCUU	283
998-13-13246
CTGF-	13248	Chl	ooooooooooooo	mm0m0000m0m0m	CUGUGGAGUAUGU	284
1049-13-13248
CTGF-	13250	Chl	ooooooooooooo	000mmmm0m0000	AAAUUCUGUGGAG	285
1044-13-13250
CTGF-	13252	Chl	ooooooooooooo	mmmm00m00m0m0	UUUCAGUAGCACA	286
1327-13-13252
CTGF-	13254	Chl	ooooooooooooo	m00m00m0mmmmm	CAAUGACAUCUUU	287
1196-13-13254
CTGF-	13256	Chl	ooooooooooooo	00m0mm00m0m0m	AGUACCAGUGCAC	288
562-13-13256
CTGF-	13258	Chl	ooooooooooooo	000000m0m0mmm	GGAAGACACGUUU	289
752-13-13258
CTGF-	13260	Chl	ooooooooooooo	mm0mm000mmm00	CUAUCAAGUUUGA	290
944-13-13260
CTGF-	13262	Chl	ooooooooooooo	00mm000mmmm0m	AGCUAAAUUCUGU	291
1040-13-13262
CTGF-	13264	Chl	ooooooooooooo	000m0000m0m00	AGGUAGAAUGUAA	292
1984-13-13264
CTGF-	13266	Chl	ooooooooooooo	00mm00mm00mmm	AGCUGAUCAGUUU	293
2043-13-13266
CTGF-	13268	Chl	ooooooooooooo	mmmm0mmm000m0	UUCUGCUCAGAUA	294
2043-13-13268
CTGF-	13270	Chl	ooooooooooooo	mm0mmm000mm00	UUAUCUAAGUUAA	295
1892-13-13270
CTGF-	13272	Chl	ooooooooooooo	m0m0m000m00m0	UAUACGAGUAAUA	296
1567-13-13272
CTGF-	13274	Chl	ooooooooooooo	00mm000m00mmm	GACUGGACAGCUU	297
1780-13-13274
CTGF-	13276	Chl	ooooooooooooo	0m00mmmmm0mm0	AUGGCCUUUAUUA	298
2162-13-13276
CTGF-	13278	Chl	ooooooooooooo	0m0mm000mm000	AUACCGAGCUAAA	299
1034-13-13278
CTGF-	13280	Chl	ooooooooooooo	mm0mm00000m0m	UUGUUGAGAGUGU	300
2264-13-13280
CTGF-	13282	Chl	ooooooooooooo	0m0m0mm000mm0	ACAUACCGAGCUA	301
1032-13-13282
CTGF-	13284	Chl	ooooooooooooo	00m0000000mm0	AGCAGAAAGGUUA	302
1535-13-13284
CTGF-	13286	Chl	ooooooooooooo	00mm0mmmmmm00	AGUUGUUCCUUAA	303
1694-13-13286
CTGF-	13288	Chl	ooooooooooooo	0mmm0000m0m00	AUUUGAAGUGUAA	304
1588-13-13288
CTGF-	13290	Chl	ooooooooooooo	000mm00mmm000	AAGCUGACCUGGA	305
928-13-13290
CTGF-	13292	Chl	ooooooooooooo	00mm0m0000000	GGUCAUGAAGAAG	306
1133-13-13292
CTGF-	13294	Chl	ooooooooooooo	0m00mm000mmmm	AUGGUCAGGCCUU	307
912-13-13294
CTGF-	13296	Chl	ooooooooooooo	00000m0m0mmm0	GAAGACACGUUUG	308
753-13-13296
CTGF-	13298	Chl	ooooooooooooo	000mmmm0m0000	AGGCCUUGCGAAG	309
918-13-13298
CTGF-	13300	Chl	ooooooooooooo	m0mm0mm00000	UACCGACUGGAAG	310
744-13-13300
CTGF-	13302	Chl	ooooooooooooo	0mm0m0000mm0	ACCGCAAGAUCGG	311
466-13-13302
CTGF-	13304	Chl	ooooooooooooo	m000mmmm0m000	CAGGCCUUGCGAA	312
917-13-13304
CTGF-	13306	Chl	ooooooooooooo	m000mm000mmmm	CGAGCUAAAUUCU	313
1038-13-13306
CTGF-	13308	Chl	ooooooooooooo	mmm0m0000m0m0	UCUGUGGAGUAUG	314
1048-13-13308
CTGF-	13310	Chl	ooooooooooooo	m00000m0m00m0	CGGAGACAUGGCA	315
1235-13-13310
CTGF-	13312	Chl	ooooooooooooo	0m00m00m0mmmm	AUGACAACGCCUC	316
868-13-13312
CTGF-	13314	Chl	ooooooooooooo	0000mm0m00000	GAGGUCAUGAAGA	317
1131-13-13314
CTGF-	13316	Chl	ooooooooooooo	m000mmmm0m000	UAAAUUCUGUGGA	318
1043-13-13316
CTGF-	13318	Chl	ooooooooooooo	m000000m0m0mm	UGGAAGACACGUU	319
751-13-13318
CTGF-	13320	Chl	ooooooooooooo	0000m0m0m0000	AAGAUGUACGGAG	320
1227-13-13320
CTGF-	13322	Chl	ooooooooooooo	00m00m00m0mmm	AAUGACAACGCCU	321
867-13-13322
CTGF-	13324	Chl	ooooooooooooo	00m0000mm0m00	GGCGAGGUCAUGA	322
1128-13-13324
CTGF-	13326	Chl	ooooooooooooo	00m0m0mmm00mm	GACACGUUUGGCC	323
756-13-13326
CTGF-	13328	Chl	ooooooooooooo	0m00000m0m00m	ACGGAGACAUGGC	324
1234-13-13328
CTGF-	13330	Chl	ooooooooooooo	mm000mmmm0m00	UCAGGCCUUGCGA	325
916-13-13330
CTGF-	13332	Chl	ooooooooooooo	0m0000mm00mmm	GCGAAGCUGACCU	326
925-13-13332
CTGF-	13334	Chl	ooooooooooooo	000000m0m0m00	GUGACUUCGGCUC	328
1225-13-13334
CTGF-	13336	Chl	ooooooooooooo	0m00mmmm00mmm	GUGACUUCGGCUC	328
445-13-13336
CTGF-	13338	Chl	ooooooooooooo	m00mmmm00mmmm	UGACUUCGGCUCC	329
446-13-13338
CTGF-	13340	Chl	ooooooooooooo	m00mm000mmmm0	UGGUCAGGCCUUG	330
913-13-13340
CTGF-	13342	Chl	ooooooooooooo	mm000mmm000mm	UCAAGUUUGAGCU	331
997-13-13342
CTGF-	13344	Chl	ooooooooooooo	0mm0000mm0m00	GCCAGAACUGCAG	332
277-13-13344
CTGF-	13346	Chl	ooooooooooooo	m0000m0m0m0mm	UGGAGUAUGUACC	333
1052-13-13346
CTGF-	13348	Chl	ooooooooooooo	0mm0000000m00	GCUAGAGAAGCAG	334
887-13-13348
CTGF-	13350	Chl	ooooooooooooo	00mm000mmmm0m	GGUCAGGCCUUGC	335
914-13-13350
CTGF-	13352	Chl	ooooooooooooo	000mm000mmmm0	GAGCUAAAUUCUG	336
1039-13-13352
CTGF-	13354	Chl	ooooooooooooo	0000m0m0mmm00	AAGACACGUUUGG	337
754-13-13354
CTGF-	13356	Chl	ooooooooooooo	m0000mm0m0000	CGAGGUCAUGAAG	338
1130-13-13354
CTGF-	13358	Chl	ooooooooooooo	00mmmm0m0000m	GGCCUUGCGAAGC	339
919-13-13358
CTGF-	13360	Chl	ooooooooooooo	mmm0m0000mm00	CUUGCGAAGCUGA	340
922-13-13360
CTGF-	13362	Chl	ooooooooooooo	mm00mm000000m	CCGACUGGAAGAC	341
746-13-13362
CTGF-	13364	Chl	ooooooooooooo	mmm0mm000mmm0	CCUAUCAAGUUUG	342
993-13-13364
CTGF-	13366	Chl	ooooooooooooo	m0mmmm0000mmm	UGUUCCAAGACCU	343
825-13-13366
CTGF-	13368	Chl	ooooooooooooo	m0000mm00mmm0	CGAAGCUGACCUG	344
926-13-13368
CTGF-	13370	Chl	ooooooooooooo	mm0m0000mm00m	UUGCGAAGCUGAC	345
923-13-13370
CTGF-	13372	Chl	ooooooooooooo	m00m00m00m0mm	CAAUGACAACGCC	346
866-13-13372
CTGF-	13374	Chl	ooooooooooooo	0m0mm00m0m0m0	GUACCAGUGCACG	347
563-13-13374
CTGF-	13376	Chl	ooooooooooooo	mmm0mmmm0000m	CCUGUUCCAAGAC	348
823-13-13376
CTGF-	13378	Chl	ooooooooooooo	m0m00000m0m00	UACGGAGACAUGG	349
1233-13-13378
CTGF-	13380	Chl	ooooooooooooo	m0m0000mm00mm	UGCGAAGCUGACC	350
924-13-13380
CTGF-	13382	Chl	ooooooooooooo	mmmm0m0000mm0	CCUUGCGAAGCUG	351
921-13-13382
CTGF-	13384	Chl	ooooooooooooo	mm0m00mmmm00m	CUGUGACUUCGGC	352
443-13-13384
CTGF-	13386	Chl	ooooooooooooo	0mm000mmmm0m0	GCUAAAUUCUGUG	353
1041-13-13386
CTGF-	13388	Chl	ooooooooooooo	mm000mmmm0m00	CUAAAUUCUGUGG	354
1042-13-13388
CTGF-	13390	Chl	ooooooooooooo	000m0m0mmm00m	AGACACGUUUGGC	355
755-13-13390
CTGF-	13392	Chl	ooooooooooooo	mm0m0000mm00m	CCGCAAGAUCGGC	356
467-13-13392
CTGF-	13394	Chl	ooooooooooooo	m0mm000mmm000	UAUCAAGUUUGAG	357
995-13-13394
CTGF-	13396	Chl	ooooooooooooo	0000mm00mmm00	GAAGCUGACCUGG	358
927-13-13396
SPP1-	13398	Chl	ooooooooooooo	mmm0m000mm000	CUCAUGAAUUAGA	359
1025-13-13398
SPP1-	13400	Chl	ooooooooooooo	mm0000mm00mm0	CUGAGGUCAAUUA	360
1049-13-13400
SPP1-	13402	Chl	ooooooooooooo	0000mm00mm000	GAGGUCAAUUAAA	361
1051-13-13402
SPP1-	13404	Chl	ooooooooooooo	mmm0000mm00mm	UCUGAGGUCAAUU	362
1048-13-13404
SPP1-	13406	Chl	ooooooooooooo	m0000mm00mm00	UGAGGUCAAUUAA	363
1050-13-13406
SPP1-	13408	Chl	ooooooooooooo	mmmm0000mm00m	UUCUGAGGUCAAU	364
1047-13-13408
SPP1-	13410	Chl	ooooooooooooo	0mm00mm000m00	GUCAGCUGGAUGA	365
800-13-13410
SPP1-	13412	Chl	ooooooooooooo	mmmm00m000mmm	UUCUGAUGAAUCU	366
492-13-13412
SPP1-	13414	Chl	ooooooooooooo	m000mm0000mm0	UGGACUGAGGUCA	367
612-13-13414
SPP1-	13416	Chl	ooooooooooooo	000mmmm0mm0mm	GAGUCUCACCAUU	368
481-13-13416
SPP1-	13418	Chl	ooooooooooooo	00mm0000mm000	GACUGAGGUCAAA	369
614-13-13418
SPP1-	13420	Chl	ooooooooooooo	mm0m00mm0m000	UCACAGCCAUGAA	370
951-13-13420
SPP1-	13422	Chl	ooooooooooooo	00mmmm0mm0mmm	AGUCUCACCAUUC	371
482-13-13422
SPP1-	13424	Chl	ooooooooooooo	000m000000mm0	AAGCGGAAAGCCA	372
856-13-13424
SPP1-	13426	Chl	ooooooooooooo	00m000000mm00	AGCGGAAAGCCAA	373
857-13-13426
SPP1-	13428	Chl	ooooooooooooo	0mm0m0m000m00	ACCACAUGGAUGA	374
365-13-13428
SPP1-	13430	Chl	ooooooooooooo	0mm0m00mm0m0m	GCCAUGACCACAU	375
359-13-13430
SPP1-	13432	Chl	ooooooooooooo	000mm0m00mm0m	AAGCCAUGACCAC	376
357-13-13432
SPP1-	13434	Chl	ooooooooooooo	0m000000mm00m	GCGGAAAGCCAAU	377
858-13-13434
SPP1-	13436	Chl	ooooooooooooo	000mmmm0m0mmm	AAAUUUCGUAUUU	378
1012-13-13436
SPP1-	13438	Chl	ooooooooooooo	0mmmm0m0mmmmm	AUUUCGUAUUUCU	379
1014-13-13438
SPP1-	13440	Chl	ooooooooooooo	0000mm0m00mm0	AAAGCCAUGACCA	380
356-13-13440
SPP1-	13442	Chl	ooooooooooooo	0m0m000m00m0m	ACAUGGAUGAUAU	381
368-13-13442
SPP1-	13444	Chl	ooooooooooooo	0000mmmm0m0mm	GAAAUUUCGUAUU	382
1011-13-13444
SPP1-	13446	Chl	ooooooooooooo	0m0mmmmmm00mm	GCGCCUUCUGAUU	383
754-13-13446
SPP1-	13448	Chl	ooooooooooooo	0mmmmmm0m000m	AUUUCUCAUGAAU	384
1021-13-13448
SPP1-	13450	Chl	ooooooooooooo	mmmmm0m000m00	CUCUCAUGAAUAG	385
1330-13-13450
SPP1-	13452	Chl	ooooooooooooo	000mmm00m0000	AAGUCCAACGAAA	386
346-13-13452
SPP1-	13454	Chl	ooooooooooooo	0m00m00000m00	AUGAUGAGAGCAA	387
869-13-13454
SPP1-	13456	Chl	ooooooooooooo	0m000000mm000	GCGAGGAGUUGAA	388
701-13-13456
SPP1-	13458	Chl	ooooooooooooo	m00mm00m00mm0	UGAUUGAUAGUCA	389
896-13-13458
SPP1-	13460	Chl	ooooooooooooo	000m00m0m0mmm	AGAUAGUGCAUCU	390
1035-13-13460
SPP1-	13462	Chl	ooooooooooooo	0m0m0m0mmm0mm	AUGUGUAUCUAUU	391
1170-13-13462
SPP1-	13464	Chl	ooooooooooooo	mmmm0m0000000	UUCUAUAGAAGAA	392
1282-13-13464
SPP1-	13466	Chl	ooooooooooooo	mm0mmm00m00mm	UUGUCCAGCAAUU	393
1537-13-13466
SPP1-	13468	Chl	ooooooooooooo	0m0m000000m00	ACAUGGAAAGCGA	394
692-13-13468
SPP1-	13470	Chl	ooooooooooooo	0m00mmm000mm0	GCAGUCCAGAUUA	395
840-13-13470
SPP1-	13472	Chl	ooooooooooooo	m00mm000m0m0m	UGGUUGAAUGUGU	396
1163-13-13472
SPP1-	13474	Chl	ooooooooooooo	mm0m0000m000m	UUAUGAAACGAGU	397
789-13-13474
SPP1-	13476	Chl	ooooooooooooo	m00mmm000mm0m	CAGUCCAGAUUAU	398
841-13-13476
SPP1-	13478	Chl	ooooooooooooo	0m0m000m00000	AUAUAAGCGGAAA	399
852-13-13478
SPP1-	13480	Chl	ooooooooooooo	m0mm00mm000m0	UACCAGUUAAACA	400
209-13-13480
SPP1-	13482	Chl	ooooooooooooo	m0mmm0mmmm0m0	UGUUCAUUCUAUA	401
1276-13-13482
SPP1-	13484	Chl	ooooooooooooo	mm00mm0000000	CCGACCAAGGAAA	402
137-13-13484
SPP1-	13486	Chl	ooooooooooooo	000m00m0m0m0m	GAAUGGUGCAUAC	403
711-13-13486
SPP1-	13488	Chl	ooooooooooooo	0m0m00m00mm00	AUAUGAUGGCCGA	404
582-13-13488
SPP1-	13490	Chl	ooooooooooooo	00m00mmm000mm	AGCAGUCCAGAUU	405
839-13-13490
SPP1-	13492	Chl	ooooooooooooo	0m0mmm00mm000	GCAUUUAGUCAAA	406
1091-13-13492
SPP1-	13494	Chl	ooooooooooooo	00m0mmmm00m0m	AGCAUUCCGAUGU	407
884-13-13494
SPP1-	13496	Chl	ooooooooooooo	m00mm00000mmm	UAGUCAGGAACUU	408
884-13-13496
SPP1-	13498	Chl	ooooooooooooo	m0m0mmm00mm00	UGCAUUUAGUCAA	409
1090-13-13498
SPP1-	13500	Chl	ooooooooooooo	0mmm00m000mmm	GUCUGAUGAGUCU	410
474-13-13500
SPP1-	13502	Chl	ooooooooooooo	m000m0m0m0m00	UAGACACAUAUGA	411
575-13-13502
SPP1-	13504	Chl	ooooooooooooo	m000m00000m0m	CAGACGAGGACAU	412
671-13-13504
SPP1-	13506	Chl	ooooooooooooo	m00mm0m000mmm	CAGCCGUGAAUUC	413
924-13-13506
SPP1-	13508	Chl	ooooooooooooo	00mmm00000m00	AGUCUGGAAAUAA	414
1185-13-13508
SPP1-	13510	Chl	ooooooooooooo	00mmm0m00mmmm	AGUUUGUGGCUUC	415
1221-13-13510
SPP1-	13512	Chl	ooooooooooooo	00mmm00m00000	AGUCCAACGAAAG	416
347-13-13512
SPP1-	13514	Chl	ooooooooooooo	000mmmm0m000m	AAGUUUCGCAGAC	417
634-13-13514
SPP1-	13516	Chl	ooooooooooooo	00m00m000m0mm	AGCAAUGAGCAUU	418
877-13-13516
SPP1-	13518	Chl	ooooooooooooo	mm000m00m0m0m	UUAGAUAGUGCAU	419
1033-13-13518
SPP1-	13520	Chl	ooooooooooooo	m00m0m0m0m000	UGGUGCAUACAAG	420
714-13-13520
SPP1-	13522	Chl	ooooooooooooo	0m0000m000mm0	AUGAAACGAGUCA	421
791-13-13522
SPP1-	13524	Chl	ooooooooooooo	mm0000m0mm000	CCAGAGUGCUGAA	422
813-13-13524
SPP1-	13526	Chl	ooooooooooooo	m00mm0m000mmm	CAGCCAUGAAUUU	423
939-13-13526
SPP1-	13528	Chl	ooooooooooooo	0mm00mm000m0m	AUUGGUUGAAUGU	424
1161-13-13528
SPP1-	13530	Chl	ooooooooooooo	00mm000m0m0m0	GGUUGAAUGUGUA	425
1164-13-13530
SPP1-	13532	Chl	ooooooooooooo	00000m00mm00m	GGAAAUAACUAAU	426
1190-13-13532
SPP1-	13534	Chl	ooooooooooooo	mm0m000m00000	UCAUGAAUAGAAA	427
1333-13-13534
SPP1-	13536	Chl	ooooooooooooo	0mm00m00mm000	GCCAGCAACCGAA	428
537-13-13536
SPP1-	13538	Chl	ooooooooooooo	m0mmmm0m0m0m0	CACCUCACACAUG	429
684-13-13538
SPP1-	13540	Chl	ooooooooooooo	00mm000m00m0m	AGUUGAAUGGUGC	430
707-13-13540
SPP1-	13542	Chl	ooooooooooooo	00mm00mm000m0	AGUCAGCUGGAUG	431
799-13-13542
SPP1-	13544	Chl	ooooooooooooo	m0m000m000000	UAUAAGCGGAAAG	432
853-13-13544
SPP1-	13546	Chl	ooooooooooooo	mmmm00m0m00mm	UUCCGAUGUGAUU	433
888-13-13546
SPP1-	13548	Chl	ooooooooooooo	0m00mm00m0m0m	AUAACUAAUGUGU	434
1194-13-13548
SPP1-	13550	Chl	ooooooooooooo	mm0mmmm0m0000	UCAUUCUAUAGAA	435
1279-13-13550
SPP1-	13552	Chl	ooooooooooooo	00mm0mm0mm0m0	AACUAUCACUGUA	436
1300-13-13552
SPP1-	13554	Chl	ooooooooooooo	0mm00mm0mmm0m	GUCAAUUGCUUAU	437
1510-13-13554
SPP1-	13556	Chl	ooooooooooooo	00m00mm00m000	AGCAAUUAAUAAA	438
1543-13-13556
SPP1-	13558	Chl	ooooooooooooo	0m00mmmm00m00	ACGACUCUGAUGA	439
4340-13-13558
SPP1-	13560	Chl	ooooooooooooo	m00m0m00mmm0m	UAGUGUGGUUUAU	440
600-13-13560
SPP1-	13562	Chl	ooooooooooooo	000mm00m00m00	AAGCCAAUGAUGA	441
863-13-13560
SPP1-	13564	Chl	ooooooooooooo	0m00mm00000mm	AUAGUCAGGAACU	442
920-13-13564
SPP1-	13566	Chl	ooooooooooooo	00mm00mm0m000	AGUCAGCCGUGAA	443
921-13-13566
SPP1-	13568	Chl	ooooooooooooo	0mm0mm0m00000	ACUACCAUGAGAA	444
154-13-13568
SPP1-	13570	Chl	ooooooooooooo	000m000mm00mm	AAACAGGCUGAUU	445
217-13-13570
SPP1-	13572	Chl	ooooooooooooo	000m0mm0000mm	GAGUGCUGAAACC	446
816-13-13572
SPP1-	13574	Chl	ooooooooooooo	m000m0mmmm00m	UGAGCAUUCCGAU	447
882-13-13572
SPP1-	13576	Chl	ooooooooooooo	00mmmm0m00mm0	AAUUCCACAGCCA	448
932-13-13572
SPP1-	13578	Chl	ooooooooooooo	m0mm00mm0mmm0	UGUCAAUUGCUUA	449
1509-13-13578
SPP1-	13580	Chl	ooooooooooooo	0mm0m00000mm0	ACCAUGAGAAUUG	450
157-13-13578
SPP1-	13582	Chl	ooooooooooooo	mm00m00000mm0	CCAACGAAAGCCA	451
350-13-13582
SPP1-	13584	Chl	ooooooooooooo	mm00mm0mm00mm	CUGGUCACUGAUU	452
511-13-13584
SPP1-	13586	Chl	ooooooooooooo	m00mmm0m000mm	UGGUUUAUGGACU	453
605-13-13586
SPP1-	13588	Chl	ooooooooooooo	00mm0000m0mm0	GACCAGAGUGCUG	454
811-13-13588
SPP1-	13590	Chl	ooooooooooooo	00m0m00mm00m0	GAUGUGAUUGAUA	455
892-13-13590
SPP1-	13592	Chl	ooooooooooooo	0mm00mm0m000m	GUCAGCCGUGAAU	456
922-13-13592
SPP1-	13594	Chl	ooooooooooooo	00m0m0m0mmm0m	AAUGUGUAUCUAU	457
1169-13-13594
SPP1-	13596	Chl	ooooooooooooo	mm000mmm00000	UUGAGUCUGGAAA	458
1182-13-13596
SPP1-	13598	Chl	ooooooooooooo	0mmm00m00mm00	GUCCAGCAAUUAA	459
1539-13-13598
SPP1-	13600	Chl	ooooooooooooo	mm00m00mm00m0	CCAGCAAUUAAUA	460
1541-13-13600
SPP1-	13602	Chl	ooooooooooooo	00mmm000m00mm	GACUCGAACGACU	461
427-13-13602
SPP1-	13604	Chl	ooooooooooooo	0mmm0mm00m00m	ACCUGCCAGCAAC	462
533-13-13604
APOB--	13763	Chl	ooooooooooooo	0m+00+m0+m0+m	ACtGAaUAcCAaU	463
13-13763		TEG
APOB--	13764	Chl	ooooooooooooo	0mm000m0mm00m	ACUGAAUACCAAU	464
13-13764
MAP4K4--	13766	Chl	ooooooooooooo	DY547mm0m00000mmm0	CUGUGGAAGUCUA	465
16-13766
PPIB--	13767	Chl	ooooooooooooo	mmmmmmmmmmmmm	GGCUACAAAAACA	466
13-13767
PPIB--	13768	Chl	ooooooooooooooo	mm00mm0m00000m0	UUGGCUACAAAAACA	467
15-13768
PPIB--	13769	Chl	ooooooooooooooo	0mmm00mm0m00000m0	AUUUGGCUACAAAAACA	468
17-13769			oo
MAP4K4--	13939	Chl	ooooooooooooo	m0m0000m0mmm0	UGUAGGAUGUCUA	469
16-13939
APOB-	13940	Chl	ooooooooooooo	0mmm0000000m0	AUCUGGAGAAACA	470
4314-16-13940
APOB-	13941	Chl	ooooooooooooooo	000mmm0000000m0	AGAUCUGGAGAAACA	471
4314-17-13941
APOB--	13942	Chl	ooooooooooooo	00mmm0mmm0mm0	GACUCAUCUGCUA	472
16-13942
APOB--	13943	Chl	ooooooooooooo	00mmm0mmm0mm0	GACUCAUCUGCUA	473
16-13943
APOB--	13944	Chl	ooooooooooooooo	m000mmm0mmm0mm0	UGGACUCAUCUGCUA	474
17-13944
APOB--	13945	Chl	ooooooooooooooo	m000mmm0mmm0mm0	UGGACUCAUCUGCUA	475
19-13945
APOB-	13946	Chl	ooooooooooooo	0000000m00m0m	GGAGAAACAACAU	476
4314-16-13946
APOB-	13947	Chl	ooooooooooooooo	mm0000000m00m0m	CUGGAGAAACAACAU	477
4314-17-13947
APOB--	13948	Chl	ooooooooooooo	00mmmmmm000m0	AGUCCCUCAAACA	478
16-13948
APOB--	13949	Chl	ooooooooooooooo	0000mmmmmm000m0	AGAGUCCCUCAAACA	479
17-13949
APOB--	13950	Chl	ooooooooooooo	0mm000m0mm00m	ACUGAAUACCAAU	480
16-13950
APOB--	13951	Chl	ooooooooooooo	0mm000m0mm00m	ACUGAAUACCAAU	481
18-13951
APOB--	13952	Chl	ooooooooooooooo	0m0mm000m0mm00m	ACACUGAAUACCAAU	482
17-13952
APOB--	13953	Chl	ooooooooooooooo	0m0mm000m0mm00m	ACACUGAAUACCAAU	483
19-13953
MAP4K4--	13766.2	Chl	ooooooooooooo	DY547mm0m00000mmm0	CUGUGGAAGUCUA	484
16-13766.2
CTGF-	13980	Chl	ooooooooooooo	0m0000000m0m0	ACAGGAAGAUGUA	485
1222-16-13980
CTGF-	13981	Chl	ooooooooooooo	000m0000mmmm	GAGUGGAGCGCCU	486
813-16-13981
CTGF-	13982	Chl	ooooooooooooo	m0mm000000m0	CGACUGGAAGACA	487
747-16-13982
CTGF-	13983	Chl	ooooooooooooo	0000mmmm0mmm	GGAGCGCCUGUUC	488
817-16-13983
CTGF-	13984	Chl	ooooooooooooo	0mm0mm0m00mm0	GCCAUUACAACUG	489
1174-16-13984
CTGF-	13985	Chl	ooooooooooooo	000mmmmmm00mm	GAGCUUUCUGGCU	490
1005-16-13985
CTGF-	13986	Chl	ooooooooooooo	00m0000mmmm0	AGUGGAGCGCCUG	491
814-16-13986
CTGF-	13987	Chl	ooooooooooooo	m0000mmmm0mm	UGGAGCGCCUGUU	492
816-16-13987
CTGF-	13988	Chl	ooooooooooooo	0mmm000mmmmmm	GUUUGAGCUUUCU	493
1001-16-13988
CTGF-	13989	Chl	ooooooooooooo	m0mm0mm0m00mm	UGCCAUUACAACU	494
1173-16-13989
CTGF-	13990	Chl	ooooooooooooo	0mm000000m0m	ACUGGAAGACACG	495
749-16-13990
CTGF-	13991	Chl	ooooooooooooo	00mm0mmm00mmm	AACUGCCUGGUCC	496
792-16-13991
CTGF-	13992	Chl	ooooooooooooo	000mmm0m0mmm0	AGACCUGUGCCUG	497
1162-16-13992
CTGF-	13993	Chl	ooooooooooooo	m0000m0000mm	CAGAGUGGAGCGC	498
811-16-13993
CTGF-	13994	Chl	ooooooooooooo	mmm00mmm000mm	CCUGGUCCAGACC	499
797-16-13994
CTGF-	13995	Chl	ooooooooooooo	mm0mm0m00mm0m	CCAUUACAACUGU	500
1175-16-13995
CTGF-	13996	Chl	ooooooooooooo	mm0mm0mm0m00m	CUGCCAUUACAAC	501
1172-16-13996
CTGF-	13997	Chl	ooooooooooooo	0mm0m00mm0mmm	AUUACAACUGUCC	502
1177-16-13997
CTGF-	13998	Chl	ooooooooooooo	m0mm0m00mm0mm	CAUUACAACUGUC	503
1176-16-13998
CTGF-	13999	Chl	ooooooooooooo	0000m0000mmm	AGAGUGGAGCGCC	504
812-16-13999
CTGF-	14000	Chl	ooooooooooooo	0mm0mm000000	ACCGACUGGAAGA	505
745-16-14000
CTGF-	14001	Chl	ooooooooooooo	0m0m0m0000m0	AUGUACGGAGACA	506
1230-16-14001
CTGF-	14002	Chl	ooooooooooooo	0mmmm0m000mm	GCCUUGCGAAGCU	507
920-16-14002
CTGF-	14003	Chl	ooooooooooooo	0mm0m00000m0	GCUGCGAGGAGUG	508
679-16-14003
CTGF-	14004	Chl	ooooooooooooo	0mmm0mm000mmm	GCCUAUCAAGUUU	509
992-16-14004
CTGF-	14005	Chl	ooooooooooooo	00mmmm0m0000m	AAUUCUGUGGAGU	510
1045-16-14005
CTGF-	14006	Chl	ooooooooooooo	m0m0m0000m0m	UGUACGGAGACAU	511
1231-16-14006
CTGF-	14007	Chl	ooooooooooooo	00mmm0mm000mm	AGCCUAUCAAGUU	512
991-16-14007
CTGF-	14008	Chl	ooooooooooooo	m000mmm000mmm	CAAGUUUGAGCUU	513
998-16-14008
CTGF-	14009	Chl	ooooooooooooo	mm0m0000m0m0m	CUGUGGAGUAUGU	514
1049-16-14009
CTGF-	14010	Chl	ooooooooooooo	000mmmm0m0000	AAAUUCUGUGGAG	515
1044-16-14010
CTGF-	14011	Chl	ooooooooooooo	mmmm00m00m0m0	UUUCAGUAGCACA	516
1327-16-14011
CTGF-	14012	Chl	ooooooooooooo	m00m00m0mmmmm	CAAUGACAUCUUU	517
1196-16-14012
CTGF-	14013	Chl	ooooooooooooo	00m0mm00m0m0m	AGUACCAGUGCAC	518
562-16-14013
CTGF-	14014	Chl	ooooooooooooo	000000m0mmmm	GGAAGACACGUUU	519
752-16-14014
CTGF-	14015	Chl	ooooooooooooo	mm0mm000mmm00	CUAUCAAGUUUGA	520
994-16-14015
CTGF-	14016	Chl	ooooooooooooo	00mm000mmmm0m	AGCUAAAUUCUGU	521
1040-16-14016
CTGF-	14017	Chl	ooooooooooooo	000m0000m0m00	AGGUAGAAUGUAA	522
1984-16-14017
CTGF-	14018	Chl	ooooooooooooo	00mm00mm00mmm	AGCUGAUCAGUUU	523
2195-16-14019
CTGF-	14019	Chl	ooooooooooooo	mmmm0mmm000m0	UUCUGCUCAGAUA	524
2043-16-14019
CTGF-	14020	Chl	ooooooooooooo	mm0mmm000mm00	UUAUCUAAGUUAA	525
1892-16-14020
CTGF-	14021	Chl	ooooooooooooo	m0m0m00m00m0	UAUACGAGUAAUA	526
156-16-14021
CTGF-	14022	Chl	ooooooooooooo	00mm000m00mmm	GACUGGACAGCUU	527
1780-16-14022
CTGF-	14023	Chl	ooooooooooooo	0m00mmmmm0mm0	AUGGCCUUUAUUA	528
2162-16-14023
CTGF-	14024	Chl	ooooooooooooo	0m0mm00mm000	AUACCGAGCUAAA	529
1034-16-14024
CTGF-	14025	Chl	ooooooooooooo	mm0mm00000m0m	UUGUUGAGAGUGU	530
2264-16-14025
CTGF-	14026	Chl	ooooooooooooo	0m0m0mm00mm0	ACAUACCGAGCUA	531
1032-16-14026
CTGF-	14027	Chl	ooooooooooooo	00m0000000mm0	AGCAGAAAGGUUA	532
1535-16-14027
CTGF-	14028	Chl	ooooooooooooo	00mm0mmmmmm00	AGUUGUUCCUUAA	533
1694-13-14028
CTGF-	14029	Chl	ooooooooooooo	0mmm0000m0m00	AUUUGAAGUGUAA	534
1588-16-14029
CTGF-	14030	Chl	ooooooooooooo	000mm00mmm000	AAGCUGACCUGGA	535
928-16-14030
CTGF-	14031	Chl	ooooooooooooo	00mm0m0000000	GGUCAUGAAGAAG	536
1133-16-14031
CTGF-	14032	Chl	ooooooooooooo	0m00mm000mmmm	AUGGUCAGGCCUU	537
912-16-14032
CTGF-	14033	Chl	ooooooooooooo	00000m0mmmm0	GAAGACACGUUUG	538
753-16-14033
CTGF-	14034	Chl	ooooooooooooo	000mmmm0m000	AGGCCUUGCGAAG	539
918-16-14034
CTGF-	14035	Chl	ooooooooooooo	m0mm0mm00000	UACCGACUGGAAG	540
744-16-14035
CTGF-	14036	Chl	ooooooooooooo	0mmm0000mm0	ACCGCAAGAUCGG	541
466-16-14036
CTGF-	14037	Chl	ooooooooooooo	m000mmmm0m00	CAGGCCUUGCGAA	542
917-16-10437
CTGF-	14038	Chl	ooooooooooooo	m00mm000mmmm	CGAGCUAAAUUCU	543
1038-16-14038
CTGF-	14039	Chl	ooooooooooooo	mmm0m0000m0m0	UCUGUGGAGUAUG	544
1048-16-14039
CTGF-	14040	Chl	ooooooooooooo	m0000m0m00m0	CGGAGACAUGGCA	545
1235-16-14040
CTGF-	14041	Chl	ooooooooooooo	0m00m00mmmmm	AUGACAACGCCUC	546
868-16-14041
CTGF-	14042	Chl	ooooooooooooo	0000mm0m00000	GAGGUCAUGAAGA	547
1131-16-14042
CTGF-	14043	Chl	ooooooooooooo	m000mmmm0m000	UAAAUUCUGUGGA	548
1043-16-14043
CTGF-	14044	Chl	ooooooooooooo	m000000m0mmm	UGGAAGACACGUU	549
751-16-14044
CTGF-	14045	Chl	ooooooooooooo	0000m0m0m000	AAGAUGUACGGAG	550
1227-16-14045
CTGF-	14046	Chl	ooooooooooooo	00m00m00mmmm	AAUGACAACGCCU	551
867-16-14046
CTGF-	14047	Chl	ooooooooooooo	00m000mm0m00	GGCGAGGUCAGA	552
1128-16-14047
CTGF-	14048	Chl	ooooooooooooo	00m0m0mmm00mm	GACACGUUUGGCC	553
756-16-14048
CTGF-	14049	Chl	ooooooooooooo	0m00000m0m00m	ACGGAGACAUGGC	554
1234-16-14049
CTGF-	14050	Chl	ooooooooooooo	mm000mmmm0m00	UCAGGCCUUGCGA	555
916-16-14050
CTGF-	14051	Chl	ooooooooooooo	0m0000mm00mmm	GCGAAGCUGACCU	556
925-16-14051
CTGF-	14052	Chl	ooooooooooooo	000000m0m0m00	GGAAGAUGUACGG	557
1225-16-14052
CTGF-	14053	Chl	ooooooooooooo	0m00mmmm00mmm	GUGACUUCGGCUC	558
445-16-14053
CTGF-	14054	Chl	ooooooooooooo	m00mmmm00mmmm	UGACUUCGGCUCC	559
446-16-10454
CTGF-	14055	Chl	ooooooooooooo	m00mm000mmmm0	UGGUCAGGCCUUG	560
913-16-14055
CTGF-	14056	Chl	ooooooooooooo	mm000mmm000mm	UCAAGUUUGAGCU	561
997-16-14056
CTGF-	14057	Chl	ooooooooooooo	0mm0000mm0m00	GCCAGAACUGCAG	562
277-16-14057
CTGF-	14058	Chl	ooooooooooooo	m0000m0m0m0mm	UGGAGUAUGUACC	563
1052-16-14058
CTGF-	14059	Chl	ooooooooooooo	0mm0000000m00	GCUAGAGAAGCAG	564
887-16-14059
CTGF-	14060	Chl	ooooooooooooo	00mm000mmmm0m	GGUCAGGCCUUGC	565
914-16-14060
CTGF-	14061	Chl	ooooooooooooo	000mm000mmmm0	GAGCUAAAUUCUG	566
1039-16-14061
CTGF-	14062	Chl	ooooooooooooo	0000m0m0mmm00	AAGACACGUUUGG	567
754-16-14062
CTGF-	14063	Chl	ooooooooooooo	m0000mm0m0000	CGAGGUCAUGAAG	568
1130-16-14063
CTGF-	14064	Chl	ooooooooooooo	00mmmm0m0000m	GGCCUUGCGAAGC	569
919-16-14064
CTGF-	14065	Chl	ooooooooooooo	mmm0m0000mm00	CUUGCGAAGCUGA	570
922-16-14065
CTGF-	14066	Chl	ooooooooooooo	mm00mm000000m	CCGACUGGAAGAC	571
746-16-14066
CTGF-	14067	Chl	ooooooooooooo	mmm0mm000mmm0	CCUAUCAAGUUUG	572
993-16-14067
CTGF-	14068	Chl	ooooooooooooo	m0mmmm0000mmm	UGUUCCAAGACCU	573
825-16-14068
CTGF-	14069	Chl	ooooooooooooo	m0000mm00mmm0	CGAAGCUGACCUG	574
926-16-14069
CTGF-	14070	Chl	ooooooooooooo	mm0m0000mm00m	UUGCGAAGCUGAC	575
923-16-14070
CTGF-	14071	Chl	ooooooooooooo	m00m00m00m0mm	CAAUGACAACGCC	576
866-16-14071
CTGF-	14072	Chl	ooooooooooooo	0m0mm00m0m0m0	GUACCAGUGCACG	577
563-16-14072
CTGF-	14073	Chl	ooooooooooooo	mmm0mmmm0000m	CCUGUUCCAAGAC	578
823-16-14073
CTGF-	14074	Chl	ooooooooooooo	m0m00000m0m00	UACGGAGACAUGG	579
1233-16-14074
CTGF-	14075	Chl	ooooooooooooo	m0m0000mm00mm	UGCGAAGCUGACC	580
924-16-14075
CTGF-	14076	Chl	ooooooooooooo	mmmm0m0000mm0	CCUUGCGAAGCUG	581
921-16-10476
CTGF-	14077	Chl	ooooooooooooo	mm0m00mmmm00m	CUGUGACUUCGGC	582
443-16-14077
CTGF-	14078	Chl	ooooooooooooo	0mm000mmmm0m0	GCUAAAUUCUGUG	583
1041-16-14078
CTGF-	14079	Chl	ooooooooooooo	mm000mmmm0m00	CUAAAUUCUGUGG	584
1042-16-14079
CTGF-	14080	Chl	ooooooooooooo	000m0m0mmm00m	AGACACGUUUGGC	585
755-16-14079
CTGF-	14081	Chl	ooooooooooooo	mm0m0000mm00m	CCGCAAGAUCGGC	586
467-16-14081
CTGF-	14082	Chl	ooooooooooooo	m0mm000mmm000	UAUCAAGUUUGAG	587
995-16-14082
CTGF-	14083	Chl	ooooooooooooo	0000mm00mmm00	GAAGCUGACCUGG	588
927-16-14083
SPP1-	14131	Chl	ooooooooooooo	0m0mmm00mm000	GCAUUUAGUCAAA	589
1091-16-14131
PPIB--	14188	Chl	ooooooooooooo	mmmmmmmmmmmmm	GGCUACAAAAACA	590
16-14188
PPIB--	14189	Chl	ooooooooooooooo	mm00mm0m00000m0	UUGGCUACAAAAACA	591
17-14189
PPIB--	14190	Chl	ooooooooooooooo	0mmm00mm0m00000m0	AUUUGGCUACAAAAACA	592
18-14190			oo
pGL3-	14386	chl	ooooooooooooo	0m000m0m00mmm	ACAAAUACGAUUU	593
1172-16-14386
pGL3-	14387	chl	ooooooooooooo	DY5470m000m0m00mmm	ACAAAUACGAUUU	594
1172-16-14387
MAP4K4-	14390	Chl	ooooooooooooooo	Pmmmmmmmmmmmm000mm	CUUUGAAGAGUUCUGUGGAAG	595
2931-25-14390			oooooooooo	mmmmmmmm	UCUA
miR-	14391	Chl	ssooooooooooooo	mmmmmmmmmmmmmmmmmm	ACAAACACCAUUGUCACACUC	596
122--23-14391			oooossss	mmmmm	CA
	14084	Chl	ooooooooooooo	mmm0m000mm000	CUCAUGAAUUAGA	719
	14085	Chl	ooooooooooooo	mm0000mm00mm0	CUGAGGUCAAUUA	720
	14086	Chl	ooooooooooooo	0000mm00mm000	GAGGUCAAUUAAA	721
	14087	Chl	ooooooooooooo	mmm0000mm00mm	UCUGAGGUCAAUU	722
	14088	Chl	ooooooooooooo	m0000mm00mm00	UGAGGUCAAUUAA	723
	14089	Chl	ooooooooooooo	mmmm0000mm00m	UUCUGAGGUCAAU	724
	14090	Chl	ooooooooooooo	0mm00mm000m00	GUCAGCUGGAUGA	725
	14091	Chl	ooooooooooooo	mmmm0m000mmm	UUCUGAUGAAUCU	726
	14092	Chl	ooooooooooooo	m000mm0000mm0	UGGACUGAGGUCA	727
	14093	Chl	ooooooooooooo	000mmmm0mm0mm	GAGUCUCACCAUU	728
	14094	Chl	ooooooooooooo	00mm0000mm000	GACUGAGGUCAAA	729
	14095	Chl	ooooooooooooo	mm0m00mm0m000	UCACAGCCAUGAA	730
	14096	Chl	ooooooooooooo	00mmmm0mm0mmm	AGUCUCACCAUUC	731
	14097	Chl	ooooooooooooo	000m00000mm0	AAGCGGAAAGCCA	732
	14098	Chl	ooooooooooooo	00m00000mm00	AGCGGAAAGCCAA	733
	14099	Chl	ooooooooooooo	0mm0m0m000m00	ACCACAUGGAUGA	734
	14100	Chl	ooooooooooooo	0mm0m00mm0m0m	GCCAUGACCACAU	735
	14101	Chl	ooooooooooooo	000mm0m00mm0m	AAGCCAUGACCAC	736
	14102	Chl	ooooooooooooo	0m00000mm00m	GCGGAAAGCCAAU	737
	14103	Chl	ooooooooooooo	000mmmmm0mmm	AAAUUUCGUAUUU	738
	14104	Chl	ooooooooooooo	0mmmmm0mmmmm	AUUUCGUAUUUCU	739
	14105	Chl	ooooooooooooo	0000mm0m00mm0	AAAGCCAUGACCA	740
	14106	Chl	ooooooooooooo	0m0m000m00m0m	ACAUGGAUGAUAU	741
	14107	Chl	ooooooooooooo	0000mmmmm0mm	GAAAUUUCGUAUU	742
	14108	Chl	ooooooooooooo	0mmmmmmm00mm	GCGCCUUCUGAUU	743
	14109	Chl	ooooooooooooo	0mmmmmm0m000m	AUUUCUCAUGAAU	744
	14110	Chl	ooooooooooooo	mmmmm0m000m00	CUCUCAUGAAUAG	745
	14111	Chl	ooooooooooooo	000mmm00m000	AAGUCCAACGAAA	746
	14112	Chl	ooooooooooooo	0m00m00000m00	AUGAUGAGAGCAA	747
	14113	Chl	ooooooooooooo	0m00000mm000	GCGAGGAGUUGAA	748
	14114	Chl	ooooooooooooo	m00mm00m00mm0	UGAUUGAUAGUCA	749
	14115	Chl	ooooooooooooo	000m00m0m0mmm	AGAUAGUGCAUCU	750
	14116	Chl	ooooooooooooo	0m0m0m0mmm0mm	AUGUGUAUCUAUU	751
	14117	Chl	ooooooooooooo	mmmm0m0000000	UUCUAUAGAAGAA	752
	14118	Chl	ooooooooooooo	mm0mmm00m00mm	UUGUCCAGCAAUU	753
	14119	Chl	ooooooooooooo	0m0m000000m0	ACAUGGAAAGCGA	754
	14120	Chl	ooooooooooooo	0m00mmm000mm0	GCAGUCCAGAUUA	755
	14121	Chl	ooooooooooooo	m00mm000m0m0m	UGGUUGAAUGUGU	756
	14122	Chl	ooooooooooooo	mm0m0000m00m	UUAUGAAACGAGU	757
	14123	Chl	ooooooooooooo	m00mmm000mm0m	CAGUCCAGAUUAU	758
	14124	Chl	ooooooooooooo	0m0m000m0000	AUAUAAGCGGAAA	759
	14125	Chl	ooooooooooooo	m0mm00mm000m0	UACCAGUUAAACA	760
	14126	Chl	ooooooooooooo	m0mmm0mmmm0m0	UGUUCAUUCUAUA	761
	14127	Chl	ooooooooooooo	mm0mm0000000	CCGACCAAGGAAA	762
	14128	Chl	ooooooooooooo	000m00m0m0m0m	GAAUGGUGCAUAC	763
	14129	Chl	ooooooooooooo	0m0m00m00mm0	AUAUGAUGGCCGA	764
	14130	Chl	ooooooooooooo	00m00mmm000mm	AGCAGUCCAGAUU	765
	14132	Chl	ooooooooooooo	00m0mmmm0m0m	AGCAUUCCGAUGU	766
	14133	Chl	ooooooooooooo	m00mm00000mmm	UAGUCAGGAACUU	767
	14134	Chl	ooooooooooooo	m0m0mmm00mm00	UGCAUUUAGUCAA	768
	14135	Chl	ooooooooooooo	0mmm00m000mmm	GUCUGAUGAGUCU	769
	14136	Chl	ooooooooooooo	m000m0m0m0m00	UAGACACAUAUGA	770
	14137	Chl	ooooooooooooo	m000m0000m0m	CAGACGAGGACAU	771
	14138	Chl	ooooooooooooo	m00mmm000mmm	CAGCCGUGAAUUC	772
	14139	Chl	ooooooooooooo	00mmm00000m00	AGUCUGGAAAUAA	773
	14140	Chl	ooooooooooooo	00mmm0m00mmmm	AGUUUGUGGCUUC	774
	14141	Chl	ooooooooooooo	00mmm00m0000	AGUCCAACGAAAG	775
	14142	Chl	ooooooooooooo	000mmmmm000m	AAGUUUCGCAGAC	776
	14143	Chl	ooooooooooooo	00m00m000m0mm	AGCAAUGAGCAUU	777
	14144	Chl	ooooooooooooo	mm000m00m0m0m	UUAGAUAGUGCAU	778
	14145	Chl	ooooooooooooo	m00m0m0m0m000	UGGUGCAUACAAG	779
	14146	Chl	ooooooooooooo	0m0000m00mm0	AUGAAACGAGUCA	780
	14147	Chl	ooooooooooooo	mm0000m0mm000	CCAGAGUGCUGAA	781
	14148	Chl	ooooooooooooo	m00mm0m000mmm	CAGCCAUGAAUUU	782
	14149	Chl	ooooooooooooo	0mm00mm000m0m	AUUGGUUGAAUGU	783
	14150	Chl	ooooooooooooo	00mm000m0m0m0	GGUUGAAUGUGUA	784
	14151	Chl	ooooooooooooo	00000m00mm00m	GGAAAUAACUAAU	785
	14152	Chl	ooooooooooooo	mm0m000m00000	UCAUGAAUAGAAA	786
	14153	Chl	ooooooooooooo	0mm00m00mm00	GCCAGCAACCGAA	787
	14154	Chl	ooooooooooooo	m0mmmm0m0m0m0	CACCUCACACAUG	788
	14155	Chl	ooooooooooooo	00mm000m00m0m	AGUUGAAUGGUGC	789
	14156	Chl	ooooooooooooo	00mm00mm000m0	AGUCAGCUGGAUG	790
	14157	Chl	ooooooooooooo	m0m000m00000	UAUAAGCGGAAAG	791
	14158	Chl	ooooooooooooo	mmmm0m0m00mm	UUCCGAUGUGAUU	792
	14159	Chl	ooooooooooooo	0m00mm00m0m0m	AUAACUAAUGUGU	793
	14160	Chl	ooooooooooooo	mm0mmmm0m0000	UCAUUCUAUAGAA	794
	14161	Chl	ooooooooooooo	00mm0mm0mm0m0	AACUAUCACUGUA	795
	14162	Chl	ooooooooooooo	0mm00mm0mmm0m	GUCAAUUGCUUAU	796
	14163	Chl	ooooooooooooo	00m00mm00m000	AGCAAUUAAUAAA	797
	14164	Chl	ooooooooooooo	0m0mmmm00m00	ACGACUCUGAUGA	798
	14165	Chl	ooooooooooooo	m00m0m00mmm0m	UAGUGUGGUUUAU	799
	14166	Chl	ooooooooooooo	000mm00m00m00	AAGCCAAUGAUGA	800
	14167	Chl	ooooooooooooo	0m00mm00000mm	AUAGUCAGGAACU	801
	14168	Chl	ooooooooooooo	00mm00mmm000	AGUCAGCCGUGAA	802
	14169	Chl	ooooooooooooo	0mm0mm0m00000	ACUACCAUGAGAA	803
	14170	Chl	ooooooooooooo	000m000mm00mm	AAACAGGCUGAUU	804
	14171	Chl	ooooooooooooo	000m0mm0000mm	GAGUGCUGAAACC	805
	14172	Chl	ooooooooooooo	m000m0mmmm0m	UGAGCAUUCCGAU	806
	17173	Chl	ooooooooooooo	00mmmm0m00mm0	AAUUCCACAGCCA	807
	14174	Chl	ooooooooooooo	m0mm00mm0mmm0	UGUCAAUUGCUUA	808
	14175	Chl	ooooooooooooo	0mm0m00000mm0	ACCAUGAGAAUUG	809
	14176	Chl	ooooooooooooo	mm00m0000mm0	CCAACGAAAGCCA	810
	14177	Chl	ooooooooooooo	mm00mm0mm00mm	CUGGUCACUGAUU	811
	14178	Chl	ooooooooooooo	m00mmm0m000mm	UGGUUUAUGGACU	812
	14179	Chl	ooooooooooooo	00mm0000m0mm0	GACCAGAGUGCUG	813
	14180	Chl	ooooooooooooo	00m0m00mm00m0	GAUGUGAUUGAUA	814
	14181	Chl	ooooooooooooo	0mm00mmm000m	GUCAGCCGUGAAU	815
	14182	Chl	ooooooooooooo	00m0m0m0mmm0m	AAUGUGUAUCUAU	816
	14183	Chl	ooooooooooooo	mm000mmm00000	UUGAGUCUGGAAA	817
	14184	Chl	ooooooooooooo	0mmm00m00mm00	GUCCAGCAAUUAA	818
	14185	Chl	ooooooooooooo	mm00m00mm00m0	CCAGCAAUUAAUA	819
	14186	Chl	ooooooooooooo	00mmm00m0mm	GACUCGAACGACU	820
	14187	Chl	ooooooooooooo	0mmm0mm00m00m	ACCUGCCAGCAAC	821
Sense backbone, chemistry, and sequence information. o: phosphodiester; s: phosphorothioate;
P: 5' phosphorylation; 0: 2'-OH; F: 2'-fluror; m: 2' O-methyl; +: LNA modification. Capital letters
in the sequence signify ribonucleotides, lower case letters signify deoxyribonucleotides.

Having thus described several aspects of at least one embodiment of this invention, it is to be appreciated various alterations, modifications, and improvements will readily occur to those skilled in the art. Such alterations, modifications, and improvements are intended to be part of this disclosure, and are intended to be within the spirit and scope of the invention. Accordingly, the foregoing description and drawings are by way of example only.

EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

All references, including patent documents, disclosed herein are incorporated by reference in their entirety. This application incorporates by reference the entire contents, including all the drawings and all parts of the specification (including sequence listing or amino acid/polynucleotide sequences) of the co-pending U.S. Provisional Application No. 61/135,855, filed on Jul. 24, 2008, entitled “SHORT HAIRPIN RNAI CONSTRUCTS AND USES THEROF,” and U.S. Provisional Application No. 61/197,768, filed on Oct. 30, 2008, entitled “MINIRNA CONSTRUCTS AND USES THEREOF.”

Claims

1-6. (canceled)

7. A method for treating or preventing a fibrotic disorder in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount for treating or preventing a fibrotic disorder of a double stranded nucleic acid molecule comprising a guide strand, with a minimal length of 16 nucleotides, and a passenger strand forming a double stranded nucleic acid, having a double stranded region and a single stranded region, the double stranded region having 8-15 nucleotides in length, the single stranded region having 4-12 nucleotides in length, wherein the single stranded region comprises 2-12 phosphorothioate modifications, wherein at least 40% of the nucleotides of the double stranded nucleic acid molecule are modified, and wherein the double stranded nucleic acid molecule is directed against COX-2.

8-15. (canceled)

16. The method of claim 7, wherein the double stranded nucleic acid molecule is administered via intradermal injection.

17. The method of claim 16, wherein the double stranded nucleic acid molecule is administered via local administration to the skin.

18-25. (canceled)

26. The method of claim 7, wherein the double stranded nucleic acid molecule is administered on the skin of the subject in need thereof.

27. The method of claim 26, wherein the double stranded nucleic acid molecule is in the form of a cream or ointment.

28. The method of claim 7, wherein the double stranded nucleic acid molecule is administered by local injection.

29-31. (canceled)

32. The method of claim 7, wherein the fibrotic disorder is selected from the group consisting of pulmonary fibrosis, liver cirrhosis, scleroderma, glomerulonephritis, lung fibrosis, liver fibrosis, skin fibrosis, muscle fibrosis, radiation fibrosis, kidney fibrosis, proliferative vitreoretinopathy, and uterine fibrosis.

33. The method of claim 7, wherein the single stranded region contains 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 phosphorothioate modifications.

34. The method of claim 7, wherein the double stranded nucleic acid molecule comprises a hydrophobic conjugate attached to the guide strand or the passenger strand.

35. The method of claim 34, wherein the conjugate is cholesterol.

36. The method of claim 7, wherein at least one of the nucleotides of the isolated double stranded nucleic acid molecule that is modified comprises a 2′O-methyl or a 2′O-fluoro modification.

37. The method of claim 7, wherein at least one of the nucleotides of the isolated double stranded nucleic acid molecule that is modified comprises a hydrophobic modification.

38. The method of claim 7, wherein the double stranded region is 11, 12, 13, or 14 nucleotides long.

39. The method of claim 7, wherein each nucleotide within the single stranded region has a phosphorothioate modification.

40. The method of claim 34, wherein the hydrophobic conjugate is attached to the double stranded nucleic acid molecule through a linker.

41. The method of claim 41, wherein the linker is a TEG linker.

42. The method of claim 7, wherein the single stranded region is at least 4, at least 5, or at least 6 nucleotides long.